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ABSTRACT 
Dendritic cells (DCs) are potent antigen presenting cells (APCs) that link the innate and 
adaptive immune system by their unique ability to induce and direct immune responses 
towards various T helper (Th)-type of immune responses such as Th1-, Th2-, Th9-, Th17-
, Th22- or T regulatory (TR). The type of Th response generated very much depends on 
the nature of the antigen encountered and allows for an effective and proficient immune 
response. For example, Th1 responses are used to clear intracellular pathogens while Th2 
responses are needed to clear extracellular pathogens The ability to specifically modulate 
Th-responses is an area of intense research, as it allows for the development of more 
effective vaccines and immunotherapeutics. Immunomodulation of DCs is one strategy 
by which specific Th-type immune responses may be tailored. Current research is 
focused on identifying agents that have the capacity to immunomodulate DCs such as 
host defense peptides (HDPs). Apart from their anti-microbial activities, HDPs have a 
number of immune functions including recruitment and subsequent activation of DCs.  
 
The goal of this study was to examine the immunomodulatory effects of HDPs on porcine 
DC functions. This research was part of a larger multinational research project to develop 
a novel adjuvant platform for single-immunization vaccines against pertussis in neonates. 
The pig model was used for this research because of its physiological similarities to 
humans and the recently developed pertussis infection model in young piglets. A series of 
experiments was conducted to characterize and describe porcine DC functions. Two 
subsets of DCs were successfully characterized and tested for their response to 
stimulation with HDPs. Initial results demonstrated a minimal effect of HDPs on DC 
functions, therefore we expanded the number of HDPs used to include both synthetic 
derivatives of HDPs known as innate defense regulators (IDRs) and naturally- occurring 
HDPs. We examined these effects on peripheral blood mononuclear cells (PBMC) in 
vitro and found that HDPs induce expression of the chemokine interleukin (IL)-8, which 
resulted in PBMC recruitment in vitro. We then proceeded to evaluate the HDPs in vivo 
by intradermally administering them into the flank of pigs. Surprisingly, treatment with 
the HDPs did not result in recruitment of neutrophils in vivo. We also examined the 
effects of formulating IDR-1002 as an adjuvant with the academic antigen Keyhole 
 iii 
Limpet Hemocyanin (KLH) on the development of KLH-specific immune responses in 
vaccinated pigs. While there was no difference in antibody titers between vaccinated and 
control animals, we found that co-formulation with IDR-1002 decreased both antigen-
specific and mitogen-induced proliferation in KLH/IDR-1002 vaccinated animals as long 
as four weeks post-treatment. These results demonstrate that specific IDRs can suppress 
certain aspects of the pro-inflammatory immune response making them potentially highly 
versatile tools to modulate and tailor the immune response in disease states characterized 
by a pro-inflammatory component.  
 
  
 iv 
ACKNOWLEDGEMENTS 
 
I would like to express my gratitude to my supervisors Drs. Volker Gerdts and Lorne 
Babiuk for providing me with the opportunity to work in their laboratory and for their 
support throughout my Ph.D thesis. I would like to thank the members of my advisory 
committee, Drs. Philip Griebel, John Gordon, Hugh Townsend, and Lou Qualtiere for 
their guidance and patience throughout my program as well as my graduate chairs, Drs. 
Vikram Misra and Janet Hill. Without the support and encouragement of my supervisors 
and committee members, my undertaking of this Ph.D alongside with an undergraduate 
program in pharmacy would not have been possible.  
 
I would like to thank my laboratory for their continued support and friendship, especially 
Rachelle Buchanan, Jill van Kessel and Stacy Strom. A special thanks goes to Gael 
Auray for his mentorship and interesting music choice during our many hours spent in the 
lab working on DCs. Thank you to the fellow students including Jay, Odessa and Krupal 
whose discussions on immunology were invaluable to my learning experience; Marianela 
whose runs kept me sane; Francois who taught me that in science the glass is never half 
full or half empty; and to Joan and Heather whose encouragement has been invaluable.  
 
I would also like to thank my parents, and family for their appreciation of higher 
learning, as well as Debbie and Kevin Quinn for their never-ending encouragement. A 
very special thanks goes to my sister, Manuela for always being there and believing in 
me. Lastly and most importantly, to Brian Quinn, thank you for your endless dedication 
to me and for always supporting me in everything I chose to do no matter how 
outlandish. 
   
  
 v 
TABLE OF CONTENTS 
PERMISSION TO USE ..................................................................................................... I	  1 
ABSTRACT ...................................................................................................................... II	  2 
ACKNOWLEDGEMENTS ........................................................................................... IV	  3 
TABLE OF CONTENTS ................................................................................................. V	  4 
LIST OF FIGURES ...................................................................................................... VII	  5 
LIST OF TABLES ....................................................................................................... VIII	  6 
LIST OF ABBREVATIONS .......................................................................................... IX	  7 
CHAPTER 1	   LITERATURE REVIEW ...................................................................... 1	  8 
1.1	   Dendritic cells ....................................................................................................... 1	  9 
1.1.1	   Plasmacytoid dendritic cells ........................................................................... 1	  10 
1.1.2	   Conventional dendritic cells ........................................................................... 6	  11 
1.1.3	   Porcine dendritic cells ..................................................................................... 9	  12 
1.2	   Host defense peptides ......................................................................................... 14	  13 
1.2.1	   Cathelicidins and defensins ........................................................................... 14	  14 
1.2.2	   Structure and function ................................................................................... 17	  15 
1.2.3	   Antimicrobial activity ................................................................................... 17	  16 
1.2.4	   Immunomodulatory activity .......................................................................... 18	  17 
CHAPTER 2	   RATIONALE, HYPOTHESIS, OBJECTIVES AND AIMS ........... 22	  18 
2.1    Rationale and hypothesis ................................................................................... 22	  19 
2.1	   Overall Objective ............................................................................................... 22	  20 
2.2	   Aims ..................................................................................................................... 22	  21 
CHAPTER 3	   A COMPARISON BETWEEN ISOLATED BLOOD DENDRITIC 22 
CELLS AND MONOCYTE-DERIVED DENDRITIC CELLS IN PIGS (AS 23 
PUBLISHED IN FACCI ET AL., 2010; IMMUNOLOGY) ....................................... 24	  24 
3.1	   Abstract ............................................................................................................... 24	  25 
3.2	   Introduction ........................................................................................................ 25	  26 
3.3	   Materials and Methods ...................................................................................... 27	  27 
3.4	   Results ................................................................................................................. 33	  28 
3.5	   Discussion ........................................................................................................... 46	  29 
3.6	   Conclusion .......................................................................................................... 49	  30 
CHAPTER 4	   STABILITY OF EXPRESSION OF REFERENCE GENES IN 31 
PORCINE PERIPHERAL BLOOD MONONUCLEAR AND DENDRITIC CELLS 32 
(AS PUBLISHED IN FACCI ET AL., 2011;VET. IMMUNO. IMMUNOPATH.) .. 50	  33 
4.1	   Abstract ............................................................................................................... 50	  34 
4.2	   Introduction ........................................................................................................ 51	  35 
4.3	   Materials and Methods ...................................................................................... 52	  36 
4.4	   Results ................................................................................................................. 55	  37 
4.5	   Conclusion .......................................................................................................... 59	  38 
CHAPTER 5	   CHEMOATTRACTIVE ACTIVITY OF HDPS ON PORCINE 39 
IMMUNE CELLS (MANUSCRIPT IN PREPARATION) ........................................ 61	  40 
 vi 
5.1	   Abstract ............................................................................................................... 61	  41 
5.2	   Introduction ........................................................................................................ 62	  42 
5.3	   Materials and Methods ...................................................................................... 64	  43 
5.4	   Results ................................................................................................................. 67	  44 
5.5	   Discussion ........................................................................................................... 73	  45 
5.6	   Conclusion .......................................................................................................... 76	  46 
CHAPTER 6	   DECREASED LYPHOCYTE PROLIFERATION IN PIGS 47 
FOLLOWING INTRADERMAL APPLICATION OF THE INNATE DEFENSE 48 
REGULATOR-1002 CO-FORMULATED WITH KEYHOLE LIMPET 49 
HEMOCYANIN (MANUSCRIPT IN PREPARATION) ........................................... 77	  50 
6.1	   Abstract ............................................................................................................... 77	  51 
6.2	   Introduction ........................................................................................................ 78	  52 
6.3	   Materials and Methods ...................................................................................... 80	  53 
6.4	   Results ................................................................................................................. 83	  54 
6.5	   Discussion ........................................................................................................... 89	  55 
CHAPTER 7	   GENERAL DISCUSSION ................................................................... 94	  56 
CHAPTER 8	   OVERALL CONCLUSION ................................................................ 99	  57 
8.1	   Future work ........................................................................................................ 99	  58 
CHAPTER 9	   REFERENCES ................................................................................... 101	  59 
APPENDIX A: EFFECTS OF SYNTHETIC HOST DEFENSE PEPTIDES ON 60 
PORCINE DENDRITIC CELLS ................................................................................ 122	  61 
APPENDIX B: RECRUITMENT AND ACTIVATION OF DENDRITIC CELLS 62 
BY INNATE IMMUNE STIMULATORS (AS PUBLISHED IN FACCI ET AL., 63 
2008; RECENT DEVELOPMENTS IN IMMUNOLOGY)[45] ............................... 135	  64 
APPENDIX C: STRATEGIES TO LINK INNATE AND ADAPTIVE IMMUNITY 65 
WHEN DESIGNING VACCINE ADJUVANTS (AS PUBLISHED IN 66 
GARLAPATI, FACCI ET AL. 2009; VET IMMUNOL IMMUNOPATHOL)[229]67 
......................................................................................................................................... 150	  68 
APPENDIX D: BIOLOGICAL ROLES OF HOST DEFENSE PEPTIDES: 69 
LESSONS FROM TRANSGENIC ANIMALS AND BIOENGINEERED TISSUES 70 
(AS PUBLISHED IN DYBVIG, FACCI ET AL. 2011; CELL TISSUE RES)[320] 151	  71 
APPENDIX E: DIFFERENTIAL ACTIVATION AND MATURATION OF TWO 72 
PORCINE DC POPULATIONS FOLLOWING TLR LIGAND STIMULATION 73 
(AS PUBLISHED IN AURAY, FACCI ET AL. 2010; MOL IMMUNOL)[92] ...... 152	  74 
APPENDIX F: CONSENT FOR REPRODUCTION OF PUBLISHED PAPERS 153	  75 
BIBLIOGRAPHY ......................................................................................................... 156	  76 
 
 vii 
 
LIST OF FIGURES 
Figure 1-1 Cathelicidin structure. ..................................................................................... 15	  77 
Figure 3-1 Giemsa stained pig monocyte-derived dendritic cells (MoDCs) and blood 78 
dendritic cells (BDCs). .............................................................................................. 37	  79 
Figure 3-2 Endocytic activity of monocyte-derived dendritic cells (MoDCs) and blood 80 
dendritic cells (BDCs) by laser confocal microscopy. .............................................. 39	  81 
Figure 3-3 The effect of LPS stimulation on CD80/86 cell surface expression in 82 
monocyte-derived dendritic cells (MoDCs) (n=5 animals) and blood dendritic cells 83 
(BDCs) (n=6 animals). .............................................................................................. 40	  84 
Figure 3-4 The effect of LPS stimulation on CCR7 expression in monocyte-derived 85 
dendritic cells (MoDCs) (n=4 animals) and blood dendritic cells (BDCs) (n=4 86 
animals). .................................................................................................................... 41	  87 
Figure 3-5 Changes in gene expression of CCL-2, CCL-4, CCL-20 and CXCL2 in 88 
monocyte-derived dendritic cells (MoDCs) and blood dendritic cells (BDCs) 89 
following a 6-hour stimulation with LPS.................................................................. 42	  90 
Figure 3-6. Changes in gene expression of IL-6, IL-8 and TNF-α in monocyte-derived 91 
dendritic cells (MoDCs) and of IL-6, IL-8 IL-12 and TNF-α in blood dendritic cells 92 
(BDCs) following a 6-hour stimulation with LPS. ................................................... 43	  93 
Figure 3-7 Stimulation of autologous T cells using antigen pulsed monocyte-derived 94 
dendritic cells (MoDCs) and blood dendritic cells (BDCs). ..................................... 45	  95 
Figure 4-1 Stability of expression of reference genes in porcine PBMC, T cells, 96 
monoyctes, MoDCs and BDCs. ................................................................................ 59	  97 
Figure 5-1 Porcine model for intradermal administration of HDPs. ................................ 67	  98 
Figure 5-2 Cytotoxicity of HDPs on Porcine PBMC ....................................................... 68	  99 
Figure 5-3 HDPs increase IL-8 release in PBMC. ............................................................ 70	  100 
Figure 5-5 HDP chemoattraction of PBMC ...................................................................... 72	  101 
Figure 5-6 Porcine intradermal administration of HDPs. ................................................. 73	  102 
Figure 6-1 Effect of intradermal vaccination with IDR-1002 on antigen specific and 103 
mitogen induced lymphocyte proliferation ............................................................... 84	  104 
Figure 6-2 IgG antibody titres to immunization with various adjuvants. ......................... 85	  105 
Figure 6-3 Surface phenotype of porcine splenocytes. ..................................................... 88	  106 
Figure 7-1 HDPs as innate immune system modulators ................................................... 98	  107 
  
 viii 
LIST OF TABLES 
 
Table 1-1 Structural characterization of HDPs ................................................................. 14	  108 
Table 1-2 Structural groupings of Cathelicidins ............................................................... 16	  109 
Table 3-1 Primer sequences for Real-time PCR analysis of changes in gene expression. 36	  110 
Table 3-2 Surface phenotype of MoDCs at day 6 and BDCs at day 1 analyzed by flow 111 
cytometry. ................................................................................................................. 38	  112 
Table 3-3 Changes in protein IL-6, IL-8, TNF-α, and IL-12 concentrations following 24-113 
hour LPS stimulation. ............................................................................................... 44	  114 
Table 4-1 Functional classes of reference genes ............................................................... 56	  115 
Table 4-2 Summary of studies examining porcine reference genes ................................. 57	  116 
Table 4-3 Reference genes used in this study ................................................................... 57	  117 
Table 5-1 Peptide family and species ............................................................................... 65	  118 
 
  
 ix 
 
LIST OF ABBREVATIONS 
 
Adenosine triphosphate        ATP 
Analysis of variance         ANOVA 
Antibody          Ab 
Antigen presenting cells       APCs 
ATP synthase mitochondrial F0 complex      ATP5G1 
Bactenecin         Bac 
Beta-actin          ACTB 
Blood dendritic cell antigen        BDCA 
Blood DCs         BDCs 
Bone Marrow         BM 
Bovine serum albumin        BSA 
C-X-C chemokine receptor type      CXCR 
CC-chemokine ligands        CCL 
Chemokine receptor         CCR 
Classical swine fever virus        CSFV 
Committed DC progenitors        CDPs 
Concanavalin          Con A 
Conventional dendritic cells       cDCs 
Cytokine and hematopoietic growth factor receptor     Csf-1R 
Delayed-type hypersensitivity       DTH 
Dendritic cell immunoreceptor       DCIR 
Dendritic cells         DCs 
Deoxyribonucleic acid       DNA 
Detoxified pertussis toxin        PTd 
Dextran          DX 
2,4-dinitro-1-fluorobenzene        DNFB 
Diphtheria toxin        DTx 
 x 
Diphtheria toxin receptor       DTR 
Enzyme-linked immunosorbent assay      ELISA 
Eukaryotic elongation factor 1 gamma-like protein     eEF1 
Fluorescein isothiocyanate        FITC 
FMS-related tyrosine kinase 3 ligand      FLT3 
Foot-and-mouth disease virus       FMDV 
Forkhead Box P3+         FOXP3+ 
Formyl peptide receptor like       FPRL 
Glyceraldehyde 3-phosphate dehydrogenase     GAPDH 
Granulocyte-macrophage colony-stimulating factor     GM-CSF 
Hematopoietic stem cells        HSCs 
Hematoxylin and Eosin        H and E 
Hen egg lysozyme         HEL 
Herpes simplex virus         HSV 
High endothelial venules       HEVs 
Host defense peptides        HDPs 
Human neutrophil peptides        HNP 
Human β-defensin          hBD 
IFN-regulatory factor         IRF 
Immune complexes        ICs 
Immunoglobulin-like transcript 7       ILT7 
Immunoreceptor tyrosine-based activation motifs     ITAMS 
Innate defense regulators       IDRs 
Interferon         IFN 
Interferon-producing cells        IPCs 
Interleukin         IL 
Intracellular cell adhesion molecule       ICAM 
Keyhole Limpet Hemocyanin       KLH 
Lamina propria         LP 
Langerhans cells         LCs 
Leukocyte lineage         lin 
 xi 
Lipopolysaccharide         LPS 
Lymph node         LN 
Magnetic activated cell sorting system     MACs 
Major histocompatibility complex      MHC 
Mesenteric lymph node        MLN 
Microvilli          M 
Mixed lymphocyte reaction        MLR 
Monocyte chemotactic protein       MCP 
Monocyte dendritic cell progenitor       MDP 
Monocyte-derived        Mo 
Monocyte-derived DCs       MoDCs 
Murine β-defensin-14        mBD-14 
Murine cytomegalovirus       MCMV 
Myeloid         m 
Natural interferon producing cells      NIPC 
Natural killer          NK 
Nuclear factor         NF 
Oligodeoxynucelotides       ODNs 
Ovalbumin         OVA 
Pattern recognition receptors       PRRs 
Peripheral blood mononuclear cells       PBMC 
Peripheral lymph nodes        PLNs 
Pertussis toxoid        PTd 
Plasmacytoid DCs         pDCs 
Polymerase chain reaction        PCR 
Porcine beta-­‐defensin	  	   	   	   	   	   	   	   pBD 
Porcine circo virus type 2        PCV 
Porcine myeloid antimicrobial peptides      PMAP 
Porcine reproductive and respiratory syndrome virus    PRRSV 
Protegrin-1          PG-1 
Pseudorabies attenuated virus       PRV 
 xii 
Real time quantitative PCR       RT-qPCR 
Recombinant porcine        rp 
Regulatory T cells         TR 
Ribonucleic acid        RNA 
Ribosomal protein L19       RPL19 
RIG-1-like receptors         RLRs 
Sialic-acid-binding immunoglobulin-like lectin H     Siglec-H  
Single stranded        ss 
Staphylococcal enterotoxin B       SEB 
Stimulation index         SI 
Succinate dehydrogenase complex subunit A     SDHA 
Swine influenza virus        SIV 
Swine workshop cluster number 3       SWC3 
Systemic lupus erythematosus       SLE 
T helper         Th 
Thymic stromal lymphopoietin      TSLP 
TIR-domain containing adaptor protein      TIRAP 
TNF-α and iNOS producing DCs       Tip-DCs 
Toll-like receptor        TLR 
Transforming growth factor       TGF-β 
Transmissible gastroenteritis virus       TGEV 
Tumor necrosis factor        TNF-α 
β-galactosidase         β-gal 
 
 1 
Chapter 1 LITERATURE REVIEW 
 
1.1 Dendritic cells 
 
DCs were initially observed and characterized in murine peripheral lymphoid organs by 
Dr. Ralph Steinman in 1973 [1, 2]. Since then, DCs have been identified as an important 
link between the innate and adaptive immune system [3, 4]. As potent APCs, DCs are 
located at sites of pathogen entry in the periphery and in primary and secondary lymphoid 
tissues, where they are specialized in antigen uptake and processing. Subsequently, 
antigen is presented via the molecules of the major histocompatibility complex (MHC)I 
or MHCII for the engagement and activation of T lymphocytes (T cells), important 
members of the adaptive immune system. The functions attributed to DCs include 
playing a role in preventing or limiting infectious diseases, allergy, autoimmunity and 
graft rejection [5]. As such, DCs are being used in the design of novel vaccines and 
immunotherapeutic agents for cancer and autoimmune diseases. Accordingly, by 
modulating DC activity, we hypothesize that it is possible to modulate adaptive immune 
functioning. For this reason we chose to examine DC behavior in response to stimulation 
by various HDPs in pigs. 
 
DCs can be categorized as plasmacytoid DCs (pDCs) or conventional DCs (cDCs), which 
can be further sub-classified as migratory, lymphoid tissue-resident, monocyte-derived 
(Mo) and inflammatory DCs. pDCs differ from cDCs both phenotypically and 
functionally [6-8]. In the following section, some of these differences will be discussed in 
both human and murine models. Finally, porcine DC subsets, their morphology and 
behavior will be discussed. 
 
1.1.1 Plasmacytoid dendritic cells 
 
Historically, pDCs were known as interferon-producing cells (IPCs) and had been 
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characterized based on their robust type 1 interferon (IFN) production [9], as compared to 
other accessory cells present in human PBMC [10]. Further characterization of IPCs 
established them as being DCs [11, 12]. At steady state, IPC resemble plasma cells in 
appearance until they are activated, subsequent to which they develop the classical DC 
morphology of cytoplasmic extrusions and an irregularly shaped nucleus [13]. In the 
following paragraphs, DCs in general will be described with regards to their phenotype, 
migration, receptor expression, cytokine production, antigen uptake and T cell 
stimulatory capacity.  
 
1.1.1.1 pDC cell surface marker expression 
Phenotypically (i.e. in regard to cell surface marker expression) there are several 
commonalities between human and murine pDCs. Neither express various T cell related 
antigens (CD3, CD8β or the T-cell receptor), B cell related antigens (CD19, CD20 or 
surface antibodies) or myeloid related antigens (CD14 and CD11b) [12, 14-16]. Both 
however express co-stimulatory molecules MHCI and MHCII, CD40, CD54, CD80 and 
CD86 [16]. In contrast human pDCs are positive for CD4, CD123 (IL-3R), blood 
dendritic cell antigen (BDCA)2 (also known as CD303), BDCA4 and immunoglobulin-
like transcript 7 (ILT7) [12, 15, 17, 18]. Murine pDCs, unlike those of humans, are 
positive for sialic-acid-binding immunoglobulin-like lectin H (Siglec-H) (endocytic 
marker), CD45R (B220), Ly6C and CD11clow. Human blood pDCs express chemokine 
receptors (CCRs)-2, -5 and -7 and C-X-C chemokine receptor type (CXCR)-3 and -4 [19] 
and mouse pDCs express CCR1, CCR5, CCR7, CXCR3 and CXCR4 [20]. The 
expression of these chemokine receptors is crucial for DC migration.  
 
1.1.1.2 Migration of pDCs 
 
The migration of pDCs from the periphery into lymph nodes (LNs) remains unclear. LNs 
can be accessed either via afferent lymphatic vessels or via high endothelial venules 
(HEVs), but the route by which pDCs access LNs remains controversial. In humans, 
pDCs have been shown to roll and adhere to HEVs in a L-selectin dependent manner and 
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migrate into T cell areas of the LN [15, 21]. Cella et al. (1999) observed pDCs in the 
HEV lumen and in inflamed LNs [15] corroborating the hypothesis that human pDCs 
enter LNs via HEVs. Further, studies in sheep and pigs determined that pDCs were 
detectable in afferent lymph [22]. In contrast, rat pDCs treated with Toll-like receptor 
(TLR) 9 agonists were not observed in intestinal or hepatic afferent lymph [23] 
suggesting that pDCs do not travel via lymphatics. In mice, however, pDCs do not 
migrate via afferent lymphatic vessels but instead enter inflamed lymph nodes via HEVs 
[7]. Further, studies have shown that during steady state, murine pDCs do not 
transmigrate into the LNs [21], however, in the case of an inflammatory stimulus such as 
intranasal administration of influenza virus in mice, pDCs can be observed in LNs, as 
suggested by a decrease in pDCs in the blood and increase in the number of pDCs present 
in mediastinal LNs [24]. Within the LNs, pDCs are located in the T cell area and red pulp 
with limited numbers present in the marginal zone. Six hours following injection into the 
retro-orbital vein with TLR9 agonists, CpG oligodeoxynucleotides (ODNs), murine 
spleen pDCs formed clusters in marginal zones in the T cell area [25]. A similar finding 
was made following infection with murine cytomegalovirus (MCMV) [25] and confirmed 
that pDCs can migrate into LNs. In summary, pDC migration to LNs in humans and mice 
occurs via HEVs and is dependent on the expression of selectins and chemokine 
receptors.  
 
1.1.1.3 pDC expression of pattern recognition receptors  
pDCs express a multitude of surface receptors, which allow them to respond to a wide 
variety of invading organisms. Examples of these receptors include BDCA2, a C-type 
lectin, ILT7, NKp44 (an Ig-like receptor), dendritic cell immunoreceptor (DCIR) and 
FcεRIα (high-affinity Fc receptor for IgE) and TLRs [14]. In contrast to mice, human 
pDCs do not express TLR2, TLR3, TLR4 or TLR5 and therefore human pDCS cannot 
respond to agonists for these receptors such as peptidoglycans, LPS, flagellin, or double-
stranded ribonucleic acid (RNA), respectively [26]. Both human and mouse pDCs 
express TLR7 and TLR9 which detect single stranded (ss) RNA and deoxyribonucleic 
acid (DNA) from viruses and bacteria, respectively. Thus human and mice pDCs can 
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detect bacteria, viruses and synthetic agonists [27]. TLR engagement triggers a signaling 
cascade that involves various adapter proteins, including myeloid differentiation primary-
response gene 88 (MyD88), TIR-domain containing adaptor protein (TIRAP) and TIRAP 
inducing IFN-β (TRIF) and TRIF-related adaptor molecule (TRAM). Mobilization of 
these adapter proteins activates nuclear factor (NF)-κB, mitogen-activated protein kinases 
(MAPKs) and IFN regulatory factors (IRFs) that subsequently induce production of 
cytokines, chemokines and up-regulation of co-stimulatory molecules [27, 28]. For 
example, in response to TLR9 stimulation by CpG class A and C ODNs, pDCs produce 
large amounts of IFN-α and subsequently locate to lymphoid tissues to stimulate T cell 
responses [29]. The rapid and extensive production of IFN-α is thought to play a 
protective role during infection by bacteria or viruses.  
 
1.1.1.4 Cytokine production in pDCs  
Type I and type II IFN are the main types of IFN that are produced by pDCs, with type I 
IFN comprising of IFN-α, -β, -ω and -τ and type II IFN consisting of IFN-γ [30]. Type I 
IFNs are produced by most cells with pDCs being the main producers, whereas IFN-γ is 
produced by natural killer (NK) cells, CD4+ Th1 cells and CD8+ cytotoxic T cells [30]. 
The functions of IFNs range from inhibiting viral proliferation to modulating B [31] and 
T [32] cell responses  and activation of NK cells [33].  
 
1.1.1.5 Antigen uptake in pDCs  
With regards to antigen uptake and presentation, antigen can be taken up either in a 
receptor-mediated manner or via endocytosis. Antigen then depending on whether it is 
endogenously or exogenously derived is presented on either MHCI or MHCII. 
Endogenous and exogenous antigen can be presented via MHCI while exogenous antigen 
is presented via MHCII [34]. pDCs in both humans and mice have been demonstrated to 
take up and present endogenous and exogenous antigen. In mice it has been demonstrated 
that pDCs preferentially take up and present endogenous antigens (soluble proteins) as 
opposed to extracellular or exogenous antigens [8]. A reason for this is due to the manner 
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in which MHCII is regulated [35]. In pDCs MHCII is continuously turned over even 
following activation. This means that stable complexes of exogenous antigen for 
presentation are not available. In contrast to exogenous peptide, endogenous peptides are 
continuously presented. In mice it was shown that despite the high turnover of MHCII, 
pDCs continuously present endogenous peptide derived from viruses [35]. In humans, 
pDCs take up exogenous antigen mostly via receptor-mediated endocytosis [36]. This has 
made human pDCs potential candidates for the targeted delivery of particulate vaccines 
in vivo via receptor-mediated endocytosis [34]. 
 
1.1.1.6 T cell activation by pDCs 
 
Mature pDCs prime naive T cells [8] more strongly than freshly isolated pDCs [37, 38]. 
In contrast to naïve T cells, pDCs regardless of their maturation state are very capable of 
inducing the expansion of memory T cells [39]. When irradiated, splenic pDCs were co-
cultured with human naïve CD4+ T cells, proliferation was lower as compared to pDCs 
co-cultured with antigen-experienced T cells [40]. Such functional differences may be 
related to the lower expression of co-stimulatory molecules, such as CD80/86, by pDCs 
[41]. In mice, it was demonstrated by Sapoznikov et al. (2007) that pDCs can directly 
stimulate T cells [38]. This group used CD11c-diptheria toxin (DTR) transgenic mice in 
which the DTR receptor was under the control of the Itgax (CD11c) gene promoter. 
Endocytosis of diphtheria toxin (DTx) and its subsequent binding to the DTR terminated 
protein synthesis and resulted in the ablation of CD11c cells. In the absence of CD11c 
cells, pDCs were able to prime CD4+ T cells but not CD8+ T cells in the lymph node [38]. 
This study demonstrated that mouse pDCs can prime naïve CD4+ T cells. In summary, 
both human and mouse pDCs have been demonstrated to prime naïve T cells, just not to 
the same extent as cDCs.  
 
Recent evidence suggests that pDCs also play a key role in suppressing immune 
responses. Using a murine model of hapten-specific skin delayed type hypersensitivity 
(DTH), Goubier et al. (2008) demonstrated that oral tolerance relied on liver pDCs to 
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suppress DTH responses. Depletion of these hepatic pDCs abrogated suppressive 
responses in an antigen-specific manner [42]. In addition, pDCs in the thymus have been 
demonstrated to be responsive to thymic stromal lymphopoietin (TSLP) and subsequently 
increase the generation of Forkhead Box P3+ (FOXP3+) TR [43]. The ability of pDCs to 
detect self nucleic acid as well as the chronic production of IFN-α in the absence of viral 
infection was shown in the context of human autoimmune diseases such as Systemic 
Lupus Erythematosus (SLE) [14, 27]. Therefore, in both humans and mice pDCs play a 
role in suppressing immune responses.  
 
1.1.2 Conventional dendritic cells 
 
Conventional (c)DCs are derived from a common myeloid progenitor that gives rise to 
pre-cDCs, which can be divided into migratory and lymphoid tissue-resident DCs. 
Migratory DCs encompass DCs present at dermal, pulmonary and mucosal surfaces that 
act as sentinels and carry antigen from the periphery to LNs. In contrast, lymphoid tissue-
resident DCs do not travel via lymphatics but remain in a fixed location such as the 
thymus or spleen [44]. For a more detailed review of migration of DCs please refer to 
Appendix B for a book chapter that we published on this topic [45]. 
 
In the skin, the epidermis and dermis contain different populations of DCs namely 
Langerhans cells (LCs) and dermal DCs. LCs are present in the epidermis where they 
represent less than 5% of the population of nucleated cells [46] and traverse from the 
dermis to LNs. LCs are phenotypically described as being Langerin+ (CD207, a C-type 
lectin pattern recognition receptor (PRR) involved in carbohydrate moiety recognition), 
EpCAM-, and CD103- [46]. Also, unique to LCs are the presence of intracytoplasmic 
granules known as Birbeck granules. Similarly, both LCs and dermal DCs are Langerin+, 
MHCII+, CD86+, CD11c+ but only dermal DCs are Langerin+, CD103+ and EpCAM- 
[47]. LCs require transforming growth factor (TGF)-β but not FMS-related tyrosine 
kinase 3 ligand (Flt3L) for differentiation, dermal DCs require Flt3L but no TGF-β [48, 
49] demonstrating that these two DC subsets are distinct.  
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LCs are suggested to play a role in humoral responses and are considered T cell 
stimulatory cells. For example, Th1-dependent IgG2a and IgG2c synthesis was increased 
in LC-deficient skin in mice [49]. Because LCs migrate into T cell areas in draining LNs, 
they are thought to play a tolerogenic role. DCs migrate during homeostasis and are 
proposed to constantly present self-antigen to T cells thereby preventing induction of 
auto-reactivity [50]. During inflammation, LCs take up antigen, upregulate expression of 
MHCII and CCR7 and migrate to draining lymph nodes. For example, following 
infection with Leishmania major parasite, mice lacking LCs had higher concentrations of 
IFN-γ and a smaller lesion size compared to control mice suggesting that LCs can play an 
immunosuppressive role [30]. In contrast, dermal DCs are more prominent in directly 
driving CD8+ T cell responses. For example, following epidermal inoculation with 
Herpes simplex virus (HSV)-1, CD8+ DCs, which are involved in class I–restricted 
presentation of HSV antigen, were isolated from the draining brachial LNs [51]. This 
observation raised the question as to whether dermal DCs interacted directly with CD8+ T 
cells or if antigen was received by LN resident CD8+ DCs obtained from migratory DCs. 
LangDTR mice, which express the DTx receptor (DTR) under the control of the Langerin 
promoter, treated with DTx, resulted in ablation of Langerin+ DCs. Using LangDTR mice 
Stoecklinger et al. (2011), demonstrated that following gene gun vaccination dermal DCs 
directly activated CD8+ T cells and also induced more IFN-γ secreting cells [16]. 
Similarly, the priming of CD8+ T cells was also demonstrated in a model of L. major 
infection [52]. 
 
Another type of cDCs are lymphoid tissue-resident DCs, which include spleen and LN 
resident DCs. These DCs originate from cDC precursors in the bone marrow, which then 
migrate to the spleen and LNs where they fully differentiate into cDCs. These DCs 
survey blood and lymphoid tissue for foreign antigens and are known to take up soluble 
antigen from lymphatics until DCs from the periphery arrive in the LN [53]. In contrast to 
migratory DCs, that arrive in LNs in a mature state, cDCs in the lymph node and spleen 
are immature [54].  
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Inflammatory DCs are another type of cDC that can stem from monocytes. Monocytes 
are leukocytes that originate in the bone marrow in a cytokine- and hematopoietic-growth 
factor receptor (Csf-1R; also known as c-fms) dependent manner and that exist in various 
subsets [55]. Monocytes originate in the bone marrow and are recruited into tissues both 
during inflammation and at steady state [56]. This recruitment occurs into the dermis, 
LN, spleen, and mucosal surfaces [57]. Recruited monocytes can subsequently 
differentiate into DCs in vivo [58] during inflammatory conditions and potentially at 
steady state as well [59]. Inflammatory DCs produce inflammatory factors including 
tumor necrosis factor (TNF-α), nitric oxide and reactive oxygen species. DCs derived 
from monocytes originate from a myeloid progenitor whereas pDCs and cDCs derive 
from a common DC progenitor, which stems from a myeloid progenitor [59]. 
 
Given the ease of isolating monocytes, MoDCs have been studied extensively in vitro by 
culturing monocytes in the presence of IL-4 and granulocyte-macrophage colony-
stimulating factor (GM-CSF). In humans, cultured MoDCs express high levels of MHCI 
and II, CD1, FcγRII, CD40, CD80/86, CD44, and intracellular cell adhesion molecule 
(ICAM)-1, but they lack CD14. When human MoDCs were cultured with TNF-α or 
CD40L the expression of MHCI and II, CD80/86, and ICAM-1 was increased [60]. 
Similar to human MoDCs, cultured murine MoDCs display MHCI and II, CD80 and 
CD86, CD40 and ICAM [61]. Cytokines produced by MoDCs following stimulation with 
LPS include TNF-α, IL-6 and IL-12 which, can indirectly increase T cell production of 
IFN-γ and IL-4 [62]. MoDCs are also described as being highly stimulatory in a mixed 
lymphocyte reaction (MLR) [60]. In vivo examination of MoDCs demonstrated that 
MoDCs contributed to CD4+ T cell activation, CD8+ T cell cross priming and bacterial 
killing by TNF-α/iNOS production [57]. TNF-α/iNOS dependent killing was carried out 
by a subset of inflammatory DCs known as TNF-α and iNOS producing DCs (Tip-DCs). 
These DCs are involved in bacterial clearance as was demonstrated using an infection 
model of Listeria monocytogenes [63].  
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1.1.3 Porcine dendritic cells 
 
The pig model is an important experimental model given the similarity between human 
and pigs with respect to their physiology and immune biology [64]. Due to growing 
toolbox of pig reagents becoming available, the field of porcine DC immunobiology has 
significantly expanded. Many porcine DC subsets have been phenotypically described 
and work is underway to describe their function in various contexts. The following 
section provides an overview of various aspects of porcine DCs including subtypes, 
phenotype and functionality.  
 
Porcine DC are comprised of various DC subsets including blood (B) DCs [65], bone 
marrow-derived (BM) DCs [66], Langerhans-type cells [67], MoDCs [66-71], thymus 
DCs [72], LN and spleen DCs  [73],  gut DCs [74] and lung DCs [75].  
 
Similar to humans and mice, porcine BDC subsets are comprised of pDCs and cDCs, 
which constitute approximately 0·1–0·3% of all PBMC [65] and they are present in a 
ratio of 1:0.8 of cDC to pDC [76]. Characterization of an antibody for the swine 
workshop cluster number 3 (SWC3) [77], also known as CD172a, led to BDCs being 
phenotypically described as CD172a+, MHCII+, CD80/86+, CD1+/- and CD14- with pDCs 
being CD4+ and cDCs being CD4- [65]. pDC isolation and characterization has proven to 
be challenging in the pig given the lack a specific cell surface marker to select for this 
cell type. Initially, producers of porcine IFN-α in PBMC in vitro in response to infection 
with transmissible gastroenteritis virus (TGEV) were described as non-T, non-B, MHCII- 
and CD4- [78]. Most studies examining porcine pDCs in PBMC have been characterized 
using CD172a which include pDCs, cDCs and monocytes [79-81]. In our studies, we 
characterized BDCs and MoDCs as CD172a+ expressing cells [82].  
 
1.1.3.1 Porcine pDCs 
Functionally, pDC characterization has been carried out both in vitro and in vivo using 
viruses including classical swine fever virus (CSFV) [76], foot-and-mouth disease virus 
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(FMDV) [83, 84], TGEV [85, 86] pseudorabies virus (PrV) [86], swine influenza virus 
(SIV) [86] and porcine circovirus type 2 (PCV2) [87, 88]. These works have contributed 
much regarding pDC behavior as it relates to IFN production. For example, studies have 
shown that in pigs, IFN regulatory factor 3 (IRF3) and IRF7 regulate IFN-α/β 
production. CSFV induces proteasomal degradation of IRF3 [89] and modulates IRF7 
turnover thereby potentially limiting Type I interferon production at initial sites of 
replication in cDCs, macrophages and epithelial cells [90]. However, during CSFV 
infection pDCs are found in a mature state (increased expression of CD80/86 and 
decreased expression of CD1) in the blood, tonsils and spleens of infected pigs where 
they produce TNF-α and IFN-α [76]. Infection models using FMDV have demonstrated 
that natural IFN producing cells (NIPC) produce high levels of IFN-α when FMDV was 
complexed with antibody thereby demonstrating FcγRII-dependent activation of NIPCs 
[83]. Stimulation of pDCs with CSFV, FMDV, SIV but not PCV resulted in increased 
IFN-α production in vitro and to a lesser extent in vivo [91]. pDCs are also able to 
respond to CpG ODN. Stimulation with class A CpG ODN resulted in the production of 
IFN-α [91] and TNF-α by CD172a+ cell fractions [81]. Data from our laboratory 
demonstrated that while BDCs derived from adult pigs do not produce IFN-α in response 
to CpG ODN stimulation [92], neonatal BDCs produce IFN-α after poly I:C, imiquimod, 
class A or class C CpG stimulation (Gael et al, accepted PLOS ONE). Whether BDCs 
respond differently than pDCs alone in response to stimulation with CpG ODN remains 
to be determined. In summary, with the availability of reagents and tools it has become 
possible to demonstrate that porcine pDCs are producers of IFN-α following their 
stimulation by viruses and CpG ODN.  
 
Porcine blood cDCs can be phenotyped as CD4−, CD14−, CD11R2+, CD1+/-, CD16+/-, 
CD3-, CD5-, CD8-, CD21- and represent 0·2–0·6% of PBMC [65]. Blood cDCs in culture 
up-regulate MHC class II and CD80/86, have endocytic activity and they can promote T 
cell proliferation [65].  
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1.1.3.2 Porcine monocyte-derived DCs 
MoDCs can be phenotyped as CD1+, CD14+/-, CD16+, CD80/86+, CD172a+, MHCI+, 
MHCII+, CD4-, CD3- and CD8- [66, 67]. Porcine MoDCs, similar to mice and humans, 
could be generated by differentiating monocytes using growth factors IL-4 and GM-CSF. 
Porcine MoDCs express TLR4, 5, 7 and 9 [93, 94] and respond to a variety of stimuli 
including PRRSV [95] and various TLR ligands including LPS [66]. Stimulation with 
LPS and TNF-α increased the maturation of MoDCs as seen by an up-regulation of MHC 
class II and a down-regulation of CD1 expression [67]. MoDCs were able to sample 
antigen via both receptor- and non-receptor-mediated endocytosis as demonstrated by 
their uptake of dextran (DX)-fluorescein isothiocyanate (FITC), BSA-FITC and β-
galactosidase (β-gal) immune complexes (ICs) [67]. MoDCs pulsed with the superantigen 
staphylococcal enterotoxin B (SEB) and matured with either TNF-α or LPS were able to 
stimulate T cell proliferation as well as increase the production of the cytokines IFN-γ 
and IL-4 [66].  T cell proliferation was also seen by MoDCs in MLRs [67]. 
 
1.1.3.3 Porcine BM-derived DCs 
 BM cells cultured with GM-CSF and TNF-α or Flt3 can generate both pDCs and cDCs 
[96]. Stimulation of BMDCs with TNF-α and LPS gave rise to an increase in the 
expression CD80/86 respectively, with TNF-α also increasing MHCI and MHCII 
expression [66]. Furthermore, in MLRs, BMDCs were potent stimulators of allogeneic T 
lymphocytes [66]. 
 
 
1.1.3.4 Porcine DCs in tonsils, mesenteric LN and spleen 
Populations of cDCs (CD11R1+ and CD172a+) and pDCs (CD4+ and CD172a+) were 
present in large numbers in the spleen. Furthermore, in spleen, LNs and tonsils low levels 
of IFN-α were expressed mostly by pDCs with cDCs being the major producers of TNF-
α in the tonsils [73]. 
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1.1.3.5 Porcine mucosal DCs 
The first description of mucosal porcine DCs was by Makala et al. (1998) whereby a 
MHCII+ population of cells that lack B and T cell markers was identified in Peyer’s patch 
cells [97].  Subsequently, four populations of porcine DCs were identified as follows: 
lamina propria (LP) DCs characterized as CD11b+ and CD172a+, Peyer's patch DCs 
characterized as CD11b- and CD172a+ in subepithelial dome regions, DCs in 
interfollicular regions characterized as CD11b- and CD172a-, whereas MLN DC were 
characterized as CD11b+ and CD172a- [98]. It was also demonstrated that a population of 
intestinal DCs (MHCII+, CD16+ and CD11b+) extended cytoplasmic processes between 
epithelial cells and also that small intestinal DCs were present adjacent to microvilli (M) 
cells [99]. Interestingly, of the four populations identified, only CD11b+ and CD172a+ 
and CD11b+ and CD172a- were present in afferent lymph thereby suggesting that DCs 
migrate from the LP to MLN [98].  
 
1.1.3.6 Porcine pulmonary DCs 
Porcine lung DCs were phenotypically described as CR4+(CD11c), MHCI+, CD80/86+, 
CD172a+, CD1+ and 50% were CD16+ and MHCII +. Functionally, lung DCs were 
capable of dextran and ovalbumin uptake as well as driving T cell proliferation in MLRs 
[75].  
 
1.1.3.7 Porcine dermal DCs 
Characterization of porcine Langerin/CD207 led to the observation that 50–70% of skin 
DCs express Langerin and are therefore LCs. Swine epidermal LCs are CD163- 
CD172a+, CD207+ and Langerin+ [100, 101]. Three dermal DC subsets have been 
characterized, namely: (1) CD163- and CD172a- (2) CD163+ and CD172a+ and (3) the 
CD163lo and CD172a+ DCs [101]. Porcine skin DCs have been phenotypically described 
as CD172a+, CD1+, MHCII+, CD80/86+, S100β+, CD80/86+, CD3-, CD4- and CD8- [102]. 
Functionally, they were able to take up fluorescent-labeled OVA, induce T cell 
proliferation in MLRs and also in antigen specific T cells assays [102].  
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To summarize, our knowledge of porcine DCs and their phenotype, function and 
behavior is constantly increasing as recognition of the pig as a model is growing and 
better and more specific reagents are becoming available.  
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1.2 Host defense peptides  
 
1.2.1 Cathelicidins and defensins 
Hans Boman was one of the first to study HDPs in insects. Driven to find an answer to 
the question how insects survive infection without antibodies and T cells in hemolymph 
[103], Boman began in the 1970s to examine the antimicrobial system of insects. He 
isolated various antibacterial peptides including cecropins and lysozyme in the early 
1980’s [104]. Since then over 700 antimicrobial peptides have been described in 
mammals with their activity ranging from antimicrobial to immunomodulatory [105]. 
HDPs include peptides found in plants, insects, fish, amphibia, bacteria, fungi and 
mammals. They differ in conformation and length, ranging from 6-59 amino acids [106, 
107]. HDPs can be categorized structurally as shown in Table 1-1 [107]. However, recent 
studies have focused predominantly on two main families of HDPs comprised of 
cathelicidins and defensins.  
Table 1-1 Structural characterization of HDPs 
Structural classes of HDPs Examples 
1. Anionic  Dermcidin released from human sweat 
glands 
2. Linear cationic α-helical peptides LL-37- the human cathelicidin 
3. Cationic peptides enriched for specific amino acids Bactenecins (Bac) from cattle  
4. Anionic and cationic peptides that contain cysteine 
residues and form disulphide bonds 
Protegrin from pigs and defensins from 
numerous species 
5. Anionic and cationic peptide fragments of larger 
proteins 
Antimicrobial domains from lysozyme 
and ovalbumin (OVA) 
 
Cathelicidins are characterized by a conserved N-terminal pro-sequence and a variable 
C-terminal region [108] (Figure 1-1). The release of the mature peptide is regulated by 
enzymes, which cleave the pro-peptide into its mature form. For example, neutrophil-
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derived elastase cleaves Bac7 into its mature form [109], whilst the cleavage of LL-37 
from HCAP18 occurs upon exocytosis and consequent cleavage via proteinase 3 [110].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Cathelicidin structure. 
(Adapted from Nizet et al. (2003) [111]). Cathelicidins are made up of a conserved N-
terminal region and a variable C-terminal region. The conserved region consists of the 
signal peptide and a cathelin domain. The variable region gives each distinct cathelicidin 
its properties due to variations in amino-acid length and composition. Proteolytic 
cleavage of the cathelicidin holoprotein at the cleavage site releases the active form of the 
peptide [108].  
 
Cathelicidins can be grouped into three major peptide groups namely, α-helical, β-sheets, 
and extended peptide structures which are rich in certain amino acids [112, 113] (Table 
1-2). While humans express only one cathelicidin gene which gives rise to the peptide 
LL-37, other species such as pigs express 11 cathelicidin genes [113, 114]. Pigs express 
the most diverse repertoire of cathelicidins [113]. 
 
 
Signal peptide     Cathelin prosequence domain  Mature peptide 
Conserved Variable 
Cleavage site 
N-terminus C-terminus 
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Table 1-2 Structural groupings of Cathelicidins 
 
Structure Peptide Origin 
α-helical BMAP-27, -28, -34 
LL-37/hCAP18 
CRAMP  
PAMP-23, -36, -37 
SMAP-29 
Cow 
Human 
Mouse 
Pig 
Sheep 
β-sheets Protegrin-1, -2, -3, -4, -5 Pig 
Extended peptide structures 
which are rich in certain 
amino acids 
Indolicidin (tryptophan rich) 
Bac-4, -5, -7 
Prophenin-1, -2 (phenylalanine rich) 
PR-39 (proline and arginine rich) 
Cow 
Cow 
Pig 
Pig 
 
(Adapted from Lehrer et al. (2002) [114] and Linde et al. (2008) [112]). Cathelicidins can 
be structurally grouped based on the presence of α-helical or β-sheet conformations or 
enrichment of certain amino acids.  
 
Defensins contain six cysteine residues that form disulfide bridges and comprise three 
families: α-defensins, β-defensins and θ-defensins. Mature peptides range from 18-45 
amino acids, contain three intra-molecular disulfide bridges and have a positive charge. 
In contrast, θ-defensins have a cyclized peptide backbone. The expression of defensins 
differs among species [115, 116] and by cell type. In humans, six α-defensins have been 
identified [117], whereas none are detected in pigs [113]. More than 30 different β-
defensins have been described in humans [118] and 13 in pigs [119]. The expression of θ-
defensins has only been observed in Old World monkeys, lesser apes and orangutans 
[120]. 
 
Defensin gene expression is developmentally regulated. For example, in human neonatal 
lungs, no human β-defensin (hBD)-2 was detected at 18 and 22 weeks gestation as 
compared with 42 weeks of gestation, seven months and 13 years of age. In contrast LL-
37 was expressed in tissues taken from all of the ages sampled [121]. Similarly, Elahi et 
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al. (2006) demonstrated that neonatal piglets failed to express porcine beta-defensin 
(pBD)-1 in their lungs compared to >2 months old pigs, and that expression was 
correlated with protection against infection with Bordetella pertussis [122]. Whereas 
newborn piglets were susceptible to infection, four week old piglets were protected.  
1.2.2 Structure and function  
 
HDPs vary in size, sequence, charge, conformation and structure, hydrophobicity and 
amphipathicity [107]. For example, hBD-3 contains three disulfide bonds, which are not 
required for antimicrobial activity but are necessary for chemotactic functions [123]. In 
contrast, in the case of hBD-1, the reduction of these disulfide bridges was crucial for its 
antimicrobial activity against the fungus Candida albicans and the anaerobic and Gram-
positive commensals Bifidobacterium and Lactobacillus species [124]. In these examples, 
both sequence and structure were essential for biological activity. A hydrophobic 
structure of some HDPs, including hBD-3, has been attributed with increased interactions 
with membranes, cytotoxic and hemolytic effects on eukaryotic cells [125]. Based on 
these observations, novel peptides have been synthesized to possess certain desired 
characteristics. For example, Omiganan, a molecule based on the HDP Indolicidin, is 
undergoing clinical trials for its antimicrobial effects in the prevention of catheter-related 
bloodstream infections and for the treatment of acne [126]. Results demonstrate that 
Omiganan in vitro demonstrates activity against pathogens commonly causing catheter 
associated infections including Gram-positive pathogens such as staphylococci, 
enterococci, streptococci, as well as Enterobacteriaceae [127]. Similar to Omiganan the 
design of novel peptides for their antimicrobial activity may aid in the fight against 
antimicrobial resistance to current antibiotics.  
 
1.2.3 Antimicrobial activity 
 
Several HDPs demonstrate antimicrobial activity against a broad spectrum of bacteria 
through various mechanisms including, disrupting the cell membrane. Models describing 
trans-membrane pore formation include the barrel stave model, the torodial pore 
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(wormhole) model and the (micellisation) carpet model [107]. Some HDPs function by 
binding components of the cell membrane, nucleic acids and proteins [107, 128]. In the 
case of Pseudomonas aeruginosa, cationic α-helical HDPs bind the outer membrane 
protein OprI which triggers peptide internalization followed by membrane permeability 
and subsequent death [129]. HDPs have also been demonstrated to bind surface lipids. 
For example, hBD-3 displayed antimicrobial activity against Staphylococcus aureus by 
binding lipid II, a cell wall precursor, resulting in disruption of cell wall synthesis and 
causing cell wall lesions [130]. Other peptides such as Indolicidin bind inner membrane 
components to mediate the transport of anionic compounds across the membrane [131]. 
Furthermore, Indolicidin has been shown to bind both single- and double-stranded DNA 
[132]. HDPs may also act by binding intracellular proteins. An example is the peptide 
PR39, which was demonstrated to prevent the proteasomal degradation of inhibitor of 
NF-κB alpha, by binding to the 26S proteasome thereby preventing the expression of NF-
κB-dependent genes [133]. Interestingly peptide function may be dependent on their level 
of processing and/or maturity. For example, the immature form of Bac7 was chemotactic 
[134] without any antimicrobial activity, whereas in its mature form it proved 
antimicrobial against Klebsiella pneumoniae and Salmonella typhimurium [109].  
 
1.2.4 Immunomodulatory activity  
 
In addition to their antimicrobial activity, HDPs can recruit immune cells to sites of 
pathogen entry, they can influence adaptive immune responses and they can influence 
DC function. For example, hCAP, the pro-peptide of the human cathelicidin LL-37, has 
been shown to recruit human monocytes [135], neutrophils [135-137], DCs [136] and T 
cells [135, 138]. Human beta defensins 1-4 are chemotactic for human macrophages 
[139], mast cells [139], immature DCs [140], CD4+, CD45RA+ naive and CD8+, but not 
CD4+, CD45RO+ memory T cells [140, 141]. Human α and β defensins have also been 
shown to be chemotactic for human MoDCs [142]. Interspecies effects are also evident, 
for example, the human cathelicidin recruited rat mast cells [143] and the mouse 
cathelicidin CRAMP was chemotactic for human monocytes, neutrophils, and 
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macrophages. Transcriptional profiling demonstrated that bovine and human homologues 
LL-37 and BMAP-27 showed conserved trends towards profoundly suppressing many 
LPS-induced genes and suppression of LPS-induced translocation of NFκB subunits into 
the nucleus of human and bovine monocytic cells [144].  
 
Many of the receptors used by HDPs for immune cell recruitment remain unknown. 
Whereas some defensins have been shown to recruit immature DCs via CCR6 [145, 146], 
both the human and mouse cathelicidins LL-37 and CRAMP act mostly via formyl 
peptide receptor like (FPRL) [135, 147-149].  
 
HDPs influence various components of the adaptive immune system such as lymphocyte 
proliferation, cytokine and antibody production. This was demonstrated in different 
species including mice that were immunized intraperitoneally with either Keyhole Limpet 
Hemocyanin (KLH) alone or in combination with HDPs. Vaccinated animals displayed 
increased serum IgG1, IgG2a and IgG2b responses and splenocytes displayed higher 
proliferation and higher secretion of IL-4 and IFN-γ into supernatants [150]. In another 
study, mice immunized subcutaneously with CpG ODN, polyphosphazene and 
Indolicidin have increased IgG1 and IgG2a titres and IFN-γ secretion [151]. These results 
are consistent using a bovine model in which subcutaneous immunization with 
indolicidin, CpG ODN and hen egg lysozyme (HEL), increase serum IgG titres and IFN-γ 
secretion of PBMC [152]. 
 
Synthetic mimetics of HDPs known as innate defense regulator proteins (IDRs) have also 
been demonstrated to affect adaptive immune response. The intranasal administration to 
mice of a complex of CpG10101-HH2 and detoxified pertussis toxin (PTd) resulted in 
significantly higher levels of IgA as compared to PTd and CpG10101 alone or PTd and 
HH2 alone [153]. The complex of CpG10101-HH2 and PTd also resulted in higher total 
serum IgG titres with a balance seen between IgG1 (Th2 response) and IgG2a (Th1 
response) subclasses [153].	  Further evidence for the CpG-HH2 complex in modulating 
immune responses was seen following the intranasal administration of CpG-HH2 and 
examining mRNA levels in the jejunum of neonatal piglets. Both IFN-γ and IL-12 
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responses were enhanced, whereas IL-4 mRNA levels were reduced demonstrating the 
ability of IDR complexes to contribute towards Th1 type biased immunity [154, 155]. 
Furthermore, CpG-HH2 combined with attenuated PRV resulted in higher PRV-specific 
antibodies of IgG2 isotype as well as Th1 cytokines IFN-γ and IL-12 in pigs [154]. 
Similar results were seen in both adult and neonatal mice whereby the subcutaneous 
administration of a combination of the IDR HH2/CpG ODN and polyphosphazenes 
resulted in higher IgG2a responses [156]. Interestingly, neither of the components alone 
or in a double combination exerted the same effect as the triple combination suggesting 
the importance of synergy in responses using IDRs. The effect of a triple combination of 
PTd-CpG-IDR-and polyphosphazenes was demonstrated using IDR-1002 in a murine 
model. Garlapati et al. (2011) demonstrated that the subcutaneous administration of this 
combination induced higher Th1 type of responses as shown by an increase in the 
cytokines monocyte chemotactic protein (MCP)-1, TNF-α, IFN-α, IL-12 and IL-17 and a 
decrease in IL-10 concentrations [157]. In summary, these studies demonstrated the 
ability of HDPs and IDRs to influence humoral and cell-mediated adaptive immune 
responses. 
 
1.2.4.1 Dendritic cell immunomodulation 
 
Evidence exists demonstrating that cathelicidins and defensins can directly impact both 
DC phenotype and function. Stimulation of immature human MoDCs for 12 hours with 
30 µg/ml of the human cathelicidin LL-37, increased the expression of both MHCII and 
CD86 but had no effect on cytokine production [158]. In a study by Davidson et al. 
(2004), instead of using immature human MoDCs, MoDCs that were still developing 
from monocytes into DCs were exposed to 50 µg/ml of LL-37 for 24 hours. This 
exposure to LL-37 resulted in an increased expression of CD86 and FITC-labeled dextran 
uptake. Also, stimulation of LL-37 treated MoDCs with LPS, increased IL-6 and IL-12 
production, T cell proliferation and T cell production of IFN-γ production [136]. These 
studies demonstrated the ability of LL-37 to modulate human MoDC behavior. Notable, 
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is the temporal aspect of exposure i.e. the effect of pre-treatment as compared to direct 
stimulation.   
 
Aside from modulation by cathelicidins, human MoDCs are influenced by stimulation 
with human α- and β-defensins. Presicce et al. (2009), demonstrated that stimulation of 
human MoDCs with human neutrophil defensin-1, an α-defensin and human β-defensin-
1, increased the expression of the costimulatory molecules CD80, CD86, CD40 and 
MHCII, the production of TNF-α, IL-6, IL-12p70 and enhanced the proliferation of 
allogeneic T cells [142]. Also, related to the effects of α-defensins on human MoDCs, 
Rodriguez-Garcia et al. (2009), observed that the immunomodulatory effects of α-
defensins1-3 were concentration dependent [159]. Stimulation of human MoDCs with 
low concentrations of α-defensins1-3 (0.25- 1 µg/ml) resulted in an upregulation of 
CD86 and MHCII expression, and an increase in TNF-α, IL-1β, IL-12p40, IL-8 and IL-
10 production [159]. In contrast, high doses of α-defensins 1-3 (10-20 µg/ml) 
downregulated the expression of CD86 and MHCII and the production of TNF-α, IL-1β, 
IL-12p40 and IL-10. And low doses of α-defensins 1-3 increased T cell proliferation 
whereas high concentrations decreased it. Results from this study suggest that immune 
responses to HDP may be regulated by the dose of HDP used.  
 
In summary, HDPs demonstrate antimicrobial activity as well as immunomodulatory 
functions, the latter of which is of particular interest for this project.  
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Chapter 2 RATIONALE, HYPOTHESIS, OBJECTIVES AND AIMS 
2.1 Rationale and hypothesis 
 
Dendritic cells are important immune cells required for uptake and presentation of 
foreign antigens, stimulation of both innate and acquired immunity, as well modulation of 
the immune response towards either a Th1, Th2, Th9, Th17, Th22 or TR. Thus, DCs are 
often referred to as a link between the innate and acquired immune response. The ability 
to immunomodulate DCs either via recruitment, antigen uptake and presentation or T cell 
stimulatory ability may represent a key strategy for tailoring immune responses.  
 
While considerable research is underway in murine models to understand DC 
immunobiology, much remains to be examined using larger animal models such as the 
pig. Pigs represent an important animal model, which in many aspects closely resembles 
the human immune system. Therefore, the goal of this project was to characterize porcine 
DC subsets and subsequently determine how to immunomodulate them. Since, HDPs 
have been demonstrated to be immunomodulatory, my hypothesis is that HDPs can 
immunomodulate porcine dendritic cells towards a stimulatory immune response.  
 
2.1 Overall Objective 
Our overall objective was to characterize porcine DC subsets and to immunomodulate 
them with HDPs. Therefore the aims of this project were as follows:  
2.2 Aims 
 
1. To assess the immunomodulatory activity of HDPs on cultured dendritic cells. 
 
a.) Develop protocols to isolate and generate porcine MoDCs and BDCs 
b.) Characterize DCs functionally and phenotypically 
a. Cytokine production 
b. Endocytic ability 
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c. Expression of co-stimulatory molecules  
d. T cell stimulatory ability 
e. Cell surface marker expression 
c.) Examine effects of HDPs on MoDCs and BDCs 
a. Dose Response Assessment  
b. Cell surface marker expression 
c. Cytokine production 
d. Chemokine and chemokine receptor expression 
e. Endocytosis 
 
These aims were expanded to include the following aims given the results obtained from 
our DC work (Appendix A). 
 
2. To determine the immunostimulatory activity of HDPs on isolated PBMC. 
a.) In vitro recruitment  
b.) Cytokine production 
 
 
3. To assess HDP-mediated immune cell recruitment and immune stimulation in 
vivo.  
a.) In vivo recruitment 
b.) Splenocyte stimulation and assessment of proliferation and cytokine 
production 
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Chapter 3 A COMPARISON BETWEEN ISOLATED BLOOD DENDRITIC 
CELLS AND MONOCYTE-DERIVED DENDRITIC CELLS IN PIGS (as 
published in Facci et al., 2010; Immunology) 
 
Facci, M. R., Auray, G., Buchanan, R., van Kessel, J., Thompson, D. R., Mackenzie-
Dyck, S., Babiuk, L. A. and Gerdts, V. Immunology 129(3): 396-405. 
 
Chapter 3 has been published. It is reproduced here with permission of the copyright 
owner (John Wiley and Sons).  
 
All authors participated in the design of the experiments and contributed to writing of the 
manuscript. Auray, Buchanan, van Kessel and Thompson assisted in sample collection. 
All other data presented in this manuscript are the work of the thesis author. 
 
3.1  Abstract 
 
Various dendritic cell (DC) populations exist that differ in their phenotype and ability to 
present antigen to naïve and primed T cells. For example, plasmacytoid DCs (pDCs) are 
less potent T cell activators compared to conventional DCs (cDCs). In the present study 
we compared porcine blood DCs, containing pDCs, and monocyte-derived DCs 
(MoDCs), consisting of cDCs, in their phenotype, ability to uptake antigen, activation 
and maturation and their ability to present antigen to autologous T cells. Pigs represent an 
important animal model, whose immune system in many respects closely resembles that 
of humans. For example, the distribution of toll like receptors on dendritic cells is similar 
to that of humans, in contrast to that of mice. Our results demonstrate that both 
populations were able to endocytose foreign material.  Following lipopolysaccharide 
(LPS) stimulation, CD80/86 and chemokine receptor (CCR)7 expression was increased in 
both populations as was the expression of the CC chemokine ligand (CCL)-2, CCL-4, 
CCL-20 and CXC chemokine ligand (CXCL)-2. Basal protein concentrations of 
interleukins IL-6, IL-8 and tumor necrosis factor (TNF)-α were higher in MoDCs, 
although in response to LPS, BDCs displayed a higher fold increase. Proliferation of 
autologous T cells was induced in an antigen specific manner for both MoDCs and 
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BDCs. Interestingly, while MoDCs were able to induce stronger proliferation in naïve T 
cells, when compared to BDCs, no difference in proliferation was observed when primed 
T cells were studied. These results demonstrate that isolated porcine BDCs are highly 
responsive to stimulation with LPS and functionally able to increase primed T cell 
proliferation to the same extent as MoDCs.  
 
3.2 Introduction 
 
Dendritic cells (DCs) are important cells of the immune system involved in uptake and 
presentation of foreign antigens, stimulation of both innate and acquired immunity, as 
well as modulation of the immune response towards a Th1, Th2, Th17 or T regulatory 
type of response [160, 161]. At steady state, DC subtypes include type-1 interferon-
producing plasmacytoid DCs (pDCs) and conventional DCs (cDCs), both of which are 
present in lymphoid and nonlymphoid tissues as well as blood [162].  In contrast, 
monocyte-derived DCs (MoDCs) are generated during inflammation [44, 163]. DCs have 
been extensively characterized in a variety of species and protocols for obtaining DC 
subtypes range from in vitro culture methods to direct isolation of DCs from blood and 
tissues. Isolation, however, is complicated in humans and large animal species resulting 
in limited availability for functional studies. In pigs, blood DCs (BDCs) have only been 
investigated in a few studies and very little is known about the function of these DCs in 
antigen presentation and T cell activation. The objectives of the present study were to 
compare directly isolated porcine BDCs to traditionally generated porcine MoDCs in 
terms of phenotype and functionality.  
 
Various porcine DCs have been described including bone marrow-derived (BM)DCs 
[66], Langerhans-type cells [67] and MoDCs [66-71]. MoDCs are the most widely used 
subtype and can be phenotyped as CD1+, CD14+/-, CD16+, CD80/86+, CD172a+, MHCI+, 
MHCII+, CD4-, CD3-, and CD8- [66, 67]. Initially MoDCs were generated by isolation of 
PBMC followed by overnight plastic adherence. Non-adherent cells were then removed 
and the remaining monocytes were cultured in the presence of IL-4 and GM-CSF [66]. 
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More recent protocols, however, involve the isolation of monocytes using antibodies 
against CD14 [95, 164] or CD172a [165], a porcine marker known as SWC3 that is 
present on myeloid cells [166] including cDCs and pDCs [65]. Porcine BDCs, on the 
other hand, comprising of pDCs and cDCs were originally described by Summerfield et 
al. (2003) by flow cytometric analysis of PBMC as being CD172a+, MHCII+, CD80/86+, 
CD1+/-, and CD14- with pDCs being CD4+ and cDCs being CD4- [65]. Subsequently, this 
approach was further developed by isolating BDCs using antibodies against CD172a. 
However, since CD172a is also expressed on monocytes, these enriched BDC 
populations contained not only different DC subtypes but monocytes as well [93]. In the 
present study we adapt previous protocols by initially depleting monocytes and 
subsequently enriching for CD172a to achieve a more pure BDC population.  These 
BDCs were compared to MoDCs in terms of antigen uptake, activation and maturation.  
 
DC maturation occurs upon recognition of microbe-associated molecules pattern and is 
characterized by upregulation of co-stimulatory molecules such as CD80/86 and MHCII, 
various cytokines and the chemokine receptor CCR7 [167] [168]. The process of 
maturation occurs as DCs migrate towards the lymph node where they encounter naïve or 
primed T cells. In porcine MoDCs, stimulation with LPS was demonstrated to decrease 
the expression of CD16, up-regulate the expression of CD80/86 [66, 94, 169] and either 
increase [67] or have no effect [66, 94] on  expression of MHCII. Uptake of FITC-
dextran [67] or DQ-OVA [169] was decreased. Expression of cytokines including IL-6 
[169] and TNF-α [169] was increased. Interestingly, transcripts for IL-10, IL-13, IFN-γ 
and IL-12p35 were increased but no production at the protein level was detected [70, 
169]. Furthermore, LPS stimulation did not induce a change in IL-4 gene expression [94]. 
However, T cells that had been exposed to antigen-pulsed MoDCs produced protein for 
both IL-4 and IFN-γ [66]. In contrast to MoDCs, however, very little information is 
available on maturation and activation of isolated BDCs following stimulation with LPS.  
 
Following their activation and maturation, DCs are known to increase T cell proliferation 
and to modulate the immune response towards a Th1, Th2, Th17 or T regulatory type of 
response [160, 161]. Due to the limitations of studying T cell proliferation in outbred 
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species, most studies in pigs have used mixed lymphocyte reactions [66, 70, 87] and only 
very few have used autologous cells [65, 87, 169]. In the present study, both MoDCs and 
BDCs were isolated from vaccinated pigs and co-cultured with autologous T cells to 
assess the induction of antigen-specific T cell activation. We found that both MoDCs and 
BDCs were equally able to induce T cell proliferation. However, when stimulated with 
LPS BDCs that were directly isolated from blood showed a greater increase in cytokine 
and chemokine expression when compared to MoDCs. This study therefore provides 
further evidence that directly isolated BDCs represent an important cell population for 
studying DC biology in pigs. Further studies, however, are required to identify the 
specific role of pDCs within the BDC population.    
3.3 Materials and Methods 
 
Experimental design and animals 
 
Eight week old Dutch Landrace pigs purchased from Saskatoon Prairie Swine Centre, 
University of Saskatchewan were used in this study. The goal of this study was to directly 
compare MoDCs to isolated BDCs both phenotypically and functionally. Phenotypically, 
DC morphology was examined by Giemsa staining and the expression of cell surface 
markers by flow cytometry. Functionally, endocytic ability was examined by flow 
cytometry, changes in transcript expression and the production of cytokines in response 
to stimulation with LPS by quantitative real-time PCR (RT-qPCR) and ELISA 
respectively, and lastly for their ability to stimulate autologous T cell proliferation, 
thymidine uptake assays were performed. Studies were performed as per the ethical 
guidelines of the University of Saskatchewan and the Canadian Council for Animal Care. 
 
BDC and T cell isolation and generation of MoDCs  
 
Blood was collected using EDTA-coated syringes and blood mononuclear cells (BMC) 
were isolated using a 60% Ficoll-Paque™ Plus gradient (GE Healthcare, Uppsala, 
Sweden). Monocytes were isolated using magnetic beads (MACS), (Miltenyi Biotec, 
Auburn, CA) and human anti-CD14 (TÜK4) microbeads (Miltenyi Biotec, Auburn, CA) 
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[95, 164]. The cross-reactivity of this antibody was confirmed by testing it against an 
anti-porcine CD14 (MIL-2) homologue. Flow cytometry was used to verify the purity of 
the separated cells.  
 
To generate MoDCs, monocytes were cultured in RPMI 1640 (Gibco, Grand Island, NY) 
supplemented with 10% FBS, 0.5 mM β-Mercaptoethanol, 10% Antibiotic/Antimycotic 
(Gibco, Grand Island, NY), 10% HEPES (Gibco, Grand Island, NY), 10% MEM Non 
Essential Amino Acids (Gibco, Grand Island, NY), 100 ng/ml of recombinant porcine 
(rp) IL-4 (Biosource, Camarillo, CA) and 20 ng/ml of rpGM-CSF (Biosource, Camarillo, 
CA) for 6 days at 37°C with 5% carbon dioxide. Half of the medium was changed every 
3 days. MoDCs were used between day 4 and 6, at which time non-adherent MoDCs  [66, 
81, 170] were washed, counted and used in subsequent assays.  
 
To isolate BDCs, which are described to be CD172a+CD14- [65, 81], CD14- cells were 
labeled with a CD172a antibody (Serotec, Oxford, UK) and Rat Anti-Mouse IgG1 
Microbeads (Miltenyi Biotec, Auburn, CA) and positively selected using MACS. The 
purity of CD172a+ expression was consistently >95%. CD172a+ cells were rested 
overnight and then used in the assays. This procedure is slightly modified from 
Summerfield et al. (2003), in which PBMC were rested overnight and the non-adherent 
cells were depleted of CD3, CD8 and CD45RA, and then sorted for CD172a.  
 
To isolate T cells, the CD172a negative population from the BDC population was 
positively sorted for CD4+ and CD8+ cells by labeling the cells with a mouse IgG2b anti-
CD4 (Serotec, Oxford, UK) and a mouse IgG2a anti-CD8 antibody (Serotec, Oxford, 
UK) followed by incubation with Rat Anti-Mouse IgG1 Microbeads (MACS, Miltenyi 
Biotec, Auburn, CA). 
 
Cell stimulation 
 
For stimulation with LPS, day 6 MoDCs and day 1 BDCs were cultured at 1x106 cells/ml 
and stimulated with 100 ng/ml of LPS (E. coli O55:B5, Cambrex Bioscience, 
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Walkersville, MD) for 6 hours for gene expression studies or for 24 hours for ELISA 
(unless otherwise stated) and flow cytometry. 
 
Morphology 
 
To evaluate morphology, 1x105 cells in medium were centrifuged at 150g onto glass 
slides for 4 minutes, incubated with methanol for 5 minutes, air-dried and Giemsa 
(Sigma, Saint Louis, MO) stained for 15-60 minutes. Cells were then washed with 
deionised water, air dried and fixed for morphological examination by microscopy.  
 
Antibodies for phenotyping 
The following anti-porcine antibodies were used for defining the cell types: CD172a 
(BL1H7), CD1 (76-7-4), CD3 (PPT3), CD4 (74-12-4), CD8 (PT36B), CD14 (MIL-2), 
CD16 (MCA1971), CD21 (BB6-11C9.6), MHCII (K274.3G8), MHCI (SLA-I) and 
human CD80/86 or CD152 (CD80/86) (4 501-020, Ancell, Bayport, MN). All of the 
antibodies were obtained from Serotec (Oxford, UK) unless otherwise mentioned. FITC 
anti-mouse immunoglobulins IgG1, IgG2a and IgG2b (Southern Biotech, Birmingham, 
AL) were used for detection by flow cytometry. 
 
Flow Cytometry 
 
Immunofluorescence staining was performed by incubating 1x106 cells for 20 minutes at 
4°C with each antibody. Cells were washed three times with cold PBS (1X) (pH 7.2) 
(Gibco, Grand Island, NY) containing sodium azide (0.03%) and gelatin (0.02%) and 
incubated with FITC- conjugated secondary antibody for 20 minutes at 4°C, washed three 
times and fixed with paraformaldehyde (2%). Ten thousand events were collected and 
analyzed by flow cytometry (FACScalibur™, CELLQuest™ software; Becton 
Dickinson, BD Biosciences, Mountain View, CA). 
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Endocytosis by MoDCs and BDCs 
 
To evaluate endocytosis, 2x105 MoDCs or BDCs were incubated with 200 µl of FITC-
dextran (1 mg/ml) (Sigma, Saint Louis, MO) or DQ™ Red BSA (1 mg/ml) (Invitrogen, 
Carlsbad, CA) for 1 hour at either 0° or 37°C [67]. Cells were washed three times with 
cold PBS and centrifuged at 350g for 5 minutes. The uptake of the labeled particles was 
visualized by confocal microscopy and quantified by flow cytometry using 10,000 
cells/event. Since endocytosis is inhibited at 0°C, cells incubated at this temperature 
served as controls for non-specific fluorescence.  
 
Lymphocyte proliferation assay 
 
Pigs were vaccinated at 4 weeks of age with 10 µg of genetically detoxified pertussis 
toxoid (PTd) in 30% emulsigen (MPV Laboratories, Ohama, NE), and boosted every 2 
weeks for a total of 3 vaccinations. Blood was collected from these pigs to isolate 
MoDCs, BDCs, and T cells.  
 
Once generated, MoDCs and BDCs were respectively pulsed with PTd (1 µg/ml in a total 
of 1ml) or OVA (100 µg/ml in a total of 1 ml) for 3 hours and washed three times. 3x104 
MoDCs or BDCs were co-cultured in 200 µl of culture medium with a total of 3x105 
MACS purified CD4 and CD8 autologous T cells for 72 hours in 96-well U-bottom plates 
(Corning, Corning, NY). During the last 8 hours of culture 1 µCi of [3H]thymidine 
(Amersham Pharmacia Biotech, Baie de Urfe, PQ) was added and proliferative responses 
were determined using standard liquid scintillation counting. Results are expressed as a 
stimulation index (SI) and were analyzed by  Mann-Whitney tests.  
 
RT-qPCR assay for mRNA expression 
 
To evaluate differential mRNA expression, 1x106 MoDCs or BDCs were lysed in 
TRIZOL (Invitrogen, Carlsbad, CA) and stored at -80C until further processing. For 
RNA extraction, 200 µl of chloroform was added per 1 ml of TRIZOL. The sample was 
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incubated at room temperature for 3 minutes and centrifuged at 12000g for 10 minutes at 
4°C. The aqueous phase was collected and 500 µl of isopropanol was added. The sample 
was incubated for 5 minutes at room temperature and then applied to a mini-column 
(Qiagen RNeasy®, Mississauga, ON) and centrifuged for 15 seconds at 8000g. The 
sample was washed as per the manufacturer’s instructions and DNase I treatment was 
performed. The optical density at 260 nm (OD260) was used to quantify RNA and the 
ratio of OD260/280 was used to determine purity. cDNA was generated and RT-PCR was 
performed using the SuperScript™ III Platinum® Two-Step qRT-PCR Kit as per the 
manufacturers recommendations (Invitrogen, Carlsbad, CA). Refer to Table 3-1. for a list 
of primers that were used for mRNA quantification. Samples were analyzed using a Bio-
Rad iCycler iQ (Bio-Rad, Hercules, CA). Changes in gene expression were determined 
by calculating the Δ cycle threshold (Ct) [171] by subtracting the Ct for ribosomal protein 
L19 (RPL19) (housekeeping gene) from the Ct of the gene of interest for each sample. 
The  Δ Ct of the control was subtracted from the corresponding treated sample giving rise 
to the ΔΔCt. The fold change was derived from the equation 2–[ΔΔ]Ct. In order to confirm 
that the housekeeping gene ribosomal protein L19 is stably expressed in MoDCs and 
BDCs, a comparison was performed using either glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) or RPL19 as the housekeeping gene. Similar trends in fold 
change were observed. cDNA was diluted to generate a standard curve whose correlation 
coefficient was >0.99. The efficiency of qPCR was determined from the slope using the 
equation (10[-1/M]-1) x100 and ranged between 90 and 110%. 
 
Enzyme-linked immunosorbent assay (ELISA) for cytokines 
 
To evaluate changes in cytokine secretion, 1x106 MoDCs or BDCs were incubated in 1 
ml of culture medium for 24 hours in 6 well plates (Corning, Corning, NY) and culture 
supernatants were collected. Concentrations of IL-6, IL-8 and IL-10 were assayed using 
commercial kits as per the manufacturer’s instructions (R&D Systems, Minneapolis, 
MN). ELISA for IFN-α, TNF-α and IL-12 were performed as previously described 
[172].  
 
 32 
Statistical analysis 
 
Statistical analysis was performed by non-parametric Mann-Whitney t-tests (p-value < 
0.05) using the statistical software program GraphPad Prism 5.   
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3.4 Results 
 
Monocyte-derived DC generation and blood DC isolation 
 
In this study, 800 ml of EDTA blood yielded approximately 2x109 PBMC. Following 
CD14+ selection, an average of 2x108 cells were cultured in the presence of IL-4 and 
GM-CSF to generate MoDCs. On day 6, approximately 2x107 MoDCs were harvested 
and cultured for use. The CD14- population was positively selected for cells expressing 
CD172a which equates to our BDC (CD14-CD172a+) population. Approximately 3x107 
BDCs were therefore isolated and rested overnight. In contrast to other studies [96], our 
protocol resulted in lower numbers of MoDCs compared to BDCs from an equal amount 
of blood [96].  
 
 Phenotypic characterization of porcine DCs  
 
DC morphology is characterized by a large cytoplasmic/nuclear ratio and possession of 
dendrites which increase the surface area available to sample and take up antigen. In this 
study, the morphology of Giemsa-stained MoDCs (Figure 3-1a) and BDCs (Figure 3-1b) 
were compared to each other. Both DC populations displayed a typical DC morphology, 
characterized by an irregular cell border with a large cytoplasmic cell mass. Expression 
of cell surface markers CD172a, MHCII, CD16, CD1, CD80/86 and CD14 was assessed 
by flow cytometry in six day-old MoDCs and BDCs (3-2). Both MoDCs and BDCs 
expressed all of these markers, however, relative to the MoDCs, BDCs showed similar 
expression of CD172a and MHCII, higher expression of CD16 and lower expression of 
CD80/86 and CD1. CD14 was absent from the BDC population as indicated in the cell 
isolation procedure. 
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Endocytosis by MoDCs and BDCs  
 
Central to DC functions is their ability to take up antigen. In order to directly compare the 
endocytic activity of MoDCs and BDCs, we examined their uptake of FITC-dextran over 
time from day 0-7. The ability of MoDCs to uptake FITC-dextran increased from 29 ± 
30% (mean ± SD) on day 1 to 58 ± 24% on day 4 and 57 ± 27% on day 6. In contrast, 16 
± 18 % of BDCs on day 1 were endocytically active following their isolation from blood.  
Laser confocal microscopy confirmed uptake of particles of FITC-dextran in both 
MoDCs (Figure 3-2a) and BDCs (Figure 3-2b). DQ Red BSA, which only fluoresces 
when endocytosed, was also examined in MoDCs alone (Figure 3-2c). Taken together, 
these results show that BDCs were consistently less endocytic than MoDCs. 
 
Functional characterization of DC maturation following stimulation with LPS 
 
In general, as DCs mature, the expression of co-stimulatory molecules such as CD80 or 
CD86 increases giving DCs the potential to activate T cells. Furthermore, upregulation of 
the chemokine receptor CCR7 allows DCs to migrate to the lymph node where they 
encounter lymphocytes [168]. In order to compare the expression of co-stimulatory 
molecules and CCR7 within each DC population, MoDCs and BDCs were stimulated 
with LPS (100 ng/ml) for 24 hours. Flow cytometric analysis showed that CD80/86 
expression increased from 43% to 65% in MoDCs (Figure 3-3a; p<0.05), and from 14% 
to 45 % in BDCs (Figure 3-3b; p<0.05) as determined by flow cytometry. Within 6-hours 
stimulation with LPS, CCR7 gene expression increased by 2.9 ± 0.6 fold in BDCs 
(Figure 3-4) and 2.1 ± 0.6 fold in MoDCs (Figure 3-4). In summary, in response to 
stimulation with LPS both MoDCs and BDCs demonstrated characteristics of mature 
DCs in terms of co-stimulatory molecule cell surface expression and CCR7 gene 
expression.  
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Chemokine and cytokine production by DCs  
 
At sites of injury, DCs release chemokines that are involved in recruiting innate and 
adaptive immune cells. The ability of DCs to produce chemokines was examined 
following a 6-hour stimulation with LPS. Over 4-fold up-regulation was observed in 
CCL-4, CCL-20 and CXCL2 gene expression in both MoDCs and BDCs (3-4) with the 
up-regulation observed to be numerically higher in BDCs for all of the genes examined. 
In BDCs, CCL-2 was upregulated  
 
In LNs, DCs interact with T cells by delivering different types of signals including 
cytokines. The expression of cytokines in MoDCs and BDCs was compared by RT-qPCR 
following a 6-hour stimulation with LPS. No changes were observed in IFN-α and IFN-γ, 
whilst a greater than 3-fold up-regulation was observed in IL-6, IL-8 and TNF-α in both 
MoDCs and BDCs (Figure 3-6). Greater than 2-fold induction of IL-12 expression was 
observed in BDCs while no change was observed in MoDCs. 
 
Cytokine secretion was examined by ELISA following a 24-hour stimulation with LPS. 
Both MoDCs and BDCs showed an increase in IL-6, IL-8 and TNF-α production with no 
changes in IL-10, IFN-γ and IFN-α in both MoDCs and BDCs. Increased IL-12 
concentrations were observed in BDCs (Table 3). Thus, there was a high correlation 
between the results obtained from RT-qPCR and ELISA.  
 
Basal concentrations of IL-6, IL-8 and TNF-α were higher in MoDCs.  Interestingly, 
when MoDCs and BDCs were stimulated with LPS, the fold increase but not the absolute 
concentrations, was higher in BDCs than MoDCs. The same trend was observed for 
changes in chemokine expression.  
 
Stimulation of both naïve and primed T cells in an autologous proliferation assay 
 
DCs as key antigen presenting cells are able to increase T cell proliferation. We 
compared the ability of MoDCs and BDCs to increase proliferation of autologous naïve T 
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cells compared to primed T cells. Overall, PTd or OVA-stimulated MoDCs and BDCs 
co-cultured at a ratio of 1 DC to 10 T cells, showed an induction of T cell proliferation 
(Figure 3-7). However, the stimulation index was higher in PTd compared to OVA-
stimulated DCs, reflecting the difference between primed and naïve T cells. MoDCs and 
BDCs stimulated antigen-specific T cell proliferation in primed cells to the same extent. 
In contrast, MoDCs were more potent to stimulate naïve autologous T cells when pulsed 
with OVA. Thus, both MoDCs and BDCs differed in their ability to stimulate naïve T 
cell proliferation but not in their ability to stimulate proliferation of primed T cells. 
Primer sequences 
 P r i m e r  S e q u e n c e s  ( 5 ’ - 3 ’ )   
 S e n s e  A n t i - s e n s e  A c c e s s i o n  n u m b e r  
CCR7 CCCTTCCCTTCTGGGCATAC CGGTCGATGCTGATGCAGAG AB116555 
IFN-α CCACCTCAGCCAGGACAGAAGC GGTCACAGCCCAGAGAGCAGATG NM_214393.1 
IFN-γ CGAAAAGCTGATTAAAATTCCGGTA TCTTAGGTTAGATCTTGGTGACAGA NM_213948.1 
IL-12(p40)  GAAATTCAGTGTCAAAAGCAGCAG TCCACTCTGTACTTCTTATACTCCC NM_214013 
IL-6 ACCCAGCTATGAACTCCCTCTC GCATCACCTTTGGCATCT TCTTC NM_214399.1 
IL-8 AGAAGCAACAACAACAGCAGTAACAAC CCAGCACAGGAATGAGGCATAGATG AB057440.1 
TNF-α CCCTTCCACCAACGTTTTCCT TGATGGCAGAGAGGAGGTTG EU682384 
CCL-2 GCGGCTGATGAGCTACAGAAG CCCGCGATGGTCTTGAAG NM_214214 
CCL-4 CCTCTCCCTCCTGGTCCTG GGCTGCTGGTCTCATAGTAATC EF107667.1 
CCL-20 TGCTCCTGGCTGCTTTGATGTC TCATTGGCGAGCTGCTGTGTG AJ577084.1 
CXCL2 GCTGCTCCTGCTTCTAGTG ACTTCCTGACCATTCTTGAGAG NM_001001861.1 
RPL19 AACTCCCGTCAGCAGATCC AGTACCCTTCCGCTTACCG AF435591 
GAPDH CTCAACGGGAAGCTCACTGG TGATCTCATCATACTTGGCAGG DQ845173 
Table 3-1 Primer sequences for Real-time PCR analysis of changes in gene 
expression. 
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Figure 3-1 Giemsa stained pig monocyte-derived dendritic cells (MoDCs) and blood 
dendritic cells (BDCs).  
Cell morphology of MoDCs at day 6 (a) and BDCs at day 1 (b) was examined by Giemsa 
staining of cytopsins. Magnification 1000x. 
 
  
(a) (b) 
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Cell surface 
markers 
Monocyte-derived dendritic cells 
(MoDCs)  
Isolated blood dendritic 
cells 
(BDCs)  
CD172a 92 ± 3 % 96 ± 5 % 
MHCII 95 ± 2 % 94 ± 10 % 
CD16 85 ± 8% 92 ± 9 % 
CD1 61 ± 10 % 17 ± 12% 
CD80/86 43 ±10% 14 ± 7 % 
CD14 81 ± 7 % n.d.a 
 
 a n.d. The isotype of the anti-CD14 antibody was the same as that of the anti-CD172a antibody 
used to isolate the BDCs and therefore the % of CD14 expressing cells in the BDC population could not be 
determined.    
 
Table 3-2 Surface phenotype of MoDCs at day 6 and BDCs at day 1 analyzed by 
flow cytometry.  
Data shown are the mean percentage ± SD of positive cells. Data for the MoDCs are 
representative of 6 pigs and data for the BDCs are representative of 4 pigs from a 
different litter. 
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Figure 3-2 Endocytic activity of monocyte-derived dendritic cells (MoDCs) and 
blood dendritic cells (BDCs) by laser confocal microscopy. 
 MoDCs at day 3 were incubated with DQ Red BSA (a) or FITC-dextran (b). DQ Red 
BSA fluoresces following uptake. BDCs were examined for their ability to take up FITC-
dextran (c). Images for the MoDCs are representative of 6 pigs and for the BDCs are 
representative of 4 pigs. Magnification 400x. 
(a) (b) 
(c) 
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Figure 3-3 The effect of LPS stimulation on CD80/86 cell surface expression in 
monocyte-derived dendritic cells (MoDCs) (n=5 animals) and blood dendritic cells 
(BDCs) (n=6 animals).  
MoDCs at day 6 (a) and BDCs (b) were isolated from blood mononuclear cells (BMCs) 
and rested for 4 hours before being cultured with LPS (100 ng/ml) for 24 hours. The 
expression of CD80/86 was determined by flow cytometry using the CD80/86 antibody 
to examine DCs stimulated with LPS compared to DCs in medium. Results are expressed 
as the median of the percentages of positive cells ± range (p<0.05) versus the control.  
 
(a.) MoDCs 
(b.) BDCs 
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Figure 3-4 The effect of LPS stimulation on CCR7 expression in monocyte-derived 
dendritic cells (MoDCs) (n=4 animals) and blood dendritic cells (BDCs) (n=4 
animals).  
MoDCs at day 6 and BDCs were isolated from blood mononuclear cells (BMCs) and 
rested overnight before being cultured with LPS (100 ng/ml) for 6 hours. Samples were 
assessed for changes in gene expression of CCR7 by RT-qPCR using ribosomal protein 
L19 as the housekeeping gene. Results are shown as the median of the fold changes ± 
range relative to the control. 
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Figure 3-5 Changes in gene expression of CCL-2, CCL-4, CCL-20 and CXCL2 in 
monocyte-derived dendritic cells (MoDCs) and blood dendritic cells (BDCs) 
following a 6-hour stimulation with LPS.  
MoDCs at day 6 and BDCs  at day 1 were cultured with LPS (100 ng/ml). Samples were 
assessed for changes in gene expression by RT-qPCR using ribosomal protein L19 as the 
housekeeping gene. Results are shown as the median fold change ± range relative to the 
control (n=4 animals). 
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Figure 3-6. Changes in gene expression of IL-6, IL-8 and TNF-α  in monocyte-
derived dendritic cells (MoDCs) and of IL-6, IL-8 IL-12 and TNF-α  in blood 
dendritic cells (BDCs) following a 6-hour stimulation with LPS.  
MoDCs at day 6 and BDCs at day 1 were cultured for 6 hours with LPS (100 ng/ml). 
Samples were assessed for changes in gene expression by RT-qPCR using ribosomal 
protein L19 as the housekeeping gene. Results are shown as the median fold change ± 
range relative to the control (n=4 animals).  
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a  at 16 hours of culture p= 0.057 
b at 8 hours of culture p= 0.057 
n.d., Not detectable 
   
Table 3-3 Changes in protein IL-6, IL-8, TNF-α , and IL-12 concentrations following 
24-hour LPS stimulation.  
MoDCs at day 5 and BDCs at day 1 were either cultured with LPS (100 ng/ml) or were 
unstimulated (Control) for 24 hours (n= 4 animals). Supernatants were assayed by ELISA 
for protein detection. Results are expressed as mean (pg/ml) ± SD and analyzed by a 
Mann-Whitney test.  
  
 MoDCs 
(pg/ml) 
BDCs 
(pg/ml) 
 Control LPS P-value Control LPS P-value 
IL-6 426 ± 186  940 ± 277  0.2 n.d. 229 ± 260  0.03 
IL-8 5261 ±5756  10586 ±1673  0.2 a 1114 ± 496  9557 ± 3925  0.03 
TNF-α  402 ± 138 1277 ± 896 0.057b 277 ± 74 833 ± 511 0.057 
IL-12 n.d. n.d.  2000 ± 1000 8000 ± 3000 0.03 
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Figure 3-7 Stimulation of autologous T cells using antigen pulsed monocyte-derived 
dendritic cells (MoDCs) and blood dendritic cells (BDCs).  
MoDCs at day 4 of culture and BDCs rested overnight were pulsed with pertussis toxoid 
(PTd) (1µg/ml) or OVA (100 µg/ml) for 3 hours then incubated with autologous T cells 
from PTd vaccinated animals from a total of 4 pigs for 72 hours at a ratio of 1 DC to 10 T 
cells. Results are shown as the median of the stimulation index± range and calculated as 
pulsed DCs/ non-pulsed DCs. ap<0.05 OVA-MoDC versus OVA-BDC, bp<0.05 OVA-
MoDC versus PTd-MoDC, cp<0.05 OVA-BDC vs PTd-BDC.   
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3.5 Discussion 
 
In the present study, we isolated porcine BDCs and MoDCs and demonstrated that these 
DC populations differ in their endocytic activity and their response to LPS with regards 
to cytokine and chemokine gene expression. Also, when we compared BDCs to MoDCs 
in autologous proliferation assays using T cells from vaccinated and non-vaccinated 
animals, no difference was observed in their ability to present antigen to primed T cells.  
 
MoDCs were generated from MACS isolated monocytes that were cultured in the 
presence of IL-4 and GM-CSF. This isolation technique contrasts other studies which 
have used overnight adherence or CD172a MACS sorting [66-68, 94, 173], but is similar 
to the methods used in more recent studies for generating porcine MoDCs [95, 164] and 
is the same as that used to generate human [174] and mouse MoDCs [175]. BDCs, on the 
other hand, were generated using a slightly modified protocol previously described by 
Summerfield et al. (2003) [65]. Previously, antigen uptake by BDCs was examined by 
flow cytometric analysis of PBMC [65] and not on the isolated BDCs themselves. 
However, in contrast to this study we examined isolated BDCs using the negative 
fraction following CD14 MACS sorting of PBMC. Subsequently, positive selection of 
CD172a cells allowed us to study isolated BDCs. The CD14+ fraction was used to 
generate MoDCs. Advantages of our isolation procedure include the isolation of a pure 
population of monocytes that is generated on the same day without requiring overnight 
adherence. For BDCs, we obtained a purity of 96% with a higher yield compared to a 
purity of 60-75% of CD172a cells described by others [65]. Furthermore, this population 
contained only very few or no contaminating monocytes in contrast to that described by 
others [93]. Consistent with what has been described [73], as a total percentage of 
PBMC, CD14-CD172a+ cells constituted approximately 2% of the population [73].  
 
Using these isolation methods, we observed that unstimulated MoDCs displayed a more 
mature phenotype compared to unstimulated BDCs. While a similar percentage of 
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MoDCs and BDCs expressed CD172a and MHCII, BDCs showed a slightly higher 
expression of CD16 and a lower expression of CD80/86 and CD1. The more mature 
phenotype of MoDCs may be attributed to culturing artifacts such as disturbing cell-cell 
contact [176], the presence of serum in the culture medium [177] and the effects of IL-4 
[178] and GM-CSF [179]. Compared to MoDCs, BDCs were only cultured overnight 
therefore culturing artifacts were expected to be minimal. This is supported by Fearnely 
et al. (1997), who demonstrated that when human BDCs were cultured for several days 
they displayed a more mature phenotype similar to that of MoDCs [177]. 
 
Despite the more mature phenotype of MoDCs, however, BDCs displayed lower 
endocytic activity than MoDCs. Regarding IL-6, IL-8, and TNF-α cytokine production, 
the basal production  of cytokines by MoDCs was over 2-fold higher than that of BDCs. 
However, when MoDCs and BDCs were stimulated with LPS, a higher fold change of 
both cytokine and chemokine expression was observed in BDCs suggesting that BDCs 
were more responsive to LPS stimulation compared to MoDCs. Reasons for these 
differences remain to be examined but may be due to differences in cell signaling 
pathways. For example, BDCs do not express CD14 and therefore are unable to respond 
to LPS via a CD14 dependent-signaling pathway. However, the presence of CD14 
independent signaling in porcine DCs has been previously demonstrated [66] and it is 
known that BDCs do respond to LPS stimulation [180] suggesting that BDCs signal via 
a CD14 independent pathway. Further studies are required to understand the detailed 
mechanisms of LPS signaling in BDCs. 
 
Another observation in this study was that LPS-stimulated MoDCs did not produce IL-
12 whereas BDCs did. This is in contrast to previous observation made by Wilkie et al. 
(2005), who found an increase in IL-12p35 mRNA expression in porcine MoDCs 
following stimulation with LPS. Possible reasons for the observed differences include 
cell isolation by plastic adherence, collection of both adherent and non-adherent day 8 
MoDCs, and lastly a concentration of 10 g/ml of LPS for cell stimulation [94]. However, 
in a more recent study in which MoDCs were obtained by plastic adherence, no IL-
12p40 was detected at the protein level following LPS stimulation at a concentration of 1 
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µg/ml [70]. Thus, there is a discrepancy in the literature regarding the ability of porcine 
MoDCs to produce IL-12 in response to stimulation with LPS and more studies are 
required to fully address these observations. For human monocytes, it was demonstrated 
that MoDCs generated from plastic adherence as compared to CD14 bead isolation, 
produced IL-12p70 [181].  
  
We then determined if the phenotypic and endocytic differences between MoDCs and 
BDCs translated into differences in their ability to induce T cell proliferation using 
autologous T cells. To this end pigs were vaccinated with PTd and isolated cells were re-
stimulated in vitro with two different antigens to be able to compare naïve versus primed 
T cells. When the antigen OVA was used to address stimulation of naïve T cells, BDCs 
induced less proliferation compared to MoDCs. However, when PTd was used for 
stimulation of autologous primed T cells, the extent of proliferation was the same 
between MoDCs and BDCs. Since the activation threshold for naïve T cells is higher due 
to an uncoupled signaling machinery [8, 182] we assume that T cells to which OVA was 
presented were naïve and required more signals that BDCs were less able to provide. This 
could be attributed to their lower endocytic ability. With respects to primed T cells, 
however, BDCs did not differ from MoDCs in their ability to increase T cell 
proliferation, which may be a result of a lesser need for additional stimulation. It has also 
been demonstrated that the pDC population within the BDCs is better able to induce 
proliferation in antigen-experienced T cells compared to naïve T cells [40]. Therefore, 
porcine BDCs differ from MoDCs in their ability to stimulate naïve T cell proliferation 
but not primed T cell proliferation. This is in contrast to observations made in mice [40] 
and provides further evidence that BDCs indeed are able to increase T cell activation in 
both naïve and memory T cells [8].  
 
In summary, in the present study we compared two populations of DCs in their 
phenotype, endocytic ability, response to LPS stimulation and ability to induce antigen-
specific immune response in pigs. Our findings suggest that BDCs, which contain both 
pDCs and cDCs, are less endocytically active than MoDCs and have a lower expression 
of CD80/86. They also have lower basal cytokine protein concentrations but in response 
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to stimulation with LPS, there is a higher fold increase in response despite the absolute 
amounts being lower in MoDCs. Furthermore, this is the first time in the pig that 
chemokines have been examined in response to LPS in both MoDCs and BDCs and 
allows for a more comprehensive view of DC behavior. Lastly, both MoDCs and BDCs 
are able to induce T cell proliferation which is in contrast to observations made in mice 
[40], and which will further our understanding of these important cells and their role in 
driving antigen-specific immune responses. 
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3.6 Conclusion 
 
Porcine DC subsets, MoDCs and BDCs were successfully generated and characterized. 
BDCs compared to MoDCs are less endocytically active, have a lower expression of 
CD80/86 and have lower basal cytokine protein concentrations. In response to 
stimulation with LPS there is a higher fold increase in the response of BDCs compared to 
MoDCs. To further characterize these DC subsets in Chapter 4 we examined the stability 
of expression of reference gene expression. 
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Chapter 4 STABILITY OF EXPRESSION OF REFERENCE GENES IN 
PORCINE PERIPHERAL BLOOD MONONUCLEAR AND DENDRITIC 
CELLS (as published in Facci et al., 2011;Vet. Immuno. Immunopath.) 
 
Facci, M. R., Auray, G., Meurens, F., Buchanan, R., van Kessel, J. and Gerdts, V. 
Vet Immunol Immunopathol 141(1-2): 11-15. 
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4.1 Abstract 
 
 Real-time quantitative PCR (RT-qPCR) is a critical tool used to evaluate changes 
in gene expression. The precision of this tool is reliant upon the selection of reference 
genes whose expression remains unaltered in culture conditions and following 
stimulation. Stably expressed reference genes are used to normalize data so observed 
changes in expression are not due to artifacts but rather reflect physiological changes. In 
this study, we examined the expression stability of the porcine genes glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), succinate dehydrogenase complex subunit A 
(SDHA), eukaryotic elongation factor 1 gamma-like protein (eEF1), ribosomal protein 
L19 (RPL19), beta-actin (ACTB) and ATP synthase mitochondrial F0 complex 
(ATP5G1) in peripheral blood mononuclear cells (PBMC), monocytes, monocyte-derived 
dendritic cells (MoDCs), blood-derived dendritic cells (BDCs) and T cells with or 
without stimulation with LPS. An M value was used as a measure of gene stability as 
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determined using geNORM software. Recommendations for the use of reference genes 
include using GAPDH and B-actin in PBMC: RPL19 and SDHA and T cells; RPL19 and 
B-actin in monocytes; RPL-19 and SDHA in BDCs: and RPL-19 and ATP5GA in 
MoDCs. 
 
4.2 Introduction 
 
Real-time quantitative PCR (RT-qPCR) is widely used to examine changes in 
gene expression. Some variables encountered in using this technique include differences 
in starting material, enzymatic efficiency and transcriptional activity [183]. A means of 
controlling these variables is the use of reference genes. Ideally reference genes should be 
stably expressed and not change in response to stimulation with any immunostimulator. 
In a study by Vandesompele et al. (2002)[183], 10 reference genes were examined in 13 
different human tissues. Subsequently, a method for determining the stability of 
expression of reference genes was devised and is the basis of the program geNORM. This 
program calculates a gene stability measure known as M, thereby allowing for the 
ranking of reference genes. The lower the M value, the more stable is the expression of 
the gene. Furthermore, a stability of M < 0.5 is desirable for homogenous samples [184]. 
The pig is growing in importance as a large animal model for examining and 
monitoring human diseases such as influenza. As part of this process, RT-qPCR is being 
used as a technique for examining changes in gene expression. Several genes have been 
studied, to assess their potential to serve as reference genes in the pig (Table 4-2). Most 
of these studies were performed in peripheral blood mononuclear cells (PBMC), and 
none have examined monocytes, monocyte-derived dendritic cells (MoDCs), blood-
derived dendritic cells (BDCs) or T cells. However, these latter cell types are frequently 
being used to determine effector immune responses including cytokine and chemokine 
expression. For this reason we chose to examine the expression levels of 6 reference 
genes namely glyceraldehyde 3-phosphate dehydrogenase (GAPDH), succinate 
dehydrogenase complex subunit A (SDHA), eukaryotic elongation factor 1 gamma-like 
protein (eEF1), ribosomal protein L19 (RPL19), beta-actin (ACTB) and ATP synthase 
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mitochondrial F0 complex (ATP5G1) in these cell types using geNORM to determine M 
values [183]. These reference genes were chosen from different functional classes (Table 
4-1). In this study, a 6-hour stimulation with lipopolysaccharide (LPS) was used to 
determine if the levels of expression were influenced by stimulation with LPS. At this 
time expression of various cytokines or chemokines has already peaked [62]. The 
Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines were followed to process samples and perform experiments  [184].  
 
4.3 Materials and Methods 
 
Experimental design and animals 
Eight week old Dutch Landrace pigs purchased from Saskatoon Prairie Swine 
Centre, University of Saskatchewan were used in this study.  Studies were carried out in 
accordance with the ethical guidelines of the University of Saskatchewan and the 
Canadian Council for Animal Care. 
PBMC, monocytes, T cells and BDCs were isolated. Monocytes were used to 
generate MoDCs. The stability of expression of the reference genes RPL19, ACTB, 
eEF1, SDHA, ATP5GA and GAPDH was examined in these respective cells, either 
cultured in medium alone for 6 hours (control cells) or following a 6-hour stimulation 
with 1 µg/ml LPS (stimulated cells) (E. coli O55:B5, Cambrex Bioscience, Walkersville, 
MD). Isolated cells at a concentration of 1x106 cells/ml were rested overnight prior to 
stimulation with LPS. Subsequently, cells were lysed in TRIzol (Invitrogen, Carlsbad, 
CA) and stored at -80°C until further processing. Four animals per group were used in all 
of the stimulation assays with the exception of PBMC for which only three animals were 
used for the stimulation group. Studies were performed as per the ethical guidelines of the 
University of Saskatchewan and the Canadian Council for Animal Care.    
 
Cell isolation and generation 
Approximately 1 L of blood was collected by cardiac puncture from each pig 
using EDTA-coated syringes and blood mononuclear cells were isolated using a 60% 
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Ficoll-Paque™ Plus gradient (GE Healthcare, Uppsala, Sweden). PBMC were plated at 
1x106 cells/ml in 24-well plates and rested overnight before stimulation. From the 
remaining PBMC, monocytes were isolated using human anti-CD14 magnetic beads 
(MACS®; Miltenyi Biotec, Auburn, CA) [95, 164]. The cross-reactivity of this antibody 
was confirmed by testing it against an anti-porcine CD14 (MIL-2; Serotec, Oxford, UK) 
homologue. Flow cytometry was used to verify the purity of the separated cells. 
Monocytes were stimulated following an overnight rest. 
To generate MoDCs, monocytes were cultured in RPMI 1640 (Gibco, Grand 
Island, NY) supplemented with 10% FBS, 0.5 mM β-Mercaptoethanol, 10% 
Antibiotic/Antimycotic (Gibco, Grand Island, NY), 10% HEPES (Gibco, Grand Island, 
NY), 10% MEM Non Essential Amino Acids (Gibco, Grand Island, NY), 100 ng/ml of 
recombinant porcine (rp) IL-4 (Biosource, Camarillo, CA) and 20 ng/ml of rpGM-CSF 
(Biosource, Camarillo, CA) for 6 days at 37°C with 5% carbon dioxide. Half of the 
medium was changed every 3 days. MoDCs were used at day 6, at which time non-
adherent MoDCs [66, 81, 170] were washed, counted and stimulated.  
To isolate BDCs, which are described to be CD172a+CD14- [65, 81], CD14- cells 
were labeled with a mouse IgG1 anti-CD172a antibody (Serotec, Oxford, UK) and Rat 
Anti-Mouse IgG1 Microbeads (Miltenyi Biotec, Auburn, CA) and positively selected 
using MACS. The purity of CD172a+ expression was consistently >95%. CD172a+ cells 
were rested overnight and then stimulated with LPS. 
To isolate T cells, the CD172a-negative fraction was positively sorted for CD4+ 
and CD8+ cells by labeling the cells with anti-CD4 (VMRD, Inc, Pullmann, WA) and 
anti-CD8 antibody (VMRD) followed by incubation with Rat Anti-Mouse IgG1 
Microbeads (MACS, Miltenyi Biotec, Auburn, CA). 
 
RT-qPCR assay for mRNA expression 
For RNA extraction, per 1 ml of TRIzol, 200 µl of chloroform was added to 5-10 
x 106  cells. Samples were incubated at room temperature for 3 minutes and centrifuged at 
12000g for 10 minutes at 4°C. The aqueous phase was collected and 500 µl of 
isopropanol was added. The sample was incubated for 5 minutes at room temperature and 
then applied to a mini-column (Qiagen RNeasy®, Mississauga, ON) and centrifuged for 
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15 seconds at 8000g. The sample was washed and DNase I treatment was performed as 
per the manufacturer’s instructions (Qiagen). RNA quantification and purity was 
obtained using an Agilent 2100 Bioanalyzer (Agilent Technologies, Mississauga, ON). 
cDNA was generated from 500 ng of RNA per reaction and RT-qPCR was performed 
using the SuperScript™ III Platinum® Two-Step RT-qPCR Kit as per the manufacturers 
recommendations (Invitrogen, Carlsbad, CA). Each qPCR reaction consisted of 1 µl of 
500 nM of primers, 2 µl of cDNA that had been diluted 2.5X, 9.5 µl of ddH2O, and 12.5 
µl of SYBR Green Supermix UDG for a final volume of 25 µl. Each sample was run in 
duplicate. Table 4.3 shows a list of primers that were used for mRNA quantification. 
Primers not listed in Table 3 were obtained from the geNORM kit and primer sequences 
from this kit are proprietary. The geNorm kit is a commercially available kit comprising 
of reference gene real time PCR assays for various species.  
Samples were analyzed using a Bio-Rad iCycler iQ (Bio-Rad, Hercules, CA) at 
the following conditions: 95° for 3 minutes, 45 cycles each of 15 seconds at 95° 
(denaturation), 30 seconds at 60° (annealing) and 30 seconds at 72° (elongation). Melting 
curves of the products were used to evaluate the specificity of the reaction.  
The quantification cycle (Cq) or cycle threshold values for all of the samples per 
cell type were obtained. Subsequently, the geometric mean of the Cq value is subtracted 
from the individual sample Cq value. The relative quantity (2ΔCq; relative to other 
samples within the same run for the same gene) was then calculated and the file uploaded 
into geNORM to obtain the stability of gene expression or M value. To calculate the M 
value, firstly the ct value for each sample was obtained. Then for each gene the geometric 
average was determined and subtracted from each sample. The relative expression was 
then determined and this value was uploaded into geNORM. geNORM software is 
available at no cost and is accessible from: http://medgen.ugent.be/~jvdesomp/genorm/ 
Using geNORM an M value was computed (in depth calculations are described: 
http://medgen.ugent.be/~jvdesomp/genorm/example_calculations.xls). This M value was 
a measure of gene-stability derived by examining the standard deviation of control 
genes[185]. A cut-off value of 0.5 was used based on and any gene under this cut-off 
value is considered as stably expressed [184]. 
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4.4 Results 
 
The use of proper reference genes for RT-qPCR is important for the relevant 
quantification of genes of interest and takes into account variations in cDNA quantities 
between samples. When selecting reference genes, expression stability is critical and 
should be equally stable in control and stimulated cells. Given the importance of 
reference genes for expression analysis of immune effector functions, we examined 
various cell types including PBMC, T cells, monocytes, MoDCs and BDCs either alone 
or following stimulation with LPS. ACTB, ATP5GA, EF-1, GAPDH , RPL-19 and 
SDHA genes were examined  to determine which genes are suitable candidates to be used 
as reference genes. 
 cDNA dilutions were used to generate a standard curve. For each gene, the 
correlation coefficient of the standard curve was >0.99. A PCR efficiency curve was 
determined from the slope using the equation (10[-1/M]-1) x100 and ranged from 90-110%. 
 
 When control cells were examined alone, the 2 most stably expressed reference 
genes for each cell type were as follows: in PBMC: GAPDH and B-actin (Fig.4-1a); in T 
cells: RPL19 and GAPDH (Fig.4-1b); in monocytes: RPL19 and GAPDH (Fig.4-1c); in 
BDCs: RPL19 and ATP5Ga (Fig.4-1d); and in MoDCs: RPL19 and B-actin (Fig.4-1e). In 
control cells, the only reference gene that had an M value > 0.5 was ATP5GA in 
monocytes, and therefore we recommended against its use.  
  In all of the cells types examined, stimulation with LPS affected the stability of 
the two most stably expressed gene in control cells (Fig. 4-1f-j). These results confirm the 
importance of testing the expression stability of reference genes for each stimulus used.  
When control and stimulated cells were examined together, the most stably 
expressed reference genes (i.e. lowest M values) were as follows: in PBMC: GAPDH = 
B-actin < SDHA <RPL19 <ATP5GA < eEF-1 (Fig. 4-1k); in T cells: RPL19 = SDHA < 
GAPDH < B-actin  < ATP5GA < eEF-1 (Fig. 4-1l); in monocytes: RPL19 = B-actin < 
GAPDH < SDHA < eEF-1 < ATP5GA (1m); in BDCs: SDHA  < RPL19 < GAPDH < B-
actin < ATP5GA < eEF-1 (4-1n);  and in MoDCs, RPL19 = ATP5GA < SDHA < eEF-1 
< GAPDH < B-actin (4-1o). Based on these findings our recommendation for LPS 
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stimulation is to use in PBMC: GAPDH and B-actin; in T cells: RPL19 and SDHA; in 
monocytes: RPL19 and B-actin; in BDCs: RPL-19 and SDHA; and in MoDCs: RPL-19 
and ATP5GA. Of the cell types examined, the reference genes that do not match the 
required stability are eEF-1 BDCs with an M value >0.5 and ATPG5A in monocytes (M 
value =0.498). 
In conclusion, we have demonstrated the stability of expression of the reference 
genes ACTB, GAPDH, RPL-19 and SDHA in porcine cell lines with recommendations 
of which reference genes should be used when LPS is used as a stimulus. These data 
should be beneficial for porcine research teams in validating their RT-qPCR data.  
Table 4-1 Functional classes of reference genes 
 
 
Abbreviation Gene name Function 
ACTB  beta-actin Cytoskeletal protein  
ATP5G1 ATP synthase, mitochondrial F0 
complex 
Subunit of mitochondrial 
ATP synthase 
B2M beta-2-microglobulin Beta-chain of major 
histocompatibility complex 
class I molecules 
eEF-1 eukaryotic elongation factor 1 gamma-
like protein 
Role in protein translation 
GAPDH glyceraldehyde 3-phosphate 
dehydrogenase 
Role in glycolysis and 
gluconeogenesis 
HMBS hydroxymethylbilane synthase Heme synthesis 
HPRT1 hypoxanthine phosphoribosyltransferase 
I 
Purine synthesis 
RPL19 Ribosomal protein L19 Component of ribosomal 
subunit 
RPL4 ribosomal protein L4 Component of ribosomal 
subunit 
SDHA succinate dehydrogenase complex 
subunit A 
Electron transport  
TOP2B  topoisomerase II beta Role in DNA transcription 
and replication 
TPB TATA box binding protein RNA polymerase II 
transcription facots 
YWHAZ tyrosine 3-monooxygenase/tryptophan 
5-monoxygenase activation protein zeta 
polypeptide 
Involved in signal 
transduction 
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Table 4-2 Summary of studies examining porcine reference genes 
 
 
Table 4-3 Reference genes used in this study 
Gene 
symbol 
Accession 
Number 
Amplicon 
length 
Ta 
ACTB geNORM kit 130 60°C 
ATP5G1 geNORM kit 145 60°C 
eEF-1 geNORM kit 75 60°C 
SDHA geNORM kit 88 60°C 
GAPDH DQ845173 170 60°C 
RPL19 AF435591 147 60°C 
Primer sequences were supplied by PrimerDesign Ltd, UK, with the exception of GAPDH and RPL19 whose respective 
sequences(‘5→3’) are: CTTCACGACCATGGAGAAGG; CCAAGCAGTTGGTGGTACAG; and AACTCCCGTCAGCAGATCC; 
AGTACCCTTCCGCTTACCG. 
  
References genes Porcine tissues examined Stimulation Reference 
ACTB, HPRT and 
GAPDH 
Alveolar macrophages, 
spleen cells, bone marrow, 
brain, kidney, lung, Peyer’s 
patches, ileum, mesenteric 
lymph node muscle, large 
intestine and thymus 
Con A or 
PMA 
[186] 
ACTB, cyclophillin, 
GAPDH, and HPRT 
PBMC PMA [187] 
ACTB, HPRT, 
GAPDH, and 
cyclophilin 
PBMC LPS and 
Con A 
[188] 
ACTB, B2M, GAPDH, 
HMBS, HPRT1, 
RPL13A, SDHA, TBP, 
TOP2B  
 and YWHAZ  
Backfat and longissimus 
dorsi muscle 
 No 
stimulation 
[189] 
ACTB, B2, GAPDH, 
HMBS, HPRT1, RPL4, 
SDHA, TPB, and 
YWHAZ  
 
Liver, kidney, thymus, 
brain, lymph nodes, muscle, 
heart, skin, pancreas, bone 
marrow, bladder, lung and 
stomach   
 
No 
Stimulation 
[185] 
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Figure 4-1 Stability of expression of reference genes in porcine PBMC, T cells, 
monoyctes, MoDCs and BDCs.  
Stability of gene expression of eEF-1, ATP5GA, RPL19, SDHA, GAPDH and β-actin 
were examined in (a) PBMC control samples (b) T cells control samples (c) Monocytes 
control samples (d) MoDCs control samples (e) BDCs control samples (f) PBMC treated 
with LPS (g) T cells treated with LPS (h) Monocytes treated with LPS (i) BDCs treated 
with LPS (j) MoDCs treated with LPS   (k) PBMC control and LPS treated samples (l) T 
cells control and LPS treated samples (m) Monocytes control and LPS treated samples 
(n) BDCs control and LPS treated samples (o) MoDCs control and LPS treated samples. 
LPS was used at a concentration of 1 µg/ml with a stimulation time of 6 hours. Samples 
were assessed for changes in gene expression stability by RT-qPCR and then using the 
software geNORM. Results are shown as an M value (n=4 animals for controls and 
treatment group except for the PBMC treatment group in which n=3 animals). M values < 
0.5 indicate stable expression with a lower value being ideal. 
 
4.5 Conclusion 
 
In Chapter four, we describe which genes are stably expressed in porcine MoDC and 
BDC subsets. With the successful generation and characterization of porcine MoDCs and 
BDCs [82, 190], the next objective was to determine the in vitro effects of HDPs on DC 
cytokine production. For this purpose 3 peptides namely HH2 (N-VQLRIRVAVIRA-C),, 
HH17 (N-KIWVRWK-C) and HH18 (N-RLCRIVVIRVCR-C) were initially selected. 
Preliminary experiments examined peptide safety, effects on DC cell surface marker 
expression, maturity and cytokine production. The effects of the HH peptides were 
examined using a low dose of 5 µg/ml and a higher dose of 133 µg/ml. No differences 
were seen in flow cytometry for the percent of cells positive for CD172a, MHCII, CD16, 
MHCI, CTLA, CD1 and CD14 expression as well as for their mean fluorescence 
intensity (Appendix A). Also, no changes were observed in the expression of CD80, 
CD86, CCR7, MHCI and MHC2 by RT-qPCR in MoDCs and BDCs (Appendix A). The 
production of various cytokines was examined in both MoDCs and BDCs with minimal 
changes observed. Given the results obtained by stimulating DCs with HH2, HH17 and 
HH18 at 133 µg/ml it was not possible to detect a clear a Th1 type response (i.e. IL-12 
production as detected by ELISA and confirmed by RT-qPCR).  
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At this stage we postulated that the lack of an effect attributed to the peptides might have 
been attributed to either an inability of our porcine DC populations to be challenged, to 
the nature of the selected HH peptides or to a  need for the peptides to act synergistically 
with TLR ligands. The functionality of the DC populations did not appear to be factor 
contributing to the lack of effect that we were observing. Experiments in our lab 
demonstrated that porcine MoDCs and pDCs could be modulated by various TLR ligands 
including poly I:C (TLR3 ligand), LPS (TLR4 ligand), flagellin (TLR5 ligand), 
Imiquimod (TLR7 ligand), class A (8954) and class C (10103) CpG ODN (TLR9 
ligand)[92]. Results showed that Poly I:C, LPS, flagellin and Imiquimod induced a 
significant increase in the percentage of MoDCs expressing CD80/86 and that Flagellin, 
LPS, poly I:C, and imiquimod but not CpG ODNs induce a significant increase in the 
percentage of BDCs expressing CD80/86. No changes were observed in the expression of 
MHCII. Furthermore some of these ligands were able to increase CCR7 in both MoDCs 
and BDCs as well as influence cytokine production [92]. 
 
In order to determine if the HH peptides selected did not immunomodulate porcine DCs, 
a wider array of natural peptides was selected. This led to subsequent studies (Chapters 5 
and 6) in which a panel of naturally-occurring peptides was examined for their ability to 
influence immune functioning in PBMC. Furthermore, in-house vaccination experiments 
had demonstrated that the peptide IDR-1002 had significant potential as an adjuvant 
[156]. Therefore, we focused on the peptide IDR-1002 and naturally-occurring peptides 
and screened them for their effects in PBMC. The switch in cell type from DCs to PBMC 
was made in order to ensure that more cell types were available to respond to HDPs 
either via cell-cell interactions or via the production of modulatory factors.  
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Chapter 5 CHEMOATTRACTIVE ACTIVITY OF HDPS ON PORCINE 
IMMUNE CELLS (manuscript in preparation) 
 
M. Facci1, G. Auray1, R. Buchanan1, J. van Kessel1, R.E. Uwiera3, L.A. Babiuk3, R.E.W. 
Hancock4 , and V. Gerdts1, 2 
 
1Vaccine & Infectious Disease Organization and 2Department of Veterinary 
Microbiology, University of Saskatchewan, Saskatoon, Canada S7N 5E3 and 3University 
of Alberta, Edmonton, Canada T6G 2J9; 4Centre for Microbial Diseases and Immunity 
Research, Vancouver, BC V6T 1Z4  
 
All authors participated in the design of the experiments and contributed to writing of the 
manuscript. Auray, Buchanan and van Kessel assisted in sample collection. Uwiera 
analyzed slides for the histological examination of cell recruitment. All other data 
presented in this manuscript are the work of the thesis author. 
 
5.1 Abstract 
 
Host defense peptides (HDPs) are potent immunomodulators that can induce cytokine 
and chemokine production, recruit dendritic cells, as well as stimulate and modulate 
antigen-specific T cell responses. In order to detect if selected HDPs have an effect on 
porcine immune cells, we tested the ability of HDPs from various species to recruit 
porcine PBMC both in vitro and in vivo and to induce cytokine and chemokine 
expression in these cells. The HDPs examined included a synthetic innate defense 
regulator (IDR) peptide 1002, the porcine cathelicidins PR39 and Protegrin-1 (PG-1), the 
human cathelicidin LL-37, the bovine cathelicidin Indolicidin and the porcine beta-
defensin  (pBD)-1 and pBD-2. Our results demonstrate that IDR-1002, PG-1, Indolicidin, 
pBD-2, LL-37 enhanced IL-8 production in porcine PBMC, while IL-12 production 
levels were increased by PG-1. The peptides IDR-1002 and LL-37 both were able to 
chemoattract porcine PBMC in vitro however, this effect was not observed following the 
intradermal administration of HDPs in vivo.  
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5.2 Introduction 
 
Host defense peptides (HDPs) are small peptides ranging in size from 5-60 amino acids 
in length. Cationic HDPs can be divided into two main families, namely, defensins and 
cathelicidins based on the respective presence of β-sheets and α-helices [191].  HDPs 
display heterogeneity in their structure, regulation, function, and site of action, and are 
present in both plants and mammals [192]. Also known as antimicrobial peptides, many 
of these cationic peptides are able to bind to the negative charge found on bacterial cells 
walls [193], thereby allowing them to have a wide spectrum of anti-bacterial activity. 
More importantly, HDPs have a number of immunomodulatory functions including 
induction of cytokine and chemokine production, recruitment and activation of important 
immune cells such as dendritic cells, monocytes, neutrophils to name a few [194].  
 
Recruitment occurs either directly or indirectly by inducing chemokine production. Both 
cathelicidins and defensins recruit a wide array of immune cells. For example, hCAP, the 
propeptide of the human cathelicidin LL-37 has been shown to recruit human monocytes 
[135], neutrophils [135-137], dendritic cells (DCs) [136] and T cells [135, 138]. The 
human beta defensins 1-4 were chemotactic for human macrophages [139], mast cells 
[139], immature DCs [140], CD4+/CD45RA+ naive and CD8+, but not CD4+/CD45RO+ 
memory T cells [140, 141]. Human α- and β-defensins were also chemotactic for human 
monocyte-derived DCs [142]. In cattle, bovine β-defensins recruited monocyte-derived 
DCs (MoDCs) [195].	  	  Interestingly, the ability to recruit immune cells is highly conserved 
amongst some HDPs and in fact may work across species. For example, the human 
cathelicidin has been shown to recruit rat mast cells [143] and the mouse cathelicidin 
CRAMP was chemotactic for human monocytes, neutrophils and macrophages [149].  
 
Cell recruitment is an important feature of adjuvants and critical for their ability to 
propagate immune responses. For example, MF59, the adjuvant used in several H1N1 
influenza vaccines, exerts adjuvanticity by recruiting macrophages to the site of antigen 
deposition [196, 197]. Therefore, the ability of HDPs to directly recruit immune cells 
may represent a key strategy for the proposed adjuvant effects of HDPs. In addition, 
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HDPs have been shown to increase chemokine production, which indirectly results in the 
recruitment of immune cells. For example, LL-37 increased IL-8 production in human 
airway smooth muscle cells [198], human epithelial cells [199], murine macrophages 
[199], monocytes [200] and neutrophils [201]. Similar to LL-37, defensins also induced 
similar increases on IL-8 production in lung epithelial cells [202], which subsequently 
can lead to the recruitment of neutrophils and subsequent propagation of immune 
responses. In the present study we assessed the ability of selected HDPs to stimulate 
porcine dendritic cells in vitro and in vivo. The pig is a good research model due to its 
immunophysiological similarities to humans [64]. Results obtained in the pig model are 
often more predictive of outcomes in humans and therefore more relevant in the 
development of novel therapeutics [203]. For example, due to structural similarities with 
human skin and in particular the ratio of the epidermis and the ratio of dermal-epidermal 
thickness [203], we are studying the in vivo recruitment of porcine immune cells into the 
skin following intradermal administration of HDPs.  
  
IDRs have been shown to be effective adjuvants when used in combination with various 
vaccine formulations in pigs [154-156, 204]. However, little is known about the ability of 
HDPs to modulate porcine immune cells, therefore the goal of this study was to examine 
the immunomodulatory functions of HDPs from various species on pig immune cells. 
These functions included the ability to induce cytokine production as well as the 
recruitment of porcine immune cells both in vitro and in vivo. Pigs express a variety of 
HDPs including 13 β-defensins but no α-defensins [113], hepcidin, liver-expressed 
antimicrobial peptide -2, PGRP-S, NK-lysins, proline-rich lactoferricins and mucosal SP-
B to name a few. There are 11 porcine cathelicidins which comprise of the proline-
arginine-rich 39-amino-acid peptide (PR-39), proline-phenylalanine-rich prophenin-1 
(PF-1) and PF-2, cysteine-rich PG 1 (PG-1) to PG-5, and three porcine myeloid 
antimicrobial peptides (PMAP)-23, PMAP-36 and PMAP-37 [113]. The HDPs selected 
in this study include the porcine cathelicidins PG-1 and PR-39 and pBD-1; the innate 
defense regulator (IDR)-1002; the human cathelicidin LL-37 and the bovine cathelicidin 
indolicidin. Of these peptides, only PR-39 has been examined and demonstrated to recruit 
porcine neutrophils in vitro [205]. Our goal was therefore to characterize the effects of 
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these HDPs and examine if in vitro production of IL-8 and recruitment translates into in 
vivo recruitment.  
 
5.3 Materials and Methods 
Animals 
 
Eight-week old Dutch Landrace pigs were purchased from Saskatoon Prairie Swine 
Centre, University of Saskatchewan. Experiments were performed in accordance with the 
ethical standards set by the University of Saskatchewan and the Canadian Council for 
Animal Care. 
 
Isolation and stimulation of PBMC 
 
Blood was collected by cardiac puncture from each pig using EDTA-coated syringes and 
blood mononuclear cells were isolated using a 60% Ficoll-Paque™ Plus gradient (GE 
Healthcare, Uppsala, Sweden). PBMC were maintained in RPMI 1640 (Gibco, Grand 
Island, NY) supplemented with 10% FBS, 0.5 mM β-Mercaptoethanol, 10% 
Antibiotic/Antimycotic (Gibco, Grand Island, NY), 10% HEPES (Gibco, Grand Island, 
NY) and 10% MEM Non Essential Amino Acids (Gibco, Grand Island, NY) and 
incubated in humidified air containing 5% CO2. 
 
Peptides 
 
PR39, pBD-1, pBD-2 were synthesized at the Vaccine and Infectious Disease 
Organization, Saskatoon, SK, Canada as described by Elahi et al. (2006) [122], PG-1 and 
LL-37 were purchased from ChemPep Inc (Miami, Florida) and Indolicidin and IDR-
1002 were synthesized by using F-moc chemistry at the Nucleic Acid/Protein Synthesis 
Unit of University of British Columbia, Vancouver, BC, Canada. For each HDP, its 
family and the species from which it is derived are listed in Table 5-1.  
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Table 5-1 Peptide family and species 
Peptide Family Species 
IDR-1002 Newly synthesized peptide Not applicable 
PR-39 Cathelicidin Porcine 
Indolicidin Cathelicidin Bovine 
PG-1 Cathelicidin Porcine 
pBD-1 Defensin Porcine 
pBD-2  Defensin Porcine 
LL-37 Cathelicidin 
 
 
Human 
 
 
HDP cytotoxicity 
 
Cell viability in response to HDPs was evaluated by quantifying the amount of adenosine 
triphosphate (ATP) present, relative to cells in media using Cell Titre-Glo™ luminescent 
cell viability assay (Promega, Madison, WI, USA) as per the manufacturers protocol. The 
assay used to examine cytotoxicity is based on ATP production since non-viable cells do 
not produce ATP and have enzymes to degrade existing ATP stores. In order to 
determine at what concentrations the various HDPs are toxic to PBMC, a dose response 
curve was performed. Various peptides were used in a 24-hour incubation at 
concentrations of 50, 100 and 200 µg/ml, except for LL-37 which was used at  
concentrations of 1, 50 and 100 µg/ml. Briefly, 100 µl of stimulated cells (2 x106 
cells/ml) were incubated with 100 µl of mixed Glo reagent, cells were placed on shaker 
for lysis to occur and the released luminescent was read on a TD21 Luminometer (Turner 
Designs, Sunnyvale, CA, USA). Results are expressed as a stimulation index (SI) relative 
to the medium. 
 
Enzyme-linked immunosorbent assay (ELISA) for cytokines 
 
Cytokine secretion were evaluated by incubating 1x106 PBMC in 1 ml of culture medium 
for 24 hours in 6 well plates (Corning, Corning, NY) with the following peptides: IDR-
1002, PR-39, Indolicidin, PG-1, pBD-1, pBD-2 and LL-37 at concentrations of 1, 5, 10, 
25, 50 or 100 µg/ml. LPS (100 ng/ml) was also used as a control. Culture supernatants 
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were collected and concentrations of IL-6, IL-8, IL-12 and TNF-α were assayed using 
porcine DUOSET® commercial kits as per the manufacturer’s instructions (R&D 
Systems, Minneapolis, MN).  
 
Chemotaxis assay 
 
Migration of PBMC in response to HDPs was assessed using 24-well TRANSWELL® 
chamber plates (5 µm pore size, Corning) as described [92]. Briefly 600 µl of media 
contained the peptides was added in the lower chamber of the TRANSWELL® and 
5 × 105 PBMC in 100 µl of culture medium were added to the upper chamber. Following 
a 2-hour incubation at 37 °C in humidified air with 5% CO2 cells in the lower chamber 
were harvested and counted on a hemocytometer using Trypan Blue exclusion. Results 
are expressed as the number of cells that migrated into the lower chamber containing 
peptides/ by the number for cells that migrated into the lower chamber containing media 
alone 
 
Immune cell recruitment following intradermal peptide administration 
 
HDPs (LL-37, PG-1, PR-39, pBD-1, Indolicidin and IDR-1002) were intradermally 
administered to 4 pigs at concentrations of 10 and 100 µg per site in 100 µl of PBS. 
Saline was used as a negative control and IL-8 (2*10-7 M) and LPS (2.5 mg/ml) were 
used as positive controls. Each pig flank received the same treatments (Figure 5-1) and 
was used for a time point, namely, 30 minutes and 3 hours. Another experiment was set 
up in a similar manner except the samples were taken after 17 hours. Samples were 
collected in formalin, paraffin-embedded and stained with Hematoxylin and Eosin (H and 
E). Slides were examined by Dr. Richard Uwiera (DVM, PhD., University of Alberta) for 
immune cell recruitment.  
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Statistical analysis 
 
Statistical analysis was performed by non-parametric Wilcoxon signed rank test for the 
cytokine data and single column t-test for chemotaxis (p-value < 0.05). Analysis was 
performed using the statistical software program GraphPad Prism 5 (GraphPad Software, 
Inc., La Jolla, CA).  
 
 
     
Figure 5-1 Porcine model for intradermal administration of HDPs.  
Pigs were anesthetized for 3 hours (A) and intradermally administered HDPs into various 
sites (B) on either flank. Each flank received the same treatments and was stimulated for 
30 minutes on one side and 3 hours on the opposite side. Punch biopsies (5 mm) were 
taken of the injection site (C). 
 
5.4  Results 
 
LL-37 and PG-1 decrease PBMC viability at high concentrations 
 
The cytotoxic effect of various peptides at different concentrations was examined by 
measuring ATP production (Figure 5-2). Stimulations were compared to cells in media 
alone and expressed as a stimulation index (SI). Decreases in ATP production indicated 
compromised cell viability. Following a 24-hour incubation, the peptides LL-37 at a 
concentration of 100 µg/ml and PG-1 at concentrations of 100 and 200 µg/ml were 
cytotoxic to PBMC. The peptides IDR-1002, PR-39, pBD-1, pBD-2 and Indolicidin at 
concentrations ranging from 50 µg/ml to 200 µg/ml did not decrease PBMC viability and 
were therefore used at these concentrations in further experiments. The concentrations of 
A B C 
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peptides used in this study were comparable to those used in other studies for LL-37 
[206], IDR-1002 [206],  PG-1 [207], PR-39 [208], pBD-1 [209]and pBD-2 [209]. 
 
 
 
 
 
Figure 5-2 Cytotoxicity of HDPs on Porcine PBMC  
Cytotoxicity assay following a 24 hour stimulation of PBMC with peptides: IDR-1002, 
PR-39, Indolicidin, PG-1, pBD-1, pBD-2 and LL-37 at concentrations of (1, 50 and 100 
µg/ml). The experiments were performed using 2 pigs and results are shown as the 
median ± range and expressed as a stimulation index (ratio of stimulated 
cells/unstimulated cells). Technical triplicates were used.  
 
HDPs increase IL-8 cytokine release 
 
Few studies have examined cytokine production in porcine PBMC following HDP 
stimulation. Here we looked at the ability of various HDPs to induce production of IL-6, 
Co
ntr
ol
LL
-37
 1 
µg
/m
l 
L-3
7 5
0 µ
g/m
l
LL
-37
 10
0 µ
g/m
l
PG
-1 
50
 µg
/m
l
PG
-1 
10
0 µ
g/m
l
PG
-1 
20
0 µ
g/m
l
ID
R-
10
02
 50
 µg
/m
l
ID
R-
10
02
 10
0 µ
g/m
l
ID
R-
10
02
 20
0 µ
g/m
l
PR
-39
 50
 µg
/m
l
PR
-39
 10
0 µ
g/m
l
PR
-39
 20
0 µ
g/m
l
PB
D-
1 5
0 µ
g/m
l
PB
D-
1 1
00
 µg
/m
l
PB
D  
1 2
00
 µg
/m
l
Ind
oli
cid
n 5
0 µ
g/m
l
Ind
oc
idi
n 1
00
 µg
/m
l
Ind
oli
cid
in 
20
0 µ
g/m
l
0.0
0.5
1.0
1.5
2.0
St
im
ul
at
io
n 
in
de
x
 69 
IL-8, IL-12 and TNF-α in PBMC (Figure 5-3). Using ELISA we measured the presence 
of cytokines in the supernatant following 24 hours of stimulation with the HDPs. Overall, 
very low levels of cytokines were detected after stimulations with peptides. However, 
stimulation with the synthetic IDR-1002 at concentrations of 1 µg/ml and 100µg/ml 
significantly induced IL-8 production. Interestingly, at concentrations of 5 µg/ml, 25 
µg/ml and 50 µg/ml there were no statistically significant difference detectable, although 
a trend (p=0.057) was evident. IDR-1002 did not induce the production of IL-12 or TNF-
α in these cells. Similar to IDR-1002, the peptide PR-39 increased the production of IL-8 
at concentrations of 25 µg/ml and 100 µg/ml but had no effect on IL-12 or TNF-α 
production. The peptide Indolicidin increased IL-8 production at 50 µg/ml and 100 µg/ml 
with no effect observed for the other cytokines examined. PG-1 at concentrations of 5 
µg/ml, 50 µg/ml and 100 µg/ml increased IL-8 protein with the higher concentrations 
also increasing IL-12 production (Figure 5-4) but no effect on TNF-α production. 
Interestingly pBD-1 had no effect on the cytokines examined at all, whereas pBD-2 
increased IL-8 concentrations at 1 µg/ml, 5 µg/ml and 100 µg/ml.  
 
In summary we found that at concentrations of 100 µg/ml, with the exception of pBD-1, 
the peptides IDR-1002, PG-1, Indolicidin, pBD-2, PR-39, LL-37 and the lipoglycan LPS 
statistically increased IL-8 protein concentrations. Of the other cytokines examined, PG-1 
induced a statistically significant increase in IL-12 production at a concentration of 100 
µg/ml. None of the peptides examined had any effect on TNF-α production but the 
lipoglycan LPS, stimulated its increase (data not shown).  
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Figure 5-3 HDPs increase IL-8 release in PBMC. 
IL-8 production by PBMC following a 24 hour stimulation with peptides and LPS. The 
following peptides at concentrations of 1, 5, 10, 25, 50 and 100 µg/ml were used: (a) 
IDR-1002, (b) PR-39 (c) Indolicidin and (d) PG-1 (e) pBD-1 and (f) pBD-2. LPS was 
used at a concentration of 100 ng/ml. Results are shown as the median and were analyzed 
by a non-parametric Wilcoxon signed rank test (*p<0.05). The experiments were 
performed using 8 pigs and each data point represents a pig. 
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Figure 5-4 PG-1 induces IL-12 production in PBMC  
IL-12 production by PBMC following a 24 hour stimulation with the peptide PG-1 at 
concentrations of 1, 5, 10, 25, 50 and 100 µg/ml. Results are shown as the median value 
and were analyzed by a non-parametric Wilcoxon signed rank test (*p<0.05). The 
experiments were performed using 8 pigs and each data point represents a pig.  
 
IDR-1002 and LL-37 chemoattract porcine PBMC  
 
Given that various HDPs are known to chemoattract immune cells, we tested the ability 
of HDPs to chemoattract porcine PBMC by incubating PBMC with various 
concentrations of HDPs for three hours in a transwell assay system. Results demonstrate 
that LL-37 (1 µg/ml) and IDR-1002 (100 µg/ml) were able to attract significant number 
of cells (Figure 5-5). PG-1 (100 µg/ml) (n=12) was also able to significantly chemoattract 
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pigs (data not shown). Only at concentrations of 100 µg/ml was PG-1 able to 
chemoattract PBMC. The peptides PR-39, pBD-1, pBD-2 and Indolicidin had no effect 
on PBMC recruitment.  
 
 
 
Figure 5-5 HDP chemoattraction of PBMC 
The ability of the HDPs IDR-1002 (100 µg/ml), PR-39 (100 µg/ml), Indolicidin (100 
µg/ml) and PG-1 (100 µg/ml) to recruit PBMC was examined using a transwell assay 
system following a 2 hour incubation. Cells that migrated into the lower chamber were 
counted using trypan blue dye exclusion on a hemocytometer. Results are expressed as 
the number of cells that migrated into the lower chamber containing peptides/ by the 
number for cells that migrated into the lower chamber containing media alone and are 
shown as the median (n= 8 pigs). Analysis was performed using a single column t-test 
(*p-value < 0.05).  
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hours and stained with H and E (Figure 5-1). Slides were examined for immune cell 
recruitment to the site of administration. LPS was included as positive control, as it had 
been previously demonstrated that injection of LPS results in recruitment of neutrophils 
[210]. Neutrophils were present in the IL-8 and LPS treated samples at 30 minutes (data 
not shown), 3 hours (Figure 5-6) and 17 hours. These results demonstrate that despite the 
in vitro ability of HDPs to increase the production of IL-8 in PBMCs and their 
chemotactic ability in PBMC, in vivo, HDPs did not recruit neutrophils into the pig 
dermis.  
 
 
  
            
 
 
Figure 5-6 Porcine intradermal administration of HDPs. 
Pigs were anesthetized for 3 hours and HDPs intradermally administered into various 
sites on the flank. Each flank received identical treatments and represented a different 
time point i.e. 30 minutes or 3 hours. Punch biopsies (5 mm) were taken of the injection 
site. Results are shown for the 3 hour time period: Saline (A) was used as a negative 
control LPS (2.5 mg/ml) (B) and IL-8 (C) were each used respectively as positive 
controls. Sections were paraffin embedded and H and E stained. Magnification is 400x. 
(n=four pigs per treatment with each pig serving as its own control). 
 
5.5 Discussion 
 
Aluminum salts have been the predominant adjuvant present in licensed vaccines until 
the approval of MF59 as an adjuvant in an influenza vaccine [211]. Important features of 
adjuvants include both the ability to retain antigen at the site of injection and to recruit 
A B C 
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and activate antigen presenting cells [212]. HDPs are suitable candidates for vaccine 
adjuvants as they induce cytokine production, recruit immune cells and modulate TH cell 
polarization [194]. Several studies have demonstrated that HDPs or IDRs co-formulated 
with vaccine formulations enhanced the immune response to a variety of antigens [151-
153, 156, 157]. The goal of the present study was to characterize some of the mechanisms 
by which HDPs or IDRs modulate immune responses using the porcine model. We 
demonstrated that HDPs and IDR-1002 induce IL-8 production and recruit PBMC in 
vitro. However, this IL-8 production did not result in the recruitment of neutrophils in 
vivo.  
 
The peptides IDR-1002, PG-1, Indolicidin, pBD-2, PR-39, LL-37 and the lipoglycan LPS 
increased IL-8 protein concentrations in vitro. This is the first study to describe the ability 
of PR-39, IDR-1002 and PG-1, to produce IL-8 in porcine PBMC. Similar to these 
results, stimulation of human bronchial epithelial cells and human airway smooth cells 
with LL-37, pBD-1, pBD-2 and pBD-3 increased IL-8 protein concentrations [198, 202, 
209, 213]. We hypothesized that this ability to enhance IL-8 production would translate 
into increased neutrophil recruitment in vivo. 
 
Following the intradermal administration of peptides in this study, no neutrophil 
recruitment was observed. This observation was surprising given that there is evidence 
that HDPs, both natural and synthetic, recruit neutrophils both in vivo and in vitro. For 
example, it has been demonstrated that the peptide PR-39 recruits porcine neutrophils in 
vitro [205].  Using a mouse model, Nijnik et al. (2010) demonstrated that following the 
administration of IDR-1002, neutrophils are present in the intraperitoneal lavage within 
one hour [214]. Also using a mouse model, Chertov et al. (1997) have shown that 
following the subcutaneous injection of human defensins and CAP37/azurocidin both 
neutrophil and mononuclear cell infiltrates were present at four and 24 hours [215]. 
However, it is possible that the time intervals that were used to examine recruitment, the 
persistence of the peptide in vivo, or possibly the nature of the immunization route 
resulted in less recruitment.  
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Regarding the time intervals used, in this study we chose a 30 minute, 3 and 17 hour 
timeframe. At 30 minutes we expected that if the peptides were directly chemotactic then 
we would observe neutrophils at this timepoint. At 3 hours and 17 hours we anticipated 
that the peptides might be acting on local or recruited cells that in turn would release IL-8 
and recruit neutrophils. If this latter scenario was true then it would have been possible 
that later time points may have been more suitable. Future studies will examine 
timepoints extending up to 48 hours. Another consideration is that immune cells such as 
macrophages or dendritic cells may have been recruited to the injection site at the 
timepoints used in this study. This limitation could be addressed in future studies by 
performing immunocytochemistry and using a panel of markers specific to other cells 
such as DCs and macrophages. 
 
Another reason for the lack of neutrophil recruitment could be that the HDPs did not 
persist at the immunization site. This seems unlikely given that a recent study 
demonstrated that when ovalbumin (OVA) and indolicidin were subcutaneously 
administered in mice, OVA and indolicidin were retained at the immunization site for up 
to 48 hours [216]. However, it is possible that the chemistry and interaction between 
OVA and the HDP may contribute to site retention. Further studies are needed to address 
this interaction.  
 
It is plausible that the nature of the immunization route impacts on the ability of HDPs to 
recruit immune cells. In previous studies demonstrating the recruitment of immune cells 
by peptides, either an intraperitoneal route or a subcutaneous route were used. The route 
of administration may impact on the nature of the immune response demonstrated. For 
example, in the skin, keratinocytes produce innate immune regulators such as HDPs 
[217]. Since HDPs are already present in the dermis, further introduction of them alone 
may not have an effect. It is possible though that in the presence of an antigen that an 
immune response would then be elicited. Another important observation is that certain 
skin conditions such as psoriasis are characterized by high levels of HDPs. Therefore 
during normal conditions it is conceivable, that the skin has a means of regulating the 
production of HDPs to maintain homeostasis. This postulate may be addressed in future 
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studies by examining cytokines that are produced around the injection site to determine 
what type of inflammatory milieu is created if any. 
 
In summary findings from this study demonstrate the interspecies ability of HDPs to 
increase IL-8 production in PBMC, recruit PBMC in vitro but not recruit neutrophils 
following their intradermal administration of HDPs. 
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5.6 Conclusion 
 
In Chapter five we describe the ability of HDPs to attract PBMC in vitro and neutrophils 
in vivo. We demonstrate that the HDPs, LL-37, PG-1 and IDR-1002 recruit PBMC and 
induce IL-8 production in vitro, but are not able to recruit neutrophils in vivo. While 
undertaking these studies we were also examining the effects of intradermally 
administered IDR-1002 on antigen-specific proliferation. Results from this study are 
presented in Chapter six.  
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6.1 Abstract 
 
Host defense peptides (HDPs) demonstrate significant promise as potential vaccine 
adjuvants. HDPs have a plethora of immunomodulatory functions including the induction 
of cytokine and chemokine production, recruitment of dendritic cells, as well as 
stimulation and modulation of antigen-specific T cell responses. In this study, the novel 
innate defense regulator (IDR)-1002, was examined for its immunomodulatory 
characteristics in a porcine model. Previously, IDR-1002 was demonstrated to enhance 
IL-8 protein production and increased leukocyte recruitment in vitro. Here, to assess its 
immunomodulatory effects on antigen-specific proliferation, IDR-1002 was intradermally 
administered to pigs in combination with Keyhole Limpet Haemocyanin  (KLH) antigen 
and/or CpG oligodeoxynucelotides (ODN). Pigs were vaccinated, boosted after 10 days, 
and sacrificed 24 days later. IgG serum antibody titres did not differ between the groups 
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throughout the experiment. At the time of sacrifice spleen cells were isolated and co-
incubated with either media, KLH, ovalbumin (OVA) (irrelevant antigen) or Con A. 
Interestingly, both antigen-specific and mitogen-induced proliferation were lowered in 
the KLH/IDR-1002 vaccinated animals, even at four weeks post-treatment. These results 
demonstrate that specific host defense peptides can suppress certain aspects of the pro-
inflammatory immune response, making them highly versatile tools to modulate and 
tailor the immune response to vaccination. Flow cytometry was used to determine if the 
percentage or constituency of various immune cell populations was altered by IDR-1002. 
No changes in either the total percentage or mean fluorescent intensity (MFI) of CD3, 
CD4, CD8, CD21, CD25, CD172a or MHCII were evident. These results suggest that the 
suppressive effects of IDR-1002 are not attributed to its ability to modify immune cell 
populations under the conditions used in this study.  
 
6.2 Introduction 
 
Initially host defense peptides (HDPs) were recognized for their microbicidal activity. 
More recently, research efforts have identified various immunomodulatory functions 
ranging from protection against pathogens, anti-endotoxic effects, cytokine production, 
immune cell recruitment and polarization of adaptive immune responses [105]. The 
ability to tailor adaptive immune responses is a key function that is highly relevant for the 
development of novel vaccines as well as the development of therapeutic approaches for 
various diseases. Adaptive immune responses are characterized by several T helper (Th) 
subsets including Th1, Th2, Th0, Th17 and regulatory T cells (TR). Each of these subsets 
is categorized by the production of certain cytokines: amongst others Th1 cells produce 
interferon (IFN)-γ, a cytokine involved in the clearance of intracellular pathogens; Th2 
cells produce interleukin (IL)-4, IL-5 and IL-13 and are involved in the clearance 
extracellular pathogens; Th17 cells produce IL-17 and IL-22 and are implicated in the 
clearance of fungi; Th0 subsets are known for their ability to produce IL-4 and IFN-γ; 
and TR cells are known for their production of  TGF-β and IL-10 [218].  
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Various studies have described the role of HDPs in modulating these various types of 
adaptive immune responses [194]. HDPs can be grouped into two main families of HDPs, 
which comprise of defensins and cathelicidins, both of which modulate aspects of 
immune functioning. Using a mouse model, it has been demonstrated that the 
administration Keyhole Limpet Hemocyanin (KLH) in combination with defensins 
resulted in higher KLH-specific IgG1, IgG2a and IgG2b antibodies [150]. Also, spleen 
isolates from defensin treated mice had higher concentrations of IL-4 and IFN-γ as well 
increased lymphocyte proliferation [150]. The subcutaneous immunization of a 
formulation comprising of CpG ODNs, polyphosphazene and indolicidin (a bovine host 
defense peptide), gave rise to higher IgG1 and IgG2a titres and IFN-γ secretion in a 
mouse model [151]. This group also demonstrated increased IgG titres and IFN-γ 
secretion using a bovine model, and subcutaneously administering indolicidin, CpG ODN 
and hen egg lysozyme (HEL), [152]. These studies demonstrate the immunomodulatory 
capability of HDPs on immune responses.  
 
Interestingly, specific immunomodulatory functions can also be attributed to synthetic 
HDP derivatives, known as IDRs. The molecules have demonstrated substantial potential 
as immunomodulators. For example, the intranasal administration to mice of a complex 
of CpG ODN 10101, IDR-HH2 and detoxified pertussis toxin (PTd) resulted in 
significantly higher IgA and total IgG titres compared to PTd and CpG ODN 10101 alone 
or PTd and IDR-HH2 alone [153]. Furthermore, following the intranasal administration 
of CpG ODN and IDR-HH2, IFN-γ and IL-12 mRNA levels were increased while IL-4 
mRNA levels were decreased in the jejunum of neonatal piglets [145]. Another study also 
demonstrated that CpG ODN and IDR-HH2 combined with attenuated Pseudorabies virus 
(PRV) vaccine resulted in higher PRV-specific antibodies of IgG2 isotype as well the 
Th1 cytokines IFN-γ and IL-12 [154]. Similar results were seen in both adult and 
neonatal mice, whereby the subcutaneous administration of a combination of the IDR-
HH2, CpG ODN and polyphosphazenes resulted in higher IgG2a responses [156]. In 
addition to the effects seen with IDR-HH2, the novel IDR-1002 also demonstrates 
immunomodulatory capacity. IDR-1002 increased IL-8 cytokine production in pigs 
[219], recruited porcine PBMC in vitro [219], recruited mouse immune cells [214] and 
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decreased bacterial load in a mouse model of  Staphylococcus aureus [214]. The effect of 
a triple combination of PTd, CpG ODN, an IDR and polyphosphazenes was also 
demonstrated using IDR-1002 in a murine model. Garlapati et al. (2011) demonstrated 
that the subcutaneous administration of this combination induced higher Th1 type of 
responses as shown by an increase in the cytokines, monocyte chemotactic protein 
(MCP)-1, tumor necrosis factor (TNF)-α, IFN-α, IL-12 and IL-17 and decrease in IL-10 
concentrations [157].  
 
In this study the effects of intradermal administration of IDR-1002 and KLH to pigs was 
examined for its potency to modulate antigen-specific proliferation, antibody responses 
and changes in the constituency of various immune cell populations. While no changes in 
antibody titres were observed between different vaccination groups, in the KLH-IDR- 
1002 vaccinated animals antigen-specific and mitogen-induced proliferation was lowered 
and this was not attributed to changes in the constituency of immune cell populations.  
 
6.3 Materials and Methods 
 
Animals 
 
In this study eight week old Dutch Landrace pigs purchased from Saskatoon Prairie 
Swine Centre, University of Saskatchewan were used. Experiments were performed in 
accordance with the ethical standards set by the University of Saskatchewan and the 
Canadian Council for Animal Care. 
 
Intradermal vaccination of IDR-1002 
 
Pigs at four weeks of age were intradermally vaccinated with 1 mg of Keyhole Limpet 
Hemocyanin (KLH) from Megathura crenulata (Sigma Aldrich) in 30% emulsigen either 
alone or with the class C CpG ODN 10101 (TCGTCGTTTTCGGCGCGCGCCG) (150 
µg) or IDR-1002 (300 µg). IDR-1002 (VQRWLIVWRIRK-NH2), was synthesized by F-
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moc chemistry at the Nucleic Acid/Protein Acid/Synthesis Unit at the University of 
British Columbia (Vancouver, British Columbia, Canada) and was resuspended in 
endotoxin-free water. Every two weeks pigs were boosted for a total of two vaccinations. 
At the time of sacrifice spleen cells and PBMC were isolated. 
 
Isolation and stimulation of PBMC 
 
Blood was collected by venipuncture from each pig using EDTA-coated syringes for flow 
cytometric analysis at the time of the first bleed (day0), day two, day 22 and at the time 
of sacrifice. Blood mononuclear cells were isolated using a 60% Ficoll-Paque™ Plus 
gradient (GE Healthcare, Uppsala, Sweden). PBMC were maintained in RPMI 1640 
(Gibco, Grand Island, NY) supplemented with 10% FBS, 0.5 mM β-Mercaptoethanol, 
10% Antibiotic/Antimycotic (Gibco, Grand Island, NY), 10% HEPES (Gibco, Grand 
Island, NY) and 10% MEM Non Essential Amino Acids (Gibco, Grand Island, NY) and 
incubated in humidified air containing 5% CO2. 
 
Lymphocyte proliferation assay 
 
Spleen cells were pulsed with OVA, KLH or Con A for 72 hours in 96-well U-bottom 
plates (Corning, Corning, NY). During the last eight hours of culture 1 µCi of 
[3H]thymidine (Amersham Pharmacia Biotech, Baie de Urfe, PQ) was added and 
proliferative responses were determined. Results are expressed as a stimulation index 
(SI). 
 
Antibody titres 
 
Microtiter plates (Immulon 2 HB; Dynex Technologies, Chantilly, VA) were coated with 
KLH 10 µg/ml (100 µl per well) and incubated with sera that were serially diluted. KLH 
specific IgG was detected using alkaline phosphatase-conjugated goat anti-pig 
immunoglobulin G (IgG; 1:5,000 dilution; Kirkegaard & Perry Laboratories, 
Gaithersburg, MD). Biotinylated goat anti-mouse IgG (1:5,000 dilution; Zymed) was 
 82 
used for reaction amplification. Streptavidin peroxidase (1:5,000 dilution; Jackson 
Laboratories) p-nitrophenylphosphate (Sigma-Aldrich) were used to detected the reaction 
at 450 nm on a microplate reader (Bio-Rad Laboratories). 
 
Flow Cytometry 
 
The following anti-porcine antibodies were used for assessing immune cell types: 
CD172a (BL1H7), CD1 (76-7-4), CD3 (PPT3), CD4 (74-12-4), CD8 (PT36B), CD14 
(MIL-2), CD16 (MCA1971), CD21 (BB6-11C9.6), MHCII (K274.3G8) and MHCI 
(SLA-I). All of the antibodies were obtained from Serotec (Oxford, UK) unless otherwise 
mentioned. Fluorescein isothiocyanate (FITC) anti-mouse immunoglobulins IgG1, IgG2a 
and IgG2b (Southern Biotech, Birmingham, AL) were used for detection by flow 
cytometry. 
 
Immunofluorescence staining was performed by incubating 1x106 cells for 20 minutes at 
4°C with each antibody. Cells were washed three times with cold PBS (1X) (pH 7.2) 
(Gibco, Grand Island, NY) containing sodium azide (0.03%) and gelatin (0.02%) and 
incubated with FITC- conjugated secondary antibody for 20 minutes at 4°C, washed three 
times and fixed with paraformaldehyde (2%). Ten thousand events were collected and 
analyzed by flow cytometry (FACScalibur™, CELLQuest™ software; Becton 
Dickinson, BD Biosciences, Mountain View, CA). 
 
Statistical analysis 
 
Statistical analysis was performed using the statistical software program GraphPad Prism 
5 (GraphPad Software, Inc., La Jolla, CA). For lymphocyte proliferation, results are 
expressed as a stimulation index (SI) and analyzed by Kruskal-Wallis test. For flow 
cytometry, to determine treatment effects over time in PBMC, the non-normally 
distributed data were rank transformed and then analyzed by a 1-way ANOVA (p-value < 
0.05). Splenocytes were analyzed by a 1-way ANOVA (p-value < 0.05).  
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6.4 Results 
 
KLH specific lymphocyte proliferation 
 
KLH-specific in vitro proliferation of spleen cells from immunized pigs was determined 
by examining the uptake of [3H]thymidine. The four vaccinations groups comprised of 
animals immunized with KLH alone or a co-formulated with either KLH/IDR-1002, 
KLH/CpG ODN or KLH/ IDR-1002/CpG ODN. Splenocytes from these different 
vaccination groups were stimulated with either media alone, KLH, OVA or Con A to 
determine an effect of the treatment. 
 
Splenocytes from animals immunized with KLH, and stimulated with KLH (Figure 6-1A) 
compared to stimulation with OVA (Figure 6-1B) showed statistically higher 
proliferation (p<0.05). Splenocyte median stimulation indices of KLH stimulation versus 
OVA stimulation ranged for KLH alone from 16.8 to 1.2; for KLH/ IDR-1002 from 4.2 
to 1.1; for KLH/CpG ODN from 11.2 to 1.3; and for KLH/IDR-1002/CpG ODN from 7.9 
to 1.1. These results demonstrate that proliferation occurred in an antigen-specific 
manner.  
 
The effects of stimulation with KLH in the four vaccination groups were as follows:  
Splenocytes from the KLH immunized animals had a median SI of 16.8 compared to 4.2 
in the KLH/IDR- 1002 group, 11.2 in the KLH/CpG ODN group and 7.9 in the 
KLH/IDR- 1002/CpG ODN group ((Figure 6-1A). A similar trend was observed with 
Con A stimulation (Figure 6-1C), with SIs for the respective vaccination groups KLH, 
KLH/ IDR-1002, KLH/CpG ODN and KLH/ IDR-1002/CpG ODN as such: 139.4, 14.2, 
42.5, and 33.4. Vaccination groups comprising of IDR-1002 in the formulation had lower 
SIs compared to KLH alone when stimulated with either KLH or Con A respectively.  
 
In summary, when KLH immunized animals and KLH/ IDR-1002 immunized animals 
were stimulated with the mitogen Con A, there was a statistically significant decrease in 
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splenocyte proliferation in the KLH/IDR-1002 immunized animals. The same trend was 
observed when KLH was used as an antigen.  
 
In KLH immunized pigs, stimulation with the mitogen ConA as compared to KLH, 
induced a statistically higher amount of proliferation, demonstrating the viability of the 
assay. 
 
 
Figure 6-1 Effect of intradermal vaccination with IDR-1002 on antigen specific and 
mitogen induced lymphocyte proliferation 
Splenic lymphocyte proliferation following the intradermal administration of KLH was 
observed in four vaccination groups namely, KLH, KLH/IDR-1002, KLH/CpG ODN and 
KLH/IDR-1002/CpG. Eight pigs were used per group, spleens were isolated and then 
stimulated with either KLH (A), OVA (B) (irrelevant antigen) or concanavalin (Con A) 
(C) (control) for 72 hours.  
 
Antibody titres 
 
To determine if the vaccination groups influenced overall IgG antibody titres, at two 
weeks post vaccination at the time of the boost, sera was collected from immunized 
animals and examined for serum IgG levels (Figure 6-2). Animals immunized with KLH 
and KLH/IDR-1002 had similar antibody titres to animals immunized with KLH/ CpG 
ODN and KLH/IDR -1002/CpG ODN. Levels of IgG were numerically lower in animals 
immunized with KLH and KLH/IDR-1002 compared to animals immunized with 
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KLH/CPG ODN and KLH/IDR-1002/CpG ODN. At the time of sacrifice, this effect was 
absent and no differences in antibody titres were observed (Figure 6-2). 
 
 
Figure 6-2 IgG antibody titres to immunization with various adjuvants.  
Pigs (n=8 per group) were immunized intradermally with KLH, KLH/IDR-1002, KLH 
/CpG ODN or KLH, IDR-1002/CpG ODN at four weeks of age with an identical 
immunization given at six weeks. Sera were collected before the vaccination, at the time 
of the first boost which was 2 weeks later. Results are demonstrated as IgG antibody log 
titres following the first vaccination (A) and the boost (B). 
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Flow Cytometry 
 
To determine if the ability of IDR-1002 to lower lymphocyte proliferation was attributed 
to immune cell populations, we examined the cell surface marker expression of CD3, 
CD4, CD8, CD14, CD21, CD25, CD172a, MHCII and MHCI in splenocytes from 
immunized animals. No differences in both overall percentage and mean fluorescent 
intensity were observed in PBMC (data not shown) or splenocytes (Figure 6-3).   
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Figure 6-3 Surface phenotype of porcine splenocytes.  
 At day 35 splenocytes were analyzed by flow cytometry for CD3 (A), CD4 (B), CD8 
(C), CD14 (D), CD21 (E), CD25 (F), CD172a (G) and MHCII (H). Data are shown as a 
median percentage of positive cells (1.1) and mean fluorescent intensity (1.2) for each 
marker examined. Data for the splenocytes are representative of six pigs from four 
different vaccination groups of KLH, KLH/IDR-1002, KLH/CpG ODN and KLH/IDR-
1002/CpG. Data were analyzed by a 1-way ANOVA (p>0.05). 
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6.5 Discussion 
 
Vaccine research is driven by the need to develop novel vaccines and improve the 
efficacy of currently existing vaccines via the use of novel adjuvants. Candidates for 
novel adjuvants include HDPs and IDRs, which have been shown to modulate immune 
responses [151-153, 156]. We demonstrated that IDR-1002 did not alter overall IgG titres 
but decreased antigen-specific lymphocyte proliferation. Moreover, we have shown that 
this effect was not due to changes in the proportion of immune cell populations present. 
In summary the IDR-1002 demonstrated promise as an immunosuppressive agent.  
 
No other study has examined the effect of the IDR-1002 on antigen specific proliferation. 
Here we demonstrate that the IDR-1002 decreased antigen specific proliferation. It is 
important to note that the decreased proliferation was not due to cell death induced by 
IDR-1002. In the proliferation assay, splenocytes were exposed to either KLH, OVA or 
Con A and not IDR-1002. Exposure to IDR-1002 only occurred during the vaccinations.   
 
Explanations for this decreased proliferation may include the following: neutrophil 
uptake of antigen at the injection site, the generation of tolerogenic DCs or the direct 
action of the IDR-1002 on T cells. In PBMC we demonstrate that the IDR-1002 induces 
IL-8 production. Therefore, it is conceivable that in vivo neutrophils are recruited by the 
IDR-1002 to the injection site where they might compete for antigen with antigen 
presenting cells [220]. By decreasing the amount of antigen available, T cell 
responsiveness may be affected [221]. While this explanation is plausible, it seems 
unlikely since intradermal administration of the IDR-1002 did not results in neutrophil 
recruitment at 30 minutes, 3 hours and 17 hours [219]. 
 
Another theory for decreased lymphocyte proliferation is the generation of tolerogenic 
DCs. Tolerogenic DCs can be induced by IL-10 [222]. Stimulation of human monocytes 
with IDR-1002 gives rise to higher levels of IL-10 [214]. Therefore, it is possible that 
following intradermal administration of 1002, IL-10 was produced and subsequently 
induced tolerogenic DCs. Also, skin Langerhans cells have been demonstrated to be 
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tolerogenic [223]. Thus, it is possible that during intradermal administration of KLH and 
the IDR-1002 Langerhans cells were rendered tolerogenic. Future experiments to address 
this possibility would need to address which immune cell type is responding to the 
vaccination as well as what assessment of the cytokine milieu at the injection site.  
 
A final explanation for lowered lymphocyte proliferation might be that the IDR-1002 acts 
directly on T cells making them less responsive to proliferative stimuli. Evidence for this 
explanation arises from studies whereby HDPs decreased lymphocyte proliferation [224]. 
Schluesener et al. (1993) observed that at doses of 10 µg/ml Indolicidin decreased 
[3H]thymidine incorporation into T cells and was cytotoxic using a model of rat 
autoimmunity [225]. In another study, proliferation was reduced in porcine PBMC, which 
in the presence of Con A, were stimulated with BMAP-27, BMAP-28, or Indolicidin 
[224]. In the latter study, isolation of porcine CD4+/CD8+ T cells demonstrated that T cell 
proliferation was significantly lowered following stimulation with HDPs [224]. This 
decrease in proliferation was not attributed to cell necrosis but to anergy as ATP 
production was reduced and CTLA expression increased [224]. Using flow cytometry we 
examined different immune cell populations. We did not, however, examine CTLA 
expression, which could have provided more evidence that the immune suppression that 
we observed was due to anergy as was the case with BMAP-27 and BMAP-28.  In 
Dybvig’s study the addition of exogenous IL-2 reversed anergy. To determine if decrease 
lymphocyte proliferation was due to IDR-1002 inducing T cell anergy, future studies will 
involve the addition of IL-2 to proliferation assays.  
 
The ability of HDPs to induce regulatory T cells (TR) is demonstrated in a study by 
Navid et al. (2012), whereby murine β-defensin-14 (mBD-14) induced antigen specific 
TR [226]. In this study, mice that had been exposed to ultraviolet radiation were 
sensitized with 2,4-dinitro-1-fluorobenzene (DNFB). In these mice the contact allergen 
DNFB did not induce sensitization but instead immunotolerance. Ultraviolet radiation 
induced the expression of mBD-14, which was demonstrated to induce FOXP3+ in 
CD4+CD25- cells. The effects of mBD-14 were demonstrated to be APC independent and 
IL-10 dependent [226]. This study demonstrates the potential of HDPs to induce TR. In 
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this context, it would have been interesting to examine the effects of IDR-1002 on T cell 
phenotype to determine if IDR-1002 induced FOXP3+ expression as well as IL-10 
cytokine production. 
 
We did not observe a change in overall IgG titres. Results from other studies support this 
observation. In mice, it has been demonstrated that following the subcutaneous 
administration of OVA and the adjuvant indolicidin there was no change on overall IgG 
titres [151]. Similar results were shown in cattle, using the antigen HEL and the HDP 
Indolicidin [152]. Contrary to the lack of effect on IgG titres that we observed, in studies 
where the IDR-HH2 was used, overall IgG titres increased. It was demonstrated that the 
intranasal delivery of PRV alone or PRV and IDR-HH2 in pigs induced higher overall 
IgG titres [154]. A similar effect on IgG titres was observed in mice, following the 
intranasal delivery of PTd alone or in combination with HH2 [153].  
 
Reasons for the discrepancies observed in changes in IgG titres may be several-fold. The 
ability to induce higher overall IgG titres maybe a function of the HDP or IDR used, the 
antigen, animal age, animal species and/or route of immunization. Regarding the HDP or 
IDR used, it appears that HH2 as compared to the IDR-1002 or Indolicidin may have the 
ability to enhance overall IgG titres. It is important to note that we did not assess IgG1 
and IgG2 titres to determine if there was a change in the respective titres. In studies 
demonstrating an overall change in IgG titres in pigs, the peptide HH2 skewed the 
immune response towards a Th2 type of response (higher IgG1 titres) [154]. Since we did 
not see a change in overall IgG titres, it is not likely that there was a change in IgG1 or 
IgG2 shifting. The antigen used and animal age also impact on the production of IgG 
titres. In studies using CpG as an adjuvant both of these factors play a contributing role. 
In three to seven day old piglets, the use of CpG ODN increased IgG titres to PRV 
following subcutaneous immunization [154, 227]. In our study, the intradermal 
administration of CpG ODN with KLH to eight week-old pigs did not enhance overall 
IgG titres. Animal species also impacts on the production of IgG titres.  In contrast to 
some of the pig studies, in cattle, CpG ODN in combination with HEL did not give rise to 
statistically significantly higher IgG titres [152]. This effect of CpG ODN on IgG titres 
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was also not observed in BALB/c mice, where the intranasal immunization of PTd alone 
or in combination with CpG ODN had no effect on IgG, IgG1 or IgG2a titres [153]. 
Differences in the effect of HDPs or IDRs on overall IgG titres may also be impacted by 
the route of immunization used i.e. subcutaneous as compared to intranasal or 
intradermal. Studies demonstrate that the route of vaccination contributes to the nature of 
the immune response generated. For example, Kaur et al. (2008) demonstrated that 
inoculation with leishmania promastigotes via the subcutaneous route elicited a Th1 
response while the intracardiac route elicited a Th2 response [228]. Using a pig model, 
Cao et al. (2011) demonstrate that while there was no significant difference in cytokine 
production between intranasal and subcutaneous route, the latter route induced a stronger 
IFN-γ and IL-12 response than the intranasal route [154]. Therefore, it is plausible that in 
our study we are observing an effect related to the intradermal route of immunization. 
Future studies exploring different routes of immunization will allow us to understand if 
the immunosuppressive effect of IDR-1002 is related to immunization route.  
 
In conclusion we demonstrate that the IDR-1002 has potential to act in an 
immunosuppressant manner.  Certain diseases such as arthritis are characterized by a pro-
inflammatory state. Agents that suppress pro-inflammatory components of the immune 
system serve as potential immunotherapeutic agents. In summary, using this model of 
intradermal administration, IDR-1002 demonstrates merit as an immunosuppressive 
agent and may be useful in the treatment of conditions characterized by pro-inflammatory 
states.  	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Chapter 7 GENERAL DISCUSSION 
 
Dendritic cells are important surveillance cells in the immune system. They are located at 
sites of pathogen entry where they can sample and process antigens. The presentation of 
antigens by DCs can elicit potent T cell responses, which in turn links the innate and 
adaptive immune system [4]. Targeting of DCs and immunomodulation of their function 
is a key strategy in the design of more effective and novel vaccines [229]. HDPs and 
IDRs show great promise as vaccine adjuvants. As part of a larger multinational research 
effort to develop a novel adjuvant platform for neonates, we screened a number of HDPs 
in porcine, murine and human cells. We hypothesized that selected HDPs could 
immunomodulate porcine DCs. To this end we characterized two subsets of porcine DCs, 
namely MoDCs and BDCs. In chapter three we compared these two DC subsets and also 
described how they responded to stimulation by LPS [82]. Phenotypically MoDCs had a 
higher expression of CD80/86 and demonstrated higher endocytic activity. Interestingly, 
MoDCs had higher base concentrations of IL-6, IL-8 and TNF-α proteins than BDCs, but 
were less responsive to stimulation with LPS. MoDCs were better able to stimulate the 
proliferation of both naïve and primed T cells whereas BDCs were better able to 
stimulate the proliferation of primed T cells. Following the successful generation of 
porcine MoDCs and isolation of BDCs, we further characterized these subsets by 
examining the stability of reference gene expression in chapter four. This characterization 
arose from the importance of knowing which reference genes are stably expressed and 
therefore could be used for expression analysis studies in porcine immune cells. In 
chapter four, we described our recommendations for which reference genes could be used 
for expression analysis studies in porcine PBMC, T cells, monocytes, MoDC and BDCs, 
either alone or following stimulation with LPS.   
 
Following the successful generation and isolation of MoDCs and BDCs, we investigated 
the effects of HDP treatment on DC cytokine production and chemokine expression using 
the IDRs HH2, HH17 and HH18. Surprisingly, we were unable to demonstrate any 
effects of stimulation of the DCs with these peptides. This could be due to a number of 
reasons including the peptides that were selected, their inability to react with porcine 
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cells, the cell type being used, or compromised function of the isolated DCs due to the 
isolation procedure itself. I was involved in some studies with Dr. Auray involving the 
characterization of porcine MoDCs and BDCs in response to various TLR ligands. We 
demonstrated that both MoDCs and BDCs responded to TLR ligands [92]. These results 
showed that it was unlikely that the lack of effect that we were observing using HH 
peptides was due to compromised function of the DCs. It is possible that TLR ligands are 
able to modulate DCs in the absence of antigen, whereas HDPs, which are naturally 
present in many sites in the body, may require extra signals to modulate DCs. We did not 
explore this possibility with the HH peptides and DCs.  To ensure that the lack of effect 
that we observed was not due to the HH peptides that we had selected, we decided to use 
different HDPs and to include a variety of naturally-occurring peptides from different 
species that included the bovine cathelicidin indolicidin, the human cathelicidin, LL-37, 
porcine defensin pBD-1 and the porcine cathelicidins PG-1 and PR-39. We also included 
the synthetic peptide, IDR-1002, which by this time was showing promise as an 
immunomodulater from in-house vaccine trials. We also decided to screen PBMC and 
not DCs, which are an isolated cell population. This allowed us to assess the effect of 
HDPs and the IDR-1002 in a mixed cell population containing monocytes, DCs and 
leukocytes. In chapter five, the ability of these HDPs and the IDR-1002 to induce 
cytokine production and recruit porcine PBMC was examined [219]. We assessed the 
expression of cytokines IL-6, IL-8, IL-12, TNF-α. We were the first group to show that 
the peptides IDR-1002, PR39, Indolicidin, PG-1, pBD-1, pBD-2 and LL-37 enhanced IL-
8 production. The peptide PG-1 also increased IL-12 cytokine production. Of the peptides 
examined we demonstrated that IDR-1002, LL-37 and PG-1 also recruited porcine 
PBMC in vitro. These observations led us to evaluate the in vivo effects of intradermal 
administration of HDPs. While both LPS and IL-8 demonstrated a strong recruitment of 
neutrophils, none of the peptides had an effect on neutrophil recruitment at the time 
points examined. It is possible, that the peptides examined might not recruit neutrophils 
in the absence of antigens. The presence of antigens may provide additional signals, 
which in the presence of the peptides may signal the immune system’s ability to respond. 
More time points may have been required to examine neutrophil recruitment. 
Alternatively, the peptides may recruit immune cells other than neutrophils to the 
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immunization site, such as macrophages or DCs. A final consideration is that the peptides 
may have been degraded. This issue can be addressed by covalently attaching a tracer to 
the peptides to detect their stability following immunization.  
 
A major focus of this thesis was to examine the immunomodulatory effect of IDRs. 
Therefore, in chapter 6 we examined the effects of vaccinating pigs intradermally with 
KLH alone or in combination with CpG ODN, IDR-1002 or CpG ODN and IDR-1002. 
We observed a decrease in lymphocyte proliferation with the IDR-1002 and no effect on 
overall antibody titres or immune cell constituency. Further studies are required to 
examine the mechanism by which IDR-1002 is able to exert this effect. Reasons for 
which IDR-1002 decreases lymphocyte proliferation may be as follows: Neutrophil 
recruitment to the injection site. These neutrophils may compete with APCs for antigen, 
therefore making fewer antigens available for presentation. Examining the immune cells 
that are recruited to the immunization site would be important in determining if 
neutrophils play a role in the effects that we observe. Another reason may be that IDR-
1002 renders DCs tolerogenic. These DCs would be unable to stimulate T cell 
proliferation. This explanation seems unlikely as no changes in the percentage of T cells 
was detected by flow cytometry in either PBMC or spleens. Alternatively, IDR-1002 may 
interact directly with T cells rendering them less responsive or anergic or inducing TR as 
has been demonstrated with other HDPs [224, 226]. This explanation could be addressed 
by examining the expression of cell surface marker CTLA and looking for increased 
production of IL-10.  
 
In summary we have observed HDPs moderate immune responses depending on the 
context in which they are present. Notably, HDPs demonstrate a dual nature whereby 
they can enhance immune responses or suppress them. Examples of immune response 
enhancement by HDPs arises mostly from studies describing the role of HDPs as 
adjuvants in vaccine formulations [151-153, 156, 157, 230]. In contrast to these effects, 
HDPs also play an anti-inflammatory role. For example, treatment of human MoDCs 
with low concentrations of α-defensins1-3 (0.25– 1 µg/ml) enhanced immune responses 
(increased MoDC expression of costimulatory molecules, cytokine production and T cell 
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proliferation) whereas stimulation with high concentrations of α-defensins 1-3 (10-20 
µg/ml) suppressed immune responses with decreased T cell proliferation [159]. In this 
study, the importance of HDP concentration as a regulating factor was highlighted. Di 
Nardo et al. (2007), demonstrated that the intradermal injection of the mouse cathelicidin 
CRAMP reduced swelling and cell recruitment in response to the application of 2,4-­‐dinitrofluorobenzene	   [231]. Since DCs can link the innate and adaptive immune 
system, Di Nardo et al. (2007) examined the effects of CRAMP on TLR induced 
maturation of DCs. DCs were treated with CRAMP, then washed and exposed to LPS, 
DCs did not mature and IL-6 production was inhibited. Treatment with cathelicidin in 
human MoDCs, LPS induced production of IL-6, IL-8, IL-10 and TNF-α were reduced 
[231]. Also related to modulating LPS induced effects, hBD-3 downregulated TNF-α 
production in response to the TLR4 agonist LPS in human and mouse macrophages 
[232]. Semple et al. (2010), also demonstrated that Balb/c mice exposed to LPS in the 
presence of hBD-3 had lower serum TNF-α concentrations [232]. In human PBMC, LL-
37 enhanced IL-1β induced IL-6 and IL-8 production but suppressed IL-6 production 
when the immune mediators IFN-y, IL-4 or IL-12 were present [233]. LL-37 also 
inhibited human DC activation by TLR ligands, including LPS, lipoteichoic acid and 
flagellin [234]. These studies described the immunosuppressant role of HDPs and also 
the importance of the local microenvironment. For example a change in one modulator 
can switch the role of LL-37 from being pro-inflammatory to anti-inflammatory or the 
exposure to a HDP prior to encounter LPS can modify cellular responses. The 
immunosuppressant role of HDPs may be key in resolving inflammation and preventing 
tissue damage. This dual nature of HDPs can be explored by administering them in the 
presence of different modulators to determine whether or  not it is possible to orchestrate 
pro- or anti- inflammatory conditions.    
 
In this study, our work began by examining the effects of HDPs on DC functions. 
However no strong effects on immune functioning were observed and further studies 
involved looking at PBMC and eventually examining in vivo effects in whole animals. 
Given the complex interplay between the tissue environment, cell cooperation and 
individual cells [235], HDP behavior is more completely depicted when it is examined in 
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this context (Figure 7-1). HDPs can be released from epithelial cells or from various 
other leukocytes and can recruit other immune cells. Subsequently HDPs in concert with 
other immunomodulators impact on the functioning of immune cells such as DCs, which 
then link the innate and adaptive immune systems.  
 
 
 	  
Figure 7-1 HDPs as innate immune system modulators  
HDPs are immunomodulators that can act at various levels by recruiting immune cells, 
upregulating or downregulating cytokine production, modulating responses to TLR 
ligands and maturing DCs. The modulation of cells such as DCs by HDPs, depends on 
the local microenvironment created by tissue epithelial cells and stromal cells as well as 
by factors released by other cells. 
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Chapter 8 Overall Conclusion 
 
In conclusion, we have successfully isolated and characterized both BDCs and MoDCs. 
Regarding the immunomodulatory effect of HDPs and IDRs, we have demonstrated a 
lack of effect with IDRs HH2, HH17 and HH18 on the MoDC and BDC populations that 
we generated. We did however demonstrate that the IDR-1002, and various HDPs 
induced IL-8 secretion in PBMC and recruited PBMC. This in vitro production of IL-8 
did not translate into neutrophil recruitment following the intradermal administration of 
these peptides into the pig dermis. Lastly, we demonstrated that the IDR-1002 decreased 
lymphocyte proliferation and therefore may represent a strategy for immunosuppression.   
 
 
8.1 Future work  
 
There are several directions that the work from this thesis can take. Of particular interest 
is developing an understanding for the mechanism of action of IDR-1002 in decreasing 
lymphocyte proliferation. It is possible that this peptide induces anergy as was 
demonstrated with the BMAP proteins [224]. It would be noteworthy to determine if this 
immunosuppressive state could be overcome by the administration of exogenous IL-2 in 
LPRs. Also of interest would be to examine which immune cells are recruited to the 
injection site via immunohistochemistry, using specific markers for DCs, macrophages 
and lymphocytes. One could also study the cytokine milieu at the injection site possibly 
by taking biopsies for RT-qPCR analysis of cytokine gene expression. Another 
interesting aspect that could be addressed, is the effect of using different routes of 
administration for example, subcutaneous or intramuscular administration as compared to 
intradermal. When IDR-1002 is administrated subcutaneously with PTd, antibody titres 
were increased and protection was observed [214]. Differences between these studies and 
ours include the antigen tested and the route of administration. Studies comparing the 
subcutaneous administration of KLH versus PTd, as an antigen in combination with IDR-
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1002, would allow for a better understanding of the role played by each antigen as well as 
the immunization route. Another final matter to examine is that of synergy between CpG 
ODN and IDRs. In combination, IDRs demonstrate protective effects in vaccination 
studies. An understanding of which signaling pathways are activated by IDRs and CpG 
ODN would allow for a greater understanding of how these adjuvants work. 
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Appendix A: Effects of synthetic host defense peptides on porcine dendritic cells  
 
The immunomodulatory effect of the synthetic HDPs, HH2, HH17 and HH18 was 
examined in porcine MoDCs and BDCs. The effects of these HH peptides on cell surface 
marker expression via flow cytometry, cytokine production via ELISA, changes in gene 
expression in cytokines, chemokines and co-stimulatory molecules, and uptake ability via 
endocytic assay were studied.  
 
A. Dose Response Assessment 
 
To determine peptide safety, assays for cytotoxicity and for caspase activity were 
performed in porcine PBMC using kits (Promega) as per the manufacturers instructions. 
Peptide concentrations ranging up to 100 µg/ml were used at 1, 5 and 24 hours for the 
cytotoxicity assay (Figure 1A-C) and 5 hours for the caspase assay (Figure 2). We 
demonstrated that at these concentrations HH2, HH17 and HH18 were not cytotoxic nor 
did they induce apoptosis. 
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Figure 1. Cytotoxicity assay in PBMC.  
PBMC were rested overnight and incubated with CpG ODN (5 µg/ml), HH2, HH17 and 
HH18 at respectively at the following respective concentrations: 100, 10 and 1 µg/ml, for 
1 hour (A), 5 hours (B) and 24 hours (C) and then assayed by luminescence for 
cytotoxicity. Results are expressed as mean ± SEM (n=2). 
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Figure 2. Caspase activity in PBMC following a 5 hour incubation with treatments.  
PBMC were rested overnight and incubated with CpG ODN (5 µg/ml), Peptide 1, 2, and 
3 at respectively at the following respective concentrations: 100, 10 and 1 µg/ml, for 5 
hours and then assayed by luminescence for caspase activity. Results are expressed as 
mean ± SEM (n=2). 
 
B. Cell surface marker expression 
 
MoDCs were stimulated with HH2, HH17 and HH18 using a low dose of 5 µg/ml (n=2) 
for 8 hours. This peptide dose was chosen based on studies that used HDPs at similar 
concentrations [144]. MoDCs were stimulated with HH2, HH17 and HH18 for 8 hours 
and analyzed by flow cytometry for the percent of cells positive for CD172a, MHCII, 
CD16, MHCI, CTLA, CD1 and CD14 expression as well as for their mean fluorescence 
intensity (Figure 3). No changes in either of these parameters were observed. No 
differences were present for the percent of positive cells following peptide stimulation.  
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Figure 3. Cell surface marker expression in MoDCs. MoDCs were generated by 
isolating CD14+ cells by MACs and then cultured in the presence of IL-4 and GM-CSF. 
They were assessed for the expression of their cell surface markers at day 6 (n=2) by flow 
cytometric analysis. Data are expressed as a mean ± SEM % of positive cells (A-G) and 
mean fluorescent intensity (H-K).  
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C. Cytokine production via ELISA  
Preliminary data on cytokine production using the HH peptides at a low dose were 
suggestive that a higher peptide dose should be used. Similar findings were made by our 
collaborators therefore we decided to use a higher dose for future experiments (133 
µg/ml). Subsequently, protein levels of IL-6, IL-8, IL-10, IL-12 and TNF-α were 
examined by ELISA following a 24-hour stimulation with HH2, HH17, HH18 and LPS. 
No changes were seen for IL-10 production (data not shown). TNF-α production was 
only seen following stimulation by LPS (data not shown). Results for IL-6, IL-8 and IL-
12 for both MoDCs and BDCs are shown in Figure 4. With the exception of LPS, the 
only other remarkable finding was the ability of HH2 to induce high levels of IL-8 in 
MoDCs.  
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Figure 4. IL-6, IL-8 and IL-12 cytokine production by ELISA in MoDCs and BDCs. 
MoDCs (Figure 4A-C) at day5 and BDCs (Figure 4D-F) that were isolated and rested for 
4 hours were cultured with HH2 (133 µg/ml), HH17 (133 µg/ml), HH18 (133 µg/ml) or 
LPS (100 ng/ml) for 24 hours. Supernatant was assayed by ELISA for IL-6, IL-8 and IL-
12 protein. Results are expressed as median concentration ± range (n=4 pigs). 
 
D. Gene expression studies on cytokines, chemokines and co-stimulatory molecules 
 
Changes in gene expression were examined following an 8 hour stimulation with HH2, 
HH17, HH18 and LPS. Results are presented in Table 1 for both MoDCs and BDCs as an 
average fold change ± SEM (n=4). Only fold changes of more than 2 were considerable 
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MoDC and of IFN-γ in BDCs. Neither HH17 nor HH18 resulted in changes in gene 
expression. LPS treatment resulted in an increase in CCL3, IL-6, IL-8, IL-12p40, IL-13, 
IL-17, TNF-α, CCR7, CCL2 and CCL20 expression.   
 
 130 
Table 1. Changes in the relative fold change of gene expression in MoDC and BDC 
following an 8 hour stimulation with peptides and LPS. Change in DC gene expression of 
cytokine, chemokines chemokine receptors and co-stimulatory molecules following 
peptide and LPS stimulation. MoDC at day 5 were cultured with HH2 (133 µg/ml), 
HH17 (133 µg/ml), HH18 (133 µg/ml) and LPS (100 ng/ml) for 8 hours. Cells were 
collected in Trizol and then analyzed by RT-PCR for changes in gene expression of IL-6, 
IL-8, IL-12p35, IL-12p40, IL-13, IL-17, TNF-α, IFN- α, IFN-γ, TGF-β, NκFBp65, 
CCR5, CCR6, CCR7, CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL20 (MIP-
3α), CD80, CD86 and MHCII (n=4 pigs). 
 
  
HH2 
(133 µg/ml) 
HH17 
(133 µg/ml) 
HH18 
(133 µg/ml) 
LPS 
(100 ng/ml)  
BDC interleukins IL-8 2.5 ±1.3 1.1±0.1 1.0±0.4 1.0±0.4  
 TNF-α 2.5±1.3 1.1±0.1 1.0±0.4 1.0±0.4  
 IFN-α 1.1±0.4 0.9±0.3 2.1±0.8 0.3±0.1  
 IFN-γ 6.7±4.1 0.4±0.1 0.5±0.2 8.1±4.7  
BDC chemokines/ 
chemokine receptors CCR5 0.4±0.1 1.9±0.2 1.2±0.3 0.7±0.1  
 CCR6 2.5±0.8 0.7±0.2 1.1±0.2 1.4±0.6  
 CCR7 1.5±0.5 0.7±0.1 1.6±0.6 1.4±0.6  
 CCL2 0.3±0.1 1.8±0.6 6.5±5.4 11.1±7.2  
 CCL3 1.2±0.4 1.4±0.2 1.3±0.3 21.3±13.3  
 CCL20 1.0±0.4 0.8±0.5 1.9±1.0 12.6±12.0  
BDC markers CD80 1.3±0.3 1.0±0.0 0.8±0.5 3.5±1.6  
 CD86 1.1±0.4 1.4±0.4 0.5±0.1 3.6±1.4  
MoDC interleukins IL-6 18.0±17.7 1.5±0.6 1.0±0.7 33.8±17.1  
 IL-8 17.6±17.0 1.3±0.5 0.4±0.2 34.6±17.7  
 IL-12p35 1.4±0.9 1.2±0.4 1.0±0.1 2.4±0.8  
 IL-12p40 6.3±3.7 0.6±0.2 0.7±0.2 13.1±6.9  
 IL-13 6.4±6.2 2.8±1.8 1.0±0.3 44.9±30.5  
 IL-17 8.5±4.1 0.9±0.3 0.5±0.3 24.9±19.9  
 TNF-α 4.5±4.0 1.3±0.7 0.7±0.4 12.6±5.8  
 IFN-α 2.0±0.6 1.5±0.5 2.0±0.4 0.3±0.3  
 IFN-γ 1.7±0.8 0.5±0.1 1.4±0.2 5.4±4.3  
 TGF-β 1.2±0.5 1.5±0.3 1.0±0.2 0.8±0.4  
 NFKBp65 1.8±0.4 0.9±0.3 1.1±0.2 1.1±0.2  
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MoDC chemokines/ 
chemokine receptors CCR5 2.5±1.2 1.1±0.2 1.5±0.3 0.7±0.3  
 CCR6 1.7±0.6 1.0±0.2 1.4±0.7 1.9±0.2  
 CCR7 4.1±2.9 0.8±0.2 0.9±0.2 4.0±1.0  
 CCL2 2.3±1.5 0.6±0.2 0.9±0.2 4.8±2.2  
 CCL3 -1.3±1.7 2.6±1.3 0.8±0.5 -3.5±1.2  
 CCL4 -1.1±1.7 2.5±1.1 1.1±0.7 -3.1±2.1  
 CCL20 9.2±8.8 2.3±1.1 0.3±0.1 40.7±28.4  
MoDC markers CD80 1.9±0.9 1.1±0.3 0.8±0.2 2.9±1.3  
 CD86 1.0±0.1 1.0±0.3 2.6±1.1   
 MHCII 1.2±0.3 1.4±0.2 1.2±0.1 0.6±0.1  
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E. Endocytosis 
 
The ability of DCs to sample antigen is key in their functioning as antigen presenting 
cells. DCs sample antigen by various mechanisms including endocytosis. The goal of this 
experiment was to determine if HDPs are able to effect DC endocytosis via the uptake of 
FITC-dextran. Endocytosis assays for the HH peptides were performed in MoDCs 
(Figure 5 A-C) and BDCs (Figure 5 D-F). No changes were observed in either DC subset 
examined.  
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Figure 5. Endocytic activity MoDCs and BDCs following stimulation with HH 
peptides. Uptake ability of MoDCs (Figure 5A-C) and BDCs (Figure D-F) following 
stimulation with HH2 (133 µg/ml), HH17 (133 µg/ml) and HH18 (133 µg/ml) was 
assayed by examining the percentage of cells staining positive for FITC-dextran. Results 
are demonstrated as the mean of positively staining DCs  (n=6 animals). 
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F. Summary 
 
We examined the effects of stimulating porcine MoDCs and BDCs with HH2, HH17 and 
HH18. We did not see any significant changes in the parameters that we examined i.e. 
cell surface marker expression, cytokine production, chemokine production, co-
stimulatory molecule expression and endocytic ability. For this reason we expanded our 
study to include other peptides some of which are naturally-occurring. We also moved 
from screening DCs to examining effects in PBMC. Reasons for which we did not see 
any effects are discussed in Chapter 4.5.  
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Appendix B: Recruitment and activation of dendritic cells by innate immune 
stimulators (as published in Facci et al., 2008; Recent Developments in 
Immunology)[45] 
 
Abstract  
The innate immune response to infection is characterized by the fast appearance 
of effector molecules within minutes after breaching of the mucosal lining or the skin. 
Effector molecules such as cytokines, chemokines and host defense peptides are 
subsequently secreted to recruit a variety of immune cells and to activate the cells upon 
arrival at the site of infection. Amongst the cells being recruited dendritic cells are critical 
immune cells, which play a major role in linking innate and acquired immunity, thereby 
ensuring that both acquired immune responses and immune memory are induced. Here, 
we review the early stages of an innate immune response and the recruitment, activation 
and maturation of these cells by innate immune molecules. Furthermore, the potential of 
using some of these innate immune modulators to modulate the immune response to 
vaccination is discussed.  
 
 
Dendritic cells 
 
1. Introduction 
 
Innate immune responses are triggered in response to the recognition of pathogen 
associated molecular pattern (PAMPs) via pattern recognition receptors (PRRs). 
Typically, within minutes after breaching of the mucosal or dermal lining innate effector 
molecules that mediate the recruitment and activation of various types of immune cells to 
the site of infection are released. In fact, it is this first interaction between the pathogen 
and the host’s innate immune system that sets the stage for the subsequent immune 
response. Among the cells recruited are dendritic cells (DCs). These cells are efficient 
antigen-presenting cells (APCs) found in peripheral tissues as well as in primary and 
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secondary lymphoid organs [3, 236]. DCs play a central role in the induction and 
regulation of innate and adaptive immune responses, and represent an important link 
between innate and acquired immunity [237]. Their strong capacities for acquiring, 
processing, retaining, and presenting multiple peptides explain their superior role as 
APCs. For example, compared to macrophages lung DCs home more efficiently to T cell 
zones in secondary lymphoid organs [238]. Different subtypes of DCs have been 
described at steady state in mice, pigs, and humans. The two major subtypes are the type-
1 interferon-producing plasmacytoid DCs and the conventional DCs that are found in 
both non lymphoid and lymphoid tissues [162]. Conventional DCs can be further divided 
into subsets according to their tissue-specific localization, such as interstitial tissue DCs, 
lung DCs and mucosal tissue-associated DCs [162]. Depending on their maturation 
status, immature DCs are present in the periphery whilst in secondary lymphoid organs 
both mature and immature DCs are present. 
 
DCs are regulators of the innate and adaptive immune system that can be found in 
almost every organ in the body. Their recruitment and activation is mediated by a variety 
of innate immune molecules including chemokines, TLR ligands and host defense 
peptides. The presence of DCs at the mucosal surfaces and spleen allows them to 
continuously sample antigens in their surrounding environment by macropinocytosis, 
receptor-mediated endocytosis and phagocytosis [239, 240]. Resting DCs display a low 
surface expression of class II MHC and co-stimulatory molecules such as CD40, CD80 or 
CD86. In response to microbial and endogenous stimuli, these resting DCs undergo a 
complex maturation process that leads to changes in antigen capture and presentation, 
migration, expression of co-stimulatory molecules and production of T cell polarizing 
cytokines. Some of these stimuli are presented in the following sections. 
 
2. Recruitment of dendritic cells 
A large number of molecules are involved in the homing and recruitment of DCs 
including integrins, adhesins, lipid mediators, host defense peptides, cytokines and 
chemokines [241, 242] Here, we focus on the role of chemokines and host defense 
peptides as effector molecules of the innate immune system.  
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The role of chemokines in DC recruitment 
Chemokines, a family of structurally similar peptides, are involved in the 
regulation of inflammation, leukocyte trafficking, and immune cell differentiation [243, 
244]. These molecules are highly basic proteins of 70-125 amino acids, with molecular 
masses ranging from 6 to 14 kDa. They exert their functions by binding specific seven-
transmembrane G-protein-coupled receptors located on the cell surface [243, 244]. Most 
chemokines contain at least four cysteines that form two disulfide bonds, one between the 
first and third and one between the second and fourth cysteine residues [243, 244]. 
According to the relative position of the cysteine residues, chemokines can be subdivided 
into four families: CXC- (α-chemokines), CC- (β-chemokines), C- (γ-chemokines), and 
CX3C- chemokines (δ-chemokines) [243, 244]. Different chemokines are involved in the 
various stages of DC migration. 
 
 DCs originate mainly from hematopoietic stem cell precursors that are released 
into the bloodstream and account for approximately 1% of all peripheral blood 
mononuclear cells (Figure 1) [44, 241, 245]. However, some DCs are of lymphoid origin 
[162]. The egress of DCs from the bone marrow into the bloodstream is tightly controlled 
by various integrin/addressin and chemokine/chemokine receptor interactions, the most 
important being CXCR4/CXCL12 [241, 246-249]. CXCL12, secreted by stromal cells, 
controls the egress of DC precursors even in the absence of inflammatory stimuli [250, 
251]. This chemokine interacts with CXCR4, expressed on monocyte and DC precursors, 
inducing an up-regulation of cell surface integrins that retain DC precursors in the bone 
marrow [252, 253]. Thus, the immune system controls the release of precursors by 
modifying CXCL12 expression. Another receptor, CX3CR1, is involved in the 
recruitment of DCs during homeostasis and under inflammatory conditions [254-256]. 
Interestingly, other innate immune molecules such as host defense peptides also attract 
dendritic cells [257] (Figure 1).  
 
DCs reach the spleen via the blood at a very low frequency, and then migrate to 
the marginal zone where they develop into conventional populations of immature DCs 
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(Figure 1) [44, 254, 258, 259]. Once matured and activated, DCs leave the marginal zone 
towards the T cell zone in the white pulp. This migration is mediated by an upregulation 
of CCR7, which enables the DCs to respond to the chemokines CCL19 and CCL21 [260-
262]. While some DCs colonize lymph nodes via the blood [7, 263, 264], their main route 
of entry is via the afferent lymph [7, 263, 264]. Interestingly, this migration is 
substantially increased after stimulation with microbial stimuli and inflammatory 
cytokines [241, 259, 265, 266]. This stimulation leads to the downregulation of CCR1, 
CCR2, CCR5 and CCR6 and upregulation of CCR4 and CCR7, eventually enabling DCs 
to migrate to secondary lymphoid tissues in response to CCL19 and CCL21 [241, 259, 
267, 268]. Secondly, it also reduces their responsiveness to inflammatory chemokines 
(e.g., CCL3, CCL5 and CCL20). DC entry into lymphatic vessels is mediated by 
adhesion molecules such as ICAM-1 or JAM-1 [241, 269]. From lymphatic vessels DCs 
reach the subcapsular sinus of the regional lymph node in a CCL21-dependent manner 
[241, 269]. Upon entry into the sinus, DCs are further directed towards the paracortex by 
CCL21 and CCL19 [241, 269]. Although their entry into the lymph node via the afferent 
lymph is the best described route of entry, DCs can also enter the lymph node via high 
endothelial venules (HEV) [7, 15, 21, 270]. Among the different DCs subsets, 
plasmacytoid DCs, CCR2high monocytes and conventional DCs including their precursors 
have been described to use this route [7, 15, 21, 270]. Non-inflamed lymph nodes support 
adhesion but not transmigration of plasmacytoid DCs, whereas inflamed lymph nodes 
allow strong migration of DCs across the HEV. This occurs using CD62L and CD62E 
during attachment and rolling, and involves β1 and β2 integrins for endothelial 
attachment [7, 21]. CCR5 as well as ChemR23 in humans also appears to mediate the 
recruitment of DCs across HEV [7, 21, 271]. 
 
DCs enter the periphery either directly, or via precursors such as monocytes 
(Figure 1). However during inflammation, mononuclear phagocytes and DCs are 
recruited [44, 263, 272, 273]. This recruitment is controlled by various chemokines and 
matrix metalloproteinases [274]. For example, CCL3 interacts with the receptors CCR1 
and CCR5. Within the chemokine network, several functional redundancies exist, as a 
single chemokine can bind to more than one receptor, and a single receptor can be bound 
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by various chemokines (CCL3, CCL5 and CCL6 for CCR1 and CCR5; CCL25 for CCR9 
and CCX-CKR1) [241]. Recently, CCX-CKR1, which is exclusively expressed by 
stromal cells, has been implicated in the regulation of homeostatic CD11c+ MHCIIhigh DC 
migration by controlling the availability of chemokines into the extracellular space [275]. 
This finding adds another level of complexity in the understanding of leukocyte 
homeostatic migration [275]. Plasmacytoid DCs can enter normal tissues at very low 
levels in humans and mice in the presence or absence of inflammatory stimuli [162, 241, 
276] most likely via chemokines and their cognate receptors. 
 
 
 
The role of host defense peptides in DC recruitment 
 Host defense peptides are cationic peptides that can be grouped into defensins and 
cathelicidins based on the respective presence of β-sheets and α-helices [191]. These two 
families differ in their disulfide content and peptide length allowing them to have 
different functions. Being positively charged, host defense peptides are able to form pores 
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in bacterial membranes thereby being antimicrobial [193]. In addition to this property, 
host defense peptides have been demonstrated to be immunomodulatory by recruiting 
immune cells to sites of pathogen entry (Figure 2). Neutrophils are amongst the first cells 
to arrive and possess various granules that contain antimicrobial [277] and 
immunomodulatory factors [215] such as host defense peptides. The release or activity of 
these peptides is regulated by the activation state of the neutrophil and by enzymes that 
cleave the propeptide form of the peptide into its mature form. For example, neutrophil-
derived elastase cleaves Bac7 into its mature form [109], whilst the cleavage of LL-37 
from HCAP18 occurs upon exocytosis and consequent cleavage via proteinase 3 [110]. 
Interestingly, whilst the immature form of Bac7 is chemotactic [134] and does not have 
any antimicrobial activity, its mature form is antimicrobial against Klebsiella pneumoniae 
and Salmonella typhimurium [109]. This example demonstrates the importance of peptide 
maturity in determining the peptide’s function and ability to recruit immune cells. The 
ability of peptides to chemoattract other immune cells serves as means to propagate and 
amplify immune signals.  
 
Host defense peptides from various species have been demonstrated to recruit 
immune cells (Figure 1). For example, hCAP, the propeptide of the human cathelicidin 
LL-37 recruited human monocytes [135], rat mast cells [143], human neutrophils [135-
137], human DCs [136] and human T cells [135, 138]. The mouse cathelicidin CRAMP 
was chemotactic for human monocytes, neutrophils, macrophages, and mouse peripheral 
blood leukocytes [149]. The human beta defensins 1-4 were chemotactic for human 
macrophages [139], mast cells [139], immature DC [278], CD4+/CD45RA+ naive and 
CD8+, but not CD4+/CD45RO+ memory T cells [141, 278]. Murine β-defensins 2 and 3 
were able to recruit murine immature DC [145, 155]. 
 
Many of the receptors used by host defense peptides for recruitment remain unknown. 
Whereas some defensins have been shown to recruit immature DCs via CCR6 [145, 146], 
both the human and mouse cathelicidins LL-37 and CRAMP act mostly via FPRL 
(formyl peptide receptor like) [135, 147-149]. Different cells possess distinct sets of 
receptors thereby adding specificity to the recruitment process. For example DCs migrate 
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in response to fMLP (representative of formyl peptides of bacterial origin), C5a, and the 
CC-chemokines CCL7, CCL3 and CCL5, but not to the CXC-chemokines IL-8 and 
CXCL10 and the CC-chemokines CCL2 and CCL8 [147, 279] whereas neutrophils 
migrate in response to cytokines such as IL-8. In pigs, we observed that after 24-hour 
stimulation of monocyte-derived DCs with a Bactenecin peptide derivative increased 
protein levels of IL-8. Theoretically given that IL-8 recruits neutrophils and that 
neutrophils release host defense peptides, this peptide may have the potential to indirectly 
recruit more DCs. Furthermore, following an 8-hour stimulation of monocyte-derived 
DCs with the same peptide, increases in gene expression of IL-12p40 and IL-17 were 
observed. These changes in gene expression indicate the potential of host defense 
peptides to activate DCs and to skew the immune response towards a particular type of 
immune response. 
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3. Activation of dendritic cells 
 
Activation of DCs is partially induced by the recognition of pathogens via PRRs 
(Figure 3). The three main families of PRRs comprise Nod-like receptors (NLRs), C-type 
lectin receptors (CLRs) and Toll-like receptors (TLRs). Nod-like receptors function as 
cytosolic sensors for bacterial products and endogenous danger signals. This family 
includes innate receptors like nucleotide-binding oligomerization domain (nod)1 and 
nod2, which activate NF-κB, and other receptors, such as NALPs, which can activate 
caspase-1 leading to the processing of pro-IL-1β and pro-IL-18 into their active forms 
[280]. The CLR family recognizes various bacterial and fungal carbohydrate moieties 
such as D-mannose, L-fucose and N-acetylglucosamine present on the surface of 
pathogens. Their major function is to internalize antigens for further processing and 
presentation by DCs. This family includes DC-SIGN (dendritic cell-specific intercellular 
adhesion molecule 3 grabbing nonintegrin), dectin-1 and the mannose receptor [281].  
The TLR family includes 10 different receptors in humans (TLR1-10) and 12 in mice 
(TLR1-9 and 11-13) [282]. Members of the TLR family recognize a wide range of 
bacterial, viral and parasitic molecular patterns. These TLRs are either expressed on the 
cell surface or within endosomes. Amongst the cell surface expressed TLRs, TLR5 is 
triggered by flagellin from both Gram-positive and Gram-negative bacteria [283]. TLR4 
detects lipopolysaccharide (LPS) and TLR2 recognizes a variety of microbial 
components such as peptidoglycans and lipoteichoic acid (LTA) from Gram-positive 
bacteria, lipoarabinomannans from mycobacteria and zymosan from fungi [284]. TLR2 
also forms heterodimers with TLR1 or TLR6. The TLR1/2 heterodimer recognizes 
triacyllipopeptides from gram-negative bacteria whereas the TLR2/6 heterodimer is 
triggered by diacyllipopeptides expressed by mycoplasma [285]. Amongst the TLRs 
expressed in the cytoplasm, TLR3 recognizes double-stranded RNA, produced by most 
viruses, [286], whereas TLR9 recognizes unmethylated 2’-deoxyribo(cytidine-phosphate-
guanosine)(CpG) DNA motifs present in bacterial DNA [287]. Synthesized 
oligodeoxynucletides with unmethylated CpG dinucleotides (CpG ODN) can mimic the 
immunostimulatory activity of bacterial DNA through TLR9 activation. Depending on 
the number of CpG motifs present, the spacing of the CpG motifs, the flanking sequences 
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and the backbone of the ODN, three classes of ODN can be distinguished, namely A-
class ODN, B-class ODN and C-class ODN. These three classes have different 
stimulatory activities with the C-class ODN combining intermediate effects of both the 
A-class and the B-class ODN [29]. TLR7 and TLR8 specifically recognize single-
stranded RNA from pathogens such as RNA viruses. They are highly homologous to 
TLR9 and are involved in viral recognition [288]. Certain synthetic anti-viral 
imidazoquinolines were also demonstrated to stimulate TLR7- and TLR8-dependent 
signaling [289]. 
Interestingly, the pattern of expression of TLRs by DCs differs by both subset and 
species. In humans, conventional DCs express TLR2, TLR3, TLR4, TLR5, TLR6 and 
TLR8 whereas plasmacytoid DCs express TLR7 and TLR9. In mice, both conventional 
and plasmacytoid DCs express TLR9. Depending on the TLR and the DC subpopulation 
different types of immune responses are elicited. For example, in conventional DCs, 
triggering of TLR4 or TLR5 induces phosphorylation of p38 and JNK1/2 kinases, which 
stimulate Th1 responses via IL-12 production. In contrast, the TLR2 agonists Pam3Cys 
and Schistosoma egg antigens stimulate phosphorylation of ERK1/2, which results in the 
stabilization of the transcription factor c-Fos (a suppressor of IL-12) and polarization of 
the immune response towards a Th2 type [290]. TLR3 engagement leads to IRF-3 
activation via the adapter protein TRIF and IFN-β production, which induces IRF-7 in an 
autocrine fashion and subsequent production of IFN-α [291]. In plasmacytoid DCs, 
triggering of TLR7 or TLR9 by their natural ligand (single stranded RNA and bacterial 
DNA respectively) or by synthetic ligands (imidazoquinolines and CpG ODN 
respectively) induces the production of large amounts of IFN-α through a signaling 
cascade that rapidly activates IRF-7 [292], making those cells the most efficient type I 
interferon producers. Stimulation of TLR7 and TLR8 also induces the production of Th1-
like and pro-inflammatory cytokines and chemokines other than type I IFN including 
IFN-γ, CXCL10, IL-12, IL-6, TNF-α [37]. Signalling via TLR9 induces upregulation of 
costimulatory molecules, resistance to apoptosis and secretion of Th1 promoting 
chemokines and cytokines such as type III IFNs, CCL3, CCL4, CXCL10 and other IFN-
inducible genes [29]. Human pDCs do not produce significant IL-12p70 whereas mouse 
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pDCs produce measurable amounts of IL-12 in response to these TLR ligands, even in 
smaller amounts compared to the conventional DC subset [293]. 
 
4. Maturation of dendritic cells 
 
Under steady-state conditions, DCs remain in an immature state and do not 
differentiate into functional initiators of immunity. Without inflammation or infection, 
DCs continuously migrate from the periphery to the lymph nodes. DCs migrating during 
homeostasis are considered quiescent, semi-mature or not fully mature. In contrast to 
mature DCs, homeostatic DCs do not express the full set of stimulatory signals that are 
required for T cell activation. They present self-antigens or non-immunogenic proteins 
leading to T cell deletion, anergy or differentiation into regulatory cells [294]. This is an 
important immunological process designed to purge the peripheral T cell repertoire of 
autoreactive T cells that have escaped thymic depletion and potentially could give rise to 
autoimmunity.  
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As discussed previously, immature DCs express a wide repertoire of PRRs that 
specifically recognize highly conserved PAMPs. During an infection or tissue injury 
resting DCs will be exposed to pathogens and mediators of inflammation that can act as 
“danger signals” to alert these cells [295]. The triggering of these receptors by microbial 
products combined with the presence of host-derived inflammatory molecules such as 
TNF-α, IL-1, IL-6, type I interferons, CD40/CD40 ligand interaction, or molecules 
released by damaged host tissues will lead to the activation and full maturation of DCs. 
This maturation process is characterized by a loss of endocytic and phagocytic capacities 
and an increase in the surface expression of co-stimulatory molecules such as CD80, 
CD86 and CD40 [296, 297]. The mature DCs also change their pattern of chemokine 
receptor expression from the expression of receptors recognizing chemokines expressed 
in the peripheral tissues (CCR1, CCR2, CCR5 and CCR6) towards the expression of 
CCR7. This receptor recognizes CCL19 and CCL21; two chemokines constitutively 
expressed in the T-cell zones of secondary lymphoid organs, thus allowing the migration 
of mature DCs in the lymph nodes to present antigens to and activate naïve T cells [268, 
298, 299]. Depending on the nature of the maturation stimulus, the subset of DCs, and the 
local environment, DCs are able to prime naïve T cells and induce their clonal expansion 
and differentiation into Th1, Th2 or Th17 cells, which can be distinguished on the basis 
of their cytokine production [300, 301].  
 
Plasmacytoid DCs can be activated and undergo maturation, which enhances their 
potential for antigen presentation. Similar to conventional DCs, plasmacytoid DC 
maturation includes the upregulation of MHCII and co-stimulatory molecules CD80, 
CD86 and CD40. However plasmacytoid DCs present antigens less efficiently since their 
uptake, processing and loading of antigen onto MHC molecules is not as effective as that 
of conventional DCs; and even fully matured, they express less MHC class II and co-
stimulatory molecules than conventional DCs. However, plasmacytoid DCs can 
efficiently induce proliferation of previously experienced T cell clones [41, 302, 303]. 
 
Other molecules such as host defense peptides can also modulate DC maturation. 
For example, in the presence of LL-37 immature DCs increase their expression of HLA-
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DR and CD86 [158], become more endocytic and secrete Th1 cytokines [136]. When 
monocyte-derived DCs were stimulated with LPS, lipoteichoic acid and flagellin they 
produced IL-6, IL-12p70 and TNF-alpha and increased their surface expression of HLA-
DR, CD80, CD83, CD86 and the chemokine receptor CCR7. Interestingly, when these 
stimulants were combined with LL-37 the surface marker expression of the above was 
decreased. Furthermore when DC were stimulated with LL-37 and LPS and then co-
cultured with naïve T cells the production of IL-2 and IFN-y was decreased [234]. This 
data demonstrates the extent to which HDPs can alter immune responses. 
 
All stimuli involved in the activation and maturation of DCs can cooperate or 
synergize in the induction of particular aspects of DC maturation, especially cytokine 
production. For example, the secretion of large amounts of IL-12p70 by DCs requires 
synergizing stimuli such as IFN-γ, which acts as a conditioner by inducing the 
upregulation of TLR expression [304, 305], triggering of TLRs by PAMPs acting as 
specifying inducers [306, 307], and CD40L interaction that boosts the IL-12p70 
production already triggered by microbial stimuli [305, 308]. Synergy between innate 
immune receptors has been demonstrated following microbial infections. For example, 
during infection by Mycobacterium sp. or Trypanosoma sp., TLR2 and TLR9 synergize 
to induce IL-12p40 production and a Th1 response [309, 310]. Another example is the 
synergy between Nod receptors and TLR3, TLR4 or TLR9 in the induction of IL-12p70 
production [311]. Host defense peptides also contribute to the activation of DCs and 
deficiencies in host defense peptide expression can contribute to disease pathogenesis 
[118]. However in contrast, in psoriasis LL-37 appears to activate plasmacytoid DC to 
respond to self DNA and trigger TLR9 [312] a receptor, that is used to detect foreign 
DNA.  
 
 
5. Induction of acquired immunity 
 
Once matured, DCs link innate and adaptive immunity by being able to drive Th1 
or Th2 immune responses. The presence of immunomodulators, such as host defense 
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peptides or TLR ligands such as CpG ODN, is particularly important in determining the 
type of the immune response. DCs interact with naïve T cells by delivering different 
types of signals. The first signal is delivered through the T cell receptor (TCR) after its 
engagement with the peptide-MHC complex expressed by the DC. The second signal is a 
co-stimulatory signal and is mediated by signaling through CD28 when it engages CD80 
or CD86 expressed by the DCs [313]. DCs also deliver a third signal to direct the T cell 
response towards a Th1, Th2, Th17 or regulatory T cell profile by producing different 
sets of cytokines. 
 
Subsequent production of IL-12, IL-18 or IFN-α by DCs results in a bias of the 
CD4+ T-cell priming towards a Th1 profile characterized by the production of high levels 
of IFN-γ and TGF-β, cytokines that are fundamental for defense against intracellular 
pathogens. DCs are also able to promote a Th2 cell response, characterized by the high 
production of IL-4, IL-5, IL-10 and IL-13, and induction of IgE antibodies. The induction 
of Th2 cell responses by DCs is still not completely understood, but the expression of 
members of the Jagged family of Notch ligands could play a role [314]. Lastly, 
production of TGF-β together with IL-6 by DCs can mediate the differentiation of Th17 
T cells. These cells are able to produce high amounts of IL-17 and seem to be involved in 
autoimmune diseases as well as in general inflammation [315] [316]. 
 
 Evidence suggests that host defense peptides are able to enhance and strengthen 
the nature of the immune response. For example when defensins were administered 
intraperitoneally with Keyhole Limpet Hemocyanin (KLH), higher KLH-specific 
antibody titers and KLH-specific proliferative responses were seen [150]. Ovalbumin-
specific immune responses were enhanced after intranasal co-administration of 
ovalbumin and HNP1-3 in C57/Bl mice [317] and intraperitoneal injection of HNP1-3 
and KLH of B-cell lymphoma idiotype Ag into mice enhanced the resistance to 
subsequent tumor challenge [150]. Fusion of beta-defensins mBD2 or mBD3 to a B–cell 
lymphoma epitope sFv38 induced stronger anti-tumor immune responses in mice [145, 
318]. Therefore host defense peptides have the potential to strengthen immune responses. 
The presence or absence of these peptides during disease can be advantageous or 
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disadvantageous depending on the immune environment. Moreover, fusion of the murine 
β-defensin 2 with the gene encoding the human immunodeficiency virus-1 glycoprotein 
120 (HIV gp120) resulted in specific mucosal, systemic, and CTL immune responses 
after immunization [145, 318].  
 
 Two major cell types, B cells and plasmacytoid DCs, express TLR9 and therefore 
can respond to CpG ODN stimulation. Stimulation of plasmacytoid DCs by CpG ODNs 
lead to secretion of type I IFN and TNFα. Those cytokines lead to the secondary 
activation of other immune cells such as Natural Killer cells, monocytes or neutrophils. 
The TLR9-stimulated plasmacytoid DCs are able to migrate to the T-cell zones of 
secondary lymphoid tissues, express greater amounts of costimulatory molecules, 
allowing them to activate naïve and memory T cells and cross-present antigens to CD8+ T 
cells. As a consequence, CpG ODN promote strong Th1 CD4+ and CD8+ T cell responses 
[29]. With its capacity to switch immune responses towards a Th1 profile, CpG ODNs 
are good candidates for prophylactic or therapeutic treatment of infectious diseases as 
well as vaccine adjuvants.  
 
 
6. Use of immunomodulators as future adjuvants 
 
Several types of vaccines are currently being used in humans and animals. These 
include live attenuated-, inactivated-, subunit- and DNA-vaccines. Live attenuated 
vaccines are the most immunogenic and their use is common practice in animals. 
However, because of safety concerns, only very few live attenuated vaccines are licensed 
for use in humans, Subunit vaccines, consisting of recombinant protein subunits, 
synthetic peptides and DNA vaccines are safer but often less immunogenic [319]. Thus, 
adjuvants are required that can enhance the immunogenicity of these vaccines.  
 
 Adjuvants can improve vaccine efficacy by i.) optimizing the delivery of the 
vaccine, ii.) increasing depot effect iii.) improving recruitment and activation of immune 
cells to the site of vaccination and iv.) modulating the immune response towards either a 
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Th1- or Th2-type immune response. DCs are key cells that link innate and acquired 
immunity. Thus, adjuvants that can enhance the recruitment and activation of DCs 
represent very promising adjuvant candidates for future vaccines. Indeed, the potential of 
CpG ODN and host defense peptides to enhance both innate and acquired immune 
responses against a variety of infectious agents has already been demonstrated in a large 
body of studies. It is our belief that future vaccines will be dramatically improved with 
the introduction of these ‘molecular adjuvants’, which will not only enhance the kinetics 
and magnitude of the immune response but also modulate the quality of the response to 
ensure both long term memory and appropriate elimination of the pathogen. 
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Appendix C: Strategies to link innate and adaptive immunity when designing 
vaccine adjuvants (as published in Garlapati, Facci et al. 2009; Vet Immunol 
Immunopathol)[229] 
 
Abstract 
Adjuvants are important components of vaccine formulations. Their functions include the 
delivery of antigen, recruitment of specific immune cells to the site of immunization, 
activation of these cells to create an inflammatory microenvironment, and maturation of 
antigen-presenting cells for enhancement of antigen-uptake and -presentation in 
secondary lymphoid tissues. Adjuvants include a large family of molecules and 
substances, many of which were developed empirically and without knowledge of their 
specific mechanisms of action. The discovery of pattern recognition receptors including 
Toll-like-, nucleotide-binding oligomerization domain (NOD)- and mannose-receptors, 
has significantly advanced the field of adjuvant research. It is now clear that effective 
adjuvants link innate and adaptive immunity by signaling through a combination of 
pathogen recognition receptors (PRRs). Research in our lab is focused towards the 
development of novel adjuvants and immunomodulators that can be used to improve 
neonatal vaccines for humans and animals. Using a neonatal pig model for pertussis, we 
are currently analyzing the effectiveness of host defence peptides (HDPs), bacterial DNA 
and polyphosphazenes as vaccine adjuvants. 
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Appendix D: Biological roles of host defense peptides: lessons from transgenic 
animals and bioengineered tissues (as published in Dybvig, Facci et al. 2011; 
Cell Tissue Res)[320] 
 
Abstract 
Host defense peptides (HDPs) have long been recognized as microbicidal agents, but 
their roles as modulators of innate and adaptive immunity have only more recently been 
appreciated. The study of transgenic animal and tissue models has provided platforms to 
improve our understanding of the immune modulatory functions of HDPs. Here, the 
characterization of transgenic animals or tissue models that over-express and/or are 
deficient for specific HDPs is reviewed. We also attempt to reconcile this data with 
evidence from human studies monitoring HDP expression at constitutive levels and/or in 
conjunction with inflammation, infection models, or disease states. We have excluded 
activities ascribed to HDPs derived exclusively from in vitro experiments. An 
appreciation of the way that HDPs promote innate immunity or influence the adaptive 
immune response is necessary in order to exploit their therapeutic or adjuvant potential 
and to open new perspectives in understanding the basis of immunity. The potential 
applications for HDPs are discussed. 
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Appendix E: Differential activation and maturation of two porcine DC 
populations following TLR ligand stimulation (as published in Auray, Facci et 
al. 2010; Mol Immunol)[92] 
 
Abstract 
Dendritic cells (DCs) are at the interface of innate and adaptive immune responses. Once 
activated via triggering of their pattern recognition receptors (PRRs), they acquire a 
mature state and migrate to the lymph nodes where they activate T cells and direct the 
immune response. Compounds that trigger PRRs are potential vaccine adjuvants, hence 
in this study we stimulated two porcine DC populations, namely monocyte-derived DCs 
(MoDCs) and blood DCs (BDCs), with a broad range of toll-like receptors (TLRs) 
ligands and assessed the activation/maturation state of these porcine DCs. In order to 
determine if TLR ligands would have an effect on porcine DCs, we characterized the 
expression of TLRs and demonstrated that MoDCs and BDCs expressed the same set of 
TLRs but at different levels. Of the TLR ligands examined, lipopolysaccharide (LPS) and 
poly I:C were the most potent activators of MoDCs, inducing the up-regulation of co-
stimulatory molecules CD80/86 and the chemokine receptor CCR7, and production of 
pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)alpha. The 
most effective in inducing BDCs activation were LPS and class A CpG 
oligodeoxynucleotide (ODN), resulting in up-regulation of chemokine receptor (CCR)7 
and down-regulation of CCR2 and CCR5, production of IL-12p40, and expression of a 
broad range of chemokines that were able to attract porcine immune cells. 
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